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Mass Spectrometry (MS) based technologies have enabled efficient and comprehensive 
proteomic profiling for biomarker discovery. However, due to sample complexity and 
large concentration variation, the obtained data is usually biased to endogeneous high 
abundance proteins while the important disease-related information went missing. 
Targeted proteomics enables the delivery of precise and sensitive qualitative/quantitative 
data of interest to researchers by focusing analysis on a preselected population of cells or 
proteins. This project aims to develop targeted proteomic technologies through capillary 
isotachophoresis (CITP)-based technique which is capable of selectively enriching trace 
compounds for a further improved sensitivity in both discovery and validation studies. 
By employing tissue microdissection and a CITP-based multidimensional separation 
platform, homogeneous glioma cells were isolated from unwanted cells and analyzed in 
search of glioblastoma biomarker. Comparative proteomic profiling of pure tumor cells 
from different grades of infiltrative astrocytomas revealed disease specific protein 
expression variation among grades. Further validation using immunohistochemistry 
demonstrated consistent results. This targeted tissue analyzing platform provided a 
 
 
sensitive and confident methodology for biomarker discovery within minute amount of 
samples. 
With the demonstrated outstanding analyzing capacity on targeted biomarker discovery, 
we moved on to developing ultrasensitive targeted quantitation techniques. We 
demonstrated online coupling of transient-CITP/CZE (capillary zone electrophoresis) 
with selective reaction monitoring (SRM) MS for the first time via a sheathliquid 
interface for improved sensitivity and selectivity.  Ultrasensitive targeted quantitation 
was achieved through the incorporation of the selective enrichment capability of 
CITP/CZE with SRM MS, giving a limit of quantitation (LOQ) of 50 pM with a total 
sample loading of 50 attomoles. 
In order to further improve the sensitivity, we developed a novel sheathless interface 
which enables increased loading capacity and nanoflow operation by assembling a large 
size separation capillary and a small size porous emitter. LOQ was improved 5 times 
comparing to using the first sheathliquid interface, giving a LOQ of 10 pM with a total 
sample loading of 25 attomoles. This novel interface optimally preserved the high 
resolution and efficiency of CITP/CZE while improving the limited sample loading 




ULTRASENSITIVE CITP-MS BASED TARGETED 
PROTEOMICS TECHNOLOGY FOR PROTEIN 







Dissertation submitted to the Faculty of the Graduate School of the  
University of Maryland, College Park, in partial fulfillment 
of the requirements for the degree of 













Professor Cheng S. Lee, Chair 
Professor Shuwei Li 
Professor Dorothy Beckett  
Professor Neil Blough 



















Table of Contents 
Table of Contents ................................................................................................................ ii 
List of Figures .................................................................................................................... iv 
List of Tables ..................................................................................................................... vi 
List of Abbreviations ........................................................................................................ vii 
Chapter 1 : Introduction .......................................................................................................1 
1.1 Introduction ...........................................................................................................1 
1.2 Targeted proteomics ..............................................................................................3 
1.2.1 Targeted proteomics study  of homogenous tumor cells ..................................3 
1.2.2 Targeted quantification through selected reaction monitoring (SRM) MS ......7 
1.3 Capillary electrophoresis in biomarker discovery and recent advances .............11 
1.3.1 Single Dimension Capillary Electrophoretic Separation Coupled With Mass 
Spectrometry ..............................................................................................................12 
1.3.2 Capillary Electrophoretic-Based Multidimensional Separations Coupled 
With Mass Spectrometry ............................................................................................13 
1.4 CE-MS interface development .................................................................................20 
1.4.1 Sheathliquid Interfaces ......................................................................................23 
1.4.2 Sheathless interfaces ..........................................................................................27 
1.5 Project description ....................................................................................................28 
Chapter 2 :  Targeted Tissue Proteomic Analysis of Human Astrocytomas .....................32 
2.1 Introduction ..............................................................................................................32 
2.2 Experimental Section ...............................................................................................35 
2.2.1 Materials and Reagents .....................................................................................35 
2.2.2 Tissue Microdissection and Proteomic Sample Preparation .............................35 
2.2.3 CITP-Based Tissue Proteomic Analysis ...........................................................36 
2.2.4 MS Data Analysis ..............................................................................................40 
2.2.5 Protein Validation Using Immunohistochemistry (IHC) ..................................41 
2.3 Results and Discussion .............................................................................................41 
2.3.1 Overall Performance of Human Astrocytoma Proteomes .................................42 
2.3.2 Comparisons among Different Grades of Astrocytomas ..................................45 
2.3.3 Function and Network Analysis of Proteins Up-regulated in GBM .................50 
2.3.4 Selection and Validation of IQGAP1 Using IHC .............................................56 
2.4 Conclusion ................................................................................................................59 
2.5 Acknowledgement ....................................................................................................60 
Chapter 3 : Ultrasensitive Sample Quantitation via Selected Reaction Monitoring 
Using CITP/CZE-ESI-Triple Quadrupole MS...................................................................61 
3.1 Introduction ..............................................................................................................61 
3.2 Experimental Section ...............................................................................................64 
3.2.1 Chemicals ..........................................................................................................64 
3.2.2 Sample Preparation ............................................................................................64 
3.2.2 CITP/CZE-ESI-MS Interface ............................................................................65 
iii 
 
3.2.3 MS Optimization and Data Processing .............................................................68 
3.3 Results and Discussion .............................................................................................71 
3.3.1 CITP/CZE Sample Loading Capability and Optimization ................................71 
3.3.2 CITP/CZE-ESI-MS Sample Quantitation .........................................................76 
3.4 Conclusion ................................................................................................................84 
3.5 Acknowledgements ..................................................................................................84 
Chapter 4 : CITP/CZE-nanoESI-SRM MS via a Novel Sheathless Interface for High 
Sensitivity Sample Quantification .....................................................................................85 
4.1 Introduction ..............................................................................................................85 
4.2 Experimental Section ...............................................................................................88 
4.2.1 Chemicals ..........................................................................................................88 
4.2.2 Sample Separation .............................................................................................88 
4.2.3 Sheathless CITP/CZE-MS Interface .................................................................89 
4.2.4 Flow Rate Calibration .......................................................................................93 
4.2.5 MS Optimization and Data Processing .............................................................94 
4.3 Results and Discussion .............................................................................................96 
4.3.1 Sample Loading Optimization ...........................................................................96 
4.3.2 Performance Characterization of the Sheathless CITP/CZE-MS Interface ....100 
4.3.3 Targeted Peptide Quantification ......................................................................106 
4.4 Conclusion ..............................................................................................................112 
4.5 Acknowledgements ................................................................................................112 
Chapter 5 : Conclusion.....................................................................................................114 
5.1 Realization of Research Objectives ........................................................................115 
5.1.1 Targeted Tissue Proteomic through CITP/CZE Based Multidimensional 
Platform 115 
5.1.2 Online CITP/CZE-ESI-SRM MS for Targeted Quantification .......................116 
5.2 Future Research Directions ....................................................................................117 
5.2.1 Application in Real Samples with High Complexity ......................................117 
5.2.2 Incorporation of LC based separation for multidimensional separation 
platform 118 






List of Figures 
Figure 1.1 Laser capture microdissection (LCM) illustrating cell isolation method (left); 
Real view of LCM instrument (upper right) and tissue sections before and after LCM 
(bottom right). ......................................................................................................................6 
Figure 1.2 Schematic of absolute quantification using SRM-MS in combination with 
isotope-labeled internal standard .......................................................................................10 
Figure 1.3 Schematic view of the CITP-based electrokinetic stacking mechanism. .........17 
Figure 1.4 Schematic of on-line ntegration of CITP with nano-RPLC for achieving 
selective analyte enrichment and multidimensional proteome separation. ........................18 
Figure 1.5 Comparison of the coverage in the ERK/MAPK pathway achieved by the 
MuDPIT and CITP proteomic platform. 1 ..........................................................................21 
Figure 1.6 differentially expressed proteins among primary and recurrent ovarian tumors 
in the IL-6 signaling canonical pathway using the Ingenuity SystemTM. 79 .......................22 
Figure 1.7 Schematic of a sheath-flow interface for CE-MS through coaxial sheath-flow 
with sheath gas ...................................................................................................................25 
Figure 2.1 Demonstration of selective tissue microdissection of a relatively pure 
population of tumor cells. ..................................................................................................39 
Figure 2.2 The Venn diagrams comparing (A) total proteins and (B) membrane proteins 
identified from grade II astrocytoma (black), grade III anaplastic astrocytoma (blue), and 
grade IV GBM (red)...........................................................................................................44 
Figure 2.3 Pearson correlation coefficient plot of two proteomic runs analyzing adjacent 
GBM sections of the same tissue specimen. ......................................................................47 
Figure 2.4 Volcano plots of (a) grade IV vs. grade III and (b) grade IV vs. grade II. .......48 
Figure 2.5 Unsupervised hierarchical clustering of forty proteins with the most significant 
t-test values resulting from the comparison of grade III and grade IV astrocytomas. .......49 
Figure 2.6 Top functional pathways constructed from the up-regulated GBM proteome 
dataset using the Ingenuity Pathway AnalysisTM. ............................................................51 
Figure 2.7 An up-regulated GBM protein network containing EGFR and Erbb2. ............54 
Figure 2.8 IQGAP1 expression relative to correlation with astrocytoma grade. ...............57 
Figure 2.9 Scoring of TMA with IHC staining of IQGAP1. .............................................58 
Figure 3.1 Graph of CITP/CZE-ESI-QQQ MS setup used in this study. ..........................67 
v 
 
Figure 3.2 Comparison of CITP/CZE and CZE with different sample loading time using 
BSA digest for selected ion m/z 432.3 [VGTR+H]+. ........................................................73 
Figure 3.3 Sample loading capacity optimization. .............................................................74 
Figure 3.4 Peak area calibration curve, for selected BSA peptide ions of m/z 582.5 
[LVNELTEFAK+2H]2+ .....................................................................................................77 
Figure 3.5 Different ion focusing effect observed for different ions. ................................78 
Figure 3.6 Calibration curve of CITP/CZE-ESI-SRM MS quantitation of Angiotensin II 
(A) and Kemptide (B) and EIC from three replicate SRM measurements at 50 pM sample 
concentration (right). ..........................................................................................................82 
Figure 4.1 Schematic of CITP/CZE-nanoESI-QQQ MS setup used in this study. Lower 
part shows a detailed view of the sheathless interface design (not to scale). ....................92 
Figure 4.2 Measured liquid flow rate as a function of gas pressure applied at the inlet of 
the CITP/CZE separation capillary. ...................................................................................95 
Figure 4.3 Extracted ion chromatograms (EICs) of CITP/CZE separations using a 10 
peptide mixture solution at different sample loading volumes. .........................................98 
Figure 4.4 EICs for kemptide from A) CZE-MS and B) CITP/CZE-MS analyses. ........101 
Figure 4.5 Sensitivity comparison of kemptide EIC using interfaces with different sizes103 
Figure 4.6 SRM TIC of CITP/CZE separations at different flow rates. ..........................104 
Figure 4.7 CITP/CZE peak elution time (A), peak width (B) and peak intensity (C) at 
different flow rates. ..........................................................................................................107 
Figure 4.8 CITP/CZE-SRM MS quantification of kemptide (A) and angiotensin II (B) in 





List of Tables 
Table 2-1 Number of Distinct Proteins Identified from Duplicated Runs for Each 
Microdissected Astrocytoma Tissue Specimen .................................................................43 
Table 2-2 Proteins Related to Cancer Function and Up-Regulated in GBM .....................52 
Table 3-1 SRM transitions and parameters used in this study ...........................................70 
Table 3-2 CV from triplicate SRM MS analyses of Kemptide and Angiotensin II at each 
concentration for selected SRM transitions. ......................................................................83 
Table 4-1 SRM transitions and parameters used in this study. ..........................................99 
Table 4-2 Peak capacity under different flow rates. ........................................................108 
Table 4-3 Retention time deviation of triplicate CITP/CZE-SRM MS analyses at different 





List of Abbreviations 
ApoA1 Apolipoprotein A-1  
AUC Area Under Curve  
BGE Background Electrolyte  
BPC Base Peak Ion Chromatograms 
BSA Bovine Serum Albumin  
CE Capillary Electrophoresis  
CE-MS Capillary Electrophoresis-Mass Spectrometry  
CITP Capillary Isotachophoresis  
CZE Capillary Zone Electrophoresis  
CV Coefficient of Variation  
CIEF Combined Capillary Isoelectric Focusing  
DIGE Difference Gel Electrophoresis  
DTT Dithiothreitol  
ESI-MS Electrospray Ionization  
ELISA Enzyme-Linked Immunosorbent Assay  
EIC Extracted Ion Chromatograms  
FDRs False Discovery Rates  
GBM Glioblastoma  
HCV Hepatitis C Virus  
HCC Hepatocellular Carcinoma  
HER2 Human Epidermal Growth Factor Receptor 2  
IHC Immunohistochemistry  
viii 
 
IAM Iodoacetamide  
iTRAQ Isobaric Tag For Relative And Absolute Quantitation  
LCM Laser-Capture Microdissection  
LE Leading Electrolyte  
LOD Limit of Detection  
LOQ Limit of Quantitation  
LTQ Linear Ion-Trap Mass Spectrometer  
LC-MS Liquid Chromatography-Mass Spectrometry  
MALDI-MS Matrix Assisted Laser Desorption/Ionization Mass 
Spectrometry  
MALDI-TOF/TOF Matrix-Assisted Laser Desorption/Ionization-Time of 
Flight/Time of Flight  
MS Mass Spectrometry 
MuDPIT Multidimensional Protein Identification Technique  
nano-RPLC Nano-Reversed Phase Liquid Chromatography  
OMSSA Open Mass Spectrometry Search Algorithm  
FFPE Paraffin-Embedded  
PSA Prostate-Specific Antigen  
RT Retention Time  
SRM Selected Reaction Monitoring  
S/N Signal to Noise Ratio  
SPE Solid-Phase Extraction  
SCX Strong Cation-Exchange  
ix 
 
SELDI-MS Surface Enhanced Laser Desorption/Ionization-Mass 
Spectrometry  
TMA Tissue Microarray  
HF Hydrofluoric Acid  
1 
 
Chapter 1 : Introduction 
Section 1.3 Capillary electrophoresis in biomarker discovery and recent advances is reproduced 
with permission from Wang, C.; Fang, X.; Lee, C.S.: Recent advances in capillary 
electrophoresis-based proteomic techniques for biomarker discovery. Methods Mol Biol  2013; 
984,1-12.  
Copyright 2013 Springer Science 
 
1.1 Introduction 
Despite the continued progress of drug development and surgery procedure, cancer has 
still remained to be a leading cause of mortality in both developed and developing 
countries. In order to combat cancer and other high mortality diseases, researchers have 
been actively looking for biomolecules in tissus and biofluids with diagnostic, predictive 
and prognostic functions.  Such biomolecules termed as biomarkers are defined as 
“biological molecules found in blood, other body fluids, or tissues that are a sign of a 
normal or abnormal process or of a condition or disease” by the National Cancer 
Institute. 
This definition only speaks of the diagnostic function of biomarker while successful 
biomarkers actually can do so much more in patient care. Biomarkers can be used to 
predict the probability of the occurrence or recurrence of cancers in certain individuals or 
populations; biomarkers can be utilized to estimate the likely outcome of the disease and 
develop the best therapeutic method (personalized medication); biomarkers can also be 
employed to monitor and assess the effectiveness and adverse effects of a treatment. 
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Some well-known and widely applied biomarkers are prostate-specific antigen (PSA), 
human epidermal growth factor receptor 2 (HER2).  
PSA is a diagnostic biomarker used in large scope screening for early detection and 
treatment of prostate cancer which is normally associated with elevated PSA level in 
urine or blood . HER2 on the other hand, is a predictive and prognostic biomarker for 
breast cancer. HER2 testing is performed in breast cancer patients to assess the prognosis 
and the suitability of trastazumab therapy as trastazumab is restricted to HER-2 positive 
individuals due to the severe side effect and low efficacy in HER-2 negative patients. 
Currently, the number of biomarkers approved by the Food and Drug Administration is 
still very limited due to the lengthy, costly development procedure as well as the 
demanding technical requirements for biomarker discovery and verification. 
Mass Spectrometry (MS) has played a critical role in biomarker discovery in the  recent 
years. Though this technology itself is only 20-30 years old, it has been evolving at a 
magnificent speed and has become a very effective technique for biomarker discovery 
and verification. Reproducible and comprehensive assessment of the complex human 
proteome has been achieved; thousands of proteins as well as various types of post-
translational modifications can be confidently identified in a single analysis. The 
development of MS based assays has brought revolution in human proteome research and 
has led to an exponential increase in the number of candidate biomarkers for specific 
diseases. Most recently,  potential biomarkers for pancreatic cancer1-5, lung cancer6-12, 
prostate cancer13-15, breast cancer16-22, brain cancer23-25 and other high influence cancers 
have been reported by various groups using different types of MS technologies like 
matrix assisted laser desorption ionization-mass spectrometry (MALDI-MS), surface 
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enhanced laser desorption ionization-mass spectrometry (SELDI-MS), liquid 
chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass 
spectrometry (CE-MS) for protein detection in both intact and digested forms. 
Initially, proteomic studies using MS are perofrmed with their primary goal to identify as 
many proteins as possible. As technology evolves, researchers realized that this so called 
global proteomics method is not always effective to solve specific biological problems 
such as specific disease related biomarker discovery and verification. Therefore, 
scientists have knowingly started to shift the focus from global discovery to targeted 
proteomics that is more closely related to their specific problems. Initially, the idea of MS 
based targeted proteomics was limited to the targeted quantification of a predefined set of 
analytes. It has since evolved into a hypothesis-driven methodology effectivly applied to 
much broad biological applications. Targeted proteome experiments are in general 
designed to identify and quantify a set of targeted proteins that show significant 
abundance change and/or post translational modification under different biological 
conditions or disease states.  
1.2 Targeted proteomics  
1.2.1 Targeted proteomics study  of homogenous tumor cells 
In biomarker discovery, plasma is the most studied sample type because it is easily 
accessible with minimally invasive, fast and cost-effective clinical collection procedure.  
Plasma biomarker is also highly desirable for clinical screening test in general population 
for early detection of potential disease.  However, extensive studies on plasma samples 
have revealed several barriers that pose enormous analytical challenge in identifying 
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cancer-related biomarker in plasma. Firstly, plasma composition varies significantly 
among different persons and over the time; Secondly, plasma proteome is extremely 
complex and heavily influenced by individual organs in the circulation.  
Still, the most challenging problem is the identification/quantification of analytes that 
exist in extremely low concentrations in the complex matrix of plasma which often 
exceeds the achievable sensitivity of current techniques. These analytes are typically 
small proteins or fragments that shed or secreted by the tissue at the primary site of 
cancer into the circulation with significant dilution. This situation is further complicated 
by endogenous high abundance proteins which constitute 99% of the total protein mass in 
plasma. The presence of these very high abundance proteins heavily interferes with the 
ability to detect disease-specific proteins whose concentrations are at least 10 million 
times less abundant. The dynamic range of protein concentration in human plasma 
samples can reach up to 12 orders of magnitude. Tissue sample2,19,26 or proximal fluids27-
33 like cerebrospinal fluid, seminal plasma, and tumor interstitial fluids are better 
alternatives, in which tumor-derived proteins are present at significantly high local 
concentration to be detected by conventional mass spectrometers.  
Among all the different types of samples studied, tumor tissue from the primary site 
provides the best chance to identify rare disease-specific biomarkers since less 
interference and dilution is involved. Moreover, in tumor tissue studies, related-genomic 
information can be obtained to increase confidence in the discovery and verification of a 
particular candidate biomarker through corroborating information between genomic and 
proteomic data34.  
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One important factor to be considered for tissue biomarker studies is the heterogeneity of 
the cells in constituting tumor tissues which includes fibroblasts, nerve cells, endothelial 
cells, infiltrating lymphocytes and epithelial cells. While the complexity of tumor tissue 
is greatly reduced comparing with plasma samples, these different groups of cells can still 
be sources of interfering and misleading information. Laser-capture microdissection 
(LCM) (Figure 1.1) is a method that permits isolation and procuring of homogeneous cell 
types from a tissue under microscopic visualization. Cells are sorted based on their 
histomorphology after a specific staining that enables accurate isolation of malignant, 
premalignant, and normal cells  from a tumor tissue35.  
LCM allows targeted analysis on specific cell populations to obtain disease-specific 
information. Studies have shown that targeted proteomics facilitated by LCM enables 
direct comparison of protein profiles between the normal and tumor cell types for a more 
accurate molecular profile and a valid approach for better understanding of molecular 
mechanisms36-38. For example, Karring and co-workers have applied LCM technology on 
corneal samples to isolate corneal amyloid deposits and the surrounding corneal stroma 










Figure 1.1 Laser capture microdissection (LCM) illustrating cell isolation (left); 
Real view of LCM instrument (upper right) and tissue sections before and after 
LCM (bottom right). 
In LCM, a cap coated with thermo labil film is used and placed in contact with stained 
tissue section. The cell selection is performed through microscopic visualization. A 
focused laser beam is then utilized to generate localized melting of the the film so that the 
underlying cells become fused to the cap and get selectively removed when the cap is 
lifted. The stained tissue biopies before LCM and the isolated cells after LCM 




Sugihara et al. have used LCM to isolate tumor cells from ulcer floor, central area, and 
invasive front and compare against normal colorectal epithelial cells to examine the intra-
tumor heterogeneity in colorectal cancer. They discovered that though the overall 
proteome is not statistically different among tumors cells from different locations, the 
proteins that are differently expressed between normal and tumor cells are found to be 
associated with different functions such as stress response in ulcer floor, glucose 
metabolism in central area and mitochondria-mediated apoptosis in invasive front, 
indicating effects of tissue microenvironment on tumor cells. Their results suggest that 
tissue localization should be taken into consideration in sampling process and well 
defined targeting is critical in obtaining meaningful and enlightening information.  
1.2.2 Targeted quantification through selected reaction monitoring (SRM) MS 
Once biomarker candidates are recognized, the next key step is to validate the specificity, 
sensitivity and reproducibility of the biomarkers in a large cohort of samples. There is 
very distinct difference between analysis of proteins at the discovery and validation 
stages. In discovery stage, relative change in protein expression level between samples is 
measured with low stringency required. In contrast, accurate absolute quantification of 
potential biomarkers has to be achieved in validation phase in order to differentiate 
normal and disease samples with a high confidence in clinical application.  
Immunoassay, such as enzyme-linked immunosorbent assay (ELISA), has been an 
effective tool for candidate biomarker quantification with an excellent sensitivity and 
specificity. However, developing individual ELISA assays for a large number of 
biomarker candidates is very time consuming and expensive, and thus impractical. 
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Selective reaction monitoring (SRM)-MS based assay can be used to relieve the 
bottleneck in the biomarker pipeline presented by immunoassay. The SRM-MS 
technology has recently been adapted for targeted quantification of candidate biomarkers 
using stable-isotope labeled peptide surrogates, and has become a gold standard in MS 
based quantification technologies. 
SRM-MS is usually performed using a triple quadrupole mass spectrometers because 
their short duty cycles. As illustrated in Figure 1.2 below, in SRM-MS analysis, precursor 
ion with specific m/z is selected in the first quadrupole (Q1), then fragmented in Q2 and 
the optimum fragment ions/product ions are then monitored using Q3.  The pair of 
selected precursor ion m/z and product ion m/z is termed a ‘transition’. Through the 
combination of isolating precursor peptide ions within a narrow mass window in Q1 and 
monitoring product ions corresponding to the specific precursor ions in Q3, outstanding 
sensitivity and specificity is achieved. Typically, 3-5 transitions for each targeted peptide 
and 3-5 peptides per protein are used in SRM-MS analysis. The  absolute abundance for 
each targeted peptide is calculated based on the comparison against the MS intensity of 
the isotope labeled counterparts spiked into the sample with known concentration40. 
Addona et al41 conducted systematic assessment of the transferability and reproducibility 
of SRM-MS based targeted assay at eight different laboratories using a three-phase study. 
This three-phase study sequentially introduced additional source of variability from phase 
I to III in both sample preparation and instrument analyses while the SRM assay 
development was configured at a single site and kept consistent across all the 
laboratories. This study demonstrated the excellent inter- and intra-laboratory 
reproducibility of SRM-MS assay even in a highly complex matrix such as plasma. This 
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study also helps established some baseline parameters for SRM-MS based assay using 
isotope labeled internal standards for biomarker verification in complex biological 
matrix. Overall, this invaluable study provided insightful evaluation of SRM-MS 
technology, made suggestions on ways to minimize experimental variations and served 
guidance for future development and application. A recent study by Prakash et al42 took a 
step further and analyzed the reproducibility of SRM-MS assay with various upfront 
enrichment strategies and different types of clinical samples across several laboratories. 
Again, reproducible results were demonstrated, proving the feasibility of SRM-MS based 
assay to verify biomarker at low abundance in clinical specimens. 
Mustafa et al.43 discovered and confirmed the down regulation of ApoA1 in hepatitis C 
virus (HCV) patients as compared to ApoA1 in hepatocellular carcinoma (HCC) patients 
by 2-dimensional difference gel electrophoresis (DIGE)-MALDI/MS/MS and  SRM-MS 
assay, respectively. Heavy 18O labeled internal standards were used for absolute 
quantification. Their study demonstrated the confidence of SRM assay for biomarker 
verification and reported ApoA1 as a candidate biomarker for HCC.  
Everley et al.44 in Dr. Gygi’s lab recently presented a work on multiplexed targeted 
quantitation to improve the throughput of SRM assay in order to apply SRM-MS assay 
for high-throughput screening, clinical diagnositic and biomarker verification on large 
cohorts of samples. They utilized isobaric tag for relative and absolute quantitation 
(iTRAQ) along with two novel 6-plex isobaric tags in combination with three mass 
































Figure 1.2 Schematic of absolute quantification using SRM-MS in combination with 
isotope-labeled internal standard 
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1.3 Capillary electrophoresis in biomarker discovery and recent advances 
The inherent disadvantage of biomarker dilution in biofluids such as serum/plasma, urine, 
and saliva has directed increasing attention at using tissues from the primary site of 
pathology for the discovery of disease biomarkers. It has been well accepted that 
molecular profiling in tumor lesion is fundamental to understand the molecular etiology 
in tumor development. However, in the absence of PCR-like protein amplification, 
comprehensive analysis of protein expression within small populations of tumor cells 
microdissected from limited tissue samples represents a significantly technological 
challenging. Especially the size of human tissue biopsies are getting increasingly smaller 
as a result of advent of minimally-invasive methods and early detection and treatment of 
lesions. In addition to sample amount constraints, the greatest bioanlytical challenge 
facing comprehensive proteomic analysis of microdissected tumor specimens is related to 
the large variation of protein relative abundances, particularly in the identification of low 
abundance proteins. For example, the protein concentration dynamics range from 106-
fold in cells to 1012-fold in blood45, 46. A more effective proteomic technology is critically 
needed to efficiently handle the small sample amount as well as to enable comprehensive 
and comparative studies of protein profiles that will have diagnostic and therapeutic 
relevance. 
Capillary electrophoresis (CE) has been known for its high separation efficiency, high 
resolving power and its broad utility in various analyses from small molecules like 
metabolites to large intact proteins. In addition, CE is intrinsically compatible with small 
sample amount which makes it an attracting technique in analyzing clinical samples. 
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Over the years, CE has evolved into an important technology for biological sample 
analysis in biomarker studies through coupling with MS detection.  
1.3.1 Single Dimension Capillary Electrophoretic Separation Coupled With Mass 
Spectrometry 
Capillary zone electrophoresis (CZE) resolves proteins and peptides based on their 
differences in electrophoretic mobility which is a function of the charge-to-size ratio. Due 
to its high throughput and excellent resolving power, the coupling of CZE with 
electrospray ionization-mass spectrometry (ESI-MS) has been employed for the analysis 
of low molecular weight proteins (below 20 kDa) and peptides for the discovery of 
biomarkers in human urine. Samples were investigated from patients suffering from a 
variety of diseases including ureteropelvic junction obstruction47, cancer48, 49, 50, 
vasculitis51, coronary artery diseases52, 53, 54, kidney diseases55, 56, 57, lithium-induced 
nephropathy58, graft-versus-host disease59, and diabetes54.  
The CZE-ESI-MS data were presented by plotting the measured molecular masses 
against their migration times and compared among healthy and diseased patients. Known 
and potential new urine biomarkers have been identified using subsequent MS/MS 
experiments60, 61. Although a variety of different proteins/peptides were discovered, most 
of these putative markers are derived from the most abundant proteins in the body such as 
collagen - mainly type I, II, and III, albumin, -2-macroglobulin, and uromodulin62. 
In addition to human urine, single dimension CZE separation was also employed for the 
proteomic analysis of other body fluids such as human plasma63 and ventricular 
cerebrospinal fluid64. Potential biomarkers of vascular disease in plasma from patients 
with chronic kidney disease were discovered by CZE-ESI-MS63. In contrast to the use of 
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ESI-MS or ESI-MS/MS for the detection and identification of protein and peptide 
markers, off-line matrix-assisted laser desorption/ionization-time of flight/time of flight 
(MALDI-TOF/TOF) MS coupled with iTRAQ labeling65 was employed for multiplexed 
quantification of proteins in human ventricular cerebrospinal fluid samples collected from 
a patient with traumatic brain injury during patient recovery64.      
1.3.2 Capillary Electrophoretic-Based Multidimensional Separations Coupled With Mass 
Spectrometry 
1.3.2.1 Capillary Isoelectric Focusing (CIEF) 
Combined CIEF/nano-reversed phase liquid chromatography (nano-RPLC) separations 
have been developed and demonstrated to achieve comprehensive and ultrasensitive 
analysis of minute protein digests extracted from microdissected tissue specimens66, 67. In 
addition to protein identification, the capabilities of the CIEF-based proteomic platform 
coupled with the spectral counting approach68, 69 to confidently and reproducibly quantify 
proteins and changes in protein expression levels among samples were evaluated by the 
measurements of coefficient of variation (CV) and the Pearson correlation coefficient70. 
Analytical reproducibility of relative protein abundance was determined to exhibit a 
Pearson R2 value greater than 0.99 and a CV of 14.1%. The platform was capable of 
measuring changes in protein expression as low as 1.5 fold with confidence as 
determined by t-test followed by Benjamini-Hochberg multiple testing adjustments. 
The protein expression profiles from two distinct ovarian endometrioid tumor-derived 
cell lines have been compared using CIEF-based multidimensional separations coupled 
with ESI-MS/MS 71. Differentially expressed proteins were further investigated by 
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ingenuity pathway analysis to reveal their association with important biological functions 
and signaling pathways such as the P13K/AKT pathway. The results illustrated the utility 
of high throughput proteomic profiling combined with bioinformatic tools to provide 
insights into the mechanisms of deregulation in neoplastic cells.   
In addition to CIEF, microscale in solution IEF was employed as the first separation 
dimension for the fractionation of intact proteins, followed by tryptic digestion and 
subsequent CZE peptide separation coupled off-line to MALDI-TOF/TOF MS72. The 
platform was used for the analysis of human follicular fluid with clinical implication. A 
total of 73 unique proteins were identified, including mostly acute phase proteins and 
proteins that are known to be extensively involved in follicular development.  
1.3.2.2 Transient capillary Isotachophoresis/Capillary Zone Electrophoresis 
In contrast to universally enriching all analytes by a similar degree, the result of the 
capillary isotachophoresis (CITP) stacking process is that major components may be 
diluted, but trace compounds are concentrated73. CITP employs a discontinuous 
electrolyte consisting of leading electrolyte such as ammonium acetate which has a 
mobility greater than any of the sample components and a terminating electrolyte such as 
acetic acid. The stacking and separation of analytes occurred in the boundary region 
between the sample and leading or terminating electrolytes under the application of an 
electric field (Figure 1.3). Under the influence of constant current across the separation 
capillary generated by applied voltage, the sections containing the high-mobility leading 
electrolyte would therefore experience lower and higher electric fields, respectively. The 
analyte ions in the sample zone initially migrating at fast speed induced by high electric 
field are slowed down and stacked at the interface of the sample and leading electrolyte 
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sections. Stable boundaries formed between analytes and analytes are aligned according 
on their relative mobility. The concentration of the analytes after focusing is mainly 
determined by the concentration of the leading electrolyte. As a result, the CITP stacking 
process can selectively enrich low abundance analytes according to their original 
concentration relative to LE concentrationg. Furthermore, CITP offers the benefits of 
speed and straightforward manipulation/switching between the stacking and separation 
modes in transient CITP/CZE. Transient CITP/CZE further provides seamless 
combination with nano-RPLC (Figure 1.3) as two highly resolving and completely 
orthogonal separation techniques critically needed for analyzing complex proteomes74, 75. 
While CITP has been widely used for analyte pre-concentration prior to electrophoretic 
separation, the application of CITP to selectively enrich trace amounts of 
proteins/peptides in complex proteome mixtures represents a completely untapped 
avenue in proteomic technology development. As illustrated by Fang and co-workers for 
the analysis of human saliva and mouse brain mitochondrial proteomes74, 75, the 
application of CITP to selectively enrich trace amounts of proteins in targeted cells 
significantly augments the ability to perform ultrasensitive and global proteomic analysis, 
particularly toward the identification of low abundance proteins.  
The ultrahigh resolving power of transient CITP/CZE as the first separation dimension 
has been demonstrated by significantly low peptide fraction overlapping for the analysis 
of protein expression within glioblastoma multiforme derived cancer stem cells76. 
Approximately 89% of distinct peptides were identified in only a single CITP fraction. In 
contrast, a high degree of peptide overlapping in strong cation-exchange (SCX) 
chromatography, as the first separation dimension of the multidimensional protein 
16 
 
identification technique (MuDPIT)77, was observed with at least 40% of carry over 
peptides that were identified in previous salt gradients. A high degree of peptide overlap 
in SCX unnecessarily burdens the subsequent nano-RPLC separation and greatly reduce 
the overall peak capacity in a multidimensional separation system. The presence of high 
abundance peptides in multiple SCX fractions further negatively impacts the selection of 




Figure 1.3 Schematic view of the CITP-based electrokinetic stacking mechanism. 
C: concentration; E: applied electric field strength; LE: leading electrolyte; TE: 
terminating electrolyte; µ: mobility; ν: velocity. 
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Figure 1.4 Schematic of on-line ntegration of CITP with nano-RPLC for achieving 
selective analyte enrichment and multidimensional proteome separation. 
Solid and dashed lines represent the flow paths for the loading of CITP fractions and the 
injection of fractions into a nano-RPLC column, respectively.  
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For the evaluation of overall cancer stem cells proteome performance76, the CITP 
proteomic platform demonstrated significant enhancements in total peptide, distinct 
peptide, and distinct protein identifications over a corresponding MuDPIT run by 119%, 
192%, and 79%, respectively. The CITP proteomic technology, equipped with selective 
analyte enrichment and ultrahigh resolving power, further accomplished superior 
coverage in key pathways than that of the MuDPIT. For example, many biologically 
relevant proteins, including MKP, the Raf family, and Src in the ERK/MAPK pathway, 
were only identified by the CITP technology (Figure 1.4). 
Jinawath and co-workers78 applied the CITP proteomic technology to perform 
comparative proteomic analysis of paired primary and recurrent post-chemotherapy 
ovarian high grade serous carcinomas from nine ovarian cancer patients. A total of 
30,884 distinct peptides were identified using a 0.1% false discovery rate for total peptide 
identifications, leading to the identification of 5,063 non-redundant proteins from the 
SwissProt human database. Of the proteins identified from primary ovarian tumor cells, a 
number of them, including merlin, ezrin, moesin79, selenium binding protein 180, 
glutathione-S-transferase, epidermal growth factor receptor, E-cadherin, - and -
catenins81, -tubulin, ubiquitin carboxyl-terminal hydrolase, glyoxalase 1, F-actin  
subunit, and cofilin82, have been reported to be present in ovarian epithelial cells. 
Furthermore, the increase in ovarian cancer proteome coverage, attributed to CITP-based 
selective analyte enrichment, allowed the application of protein network and pathway 
analysis toward the discovery of ovarian carcinoma biomarkers. For example, low 
abundance proteins such as cytokine IL-6 and signal transducer and activator of 
transcription 3 (STAT3), as well as many other proteins known to participate in the IL-6 
signaling pathway, have been identified and compared for their expression levels within 
primary and recurrent ovarian tumors (Fig. 1.6). Both STAT3 and IL-6 were found to be 
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over-expressed in the recurrent tumor cells. As supported by recent in vitro studies of 
ovarian83 and non-small cell lung84 cancer cell lines, the STAT3 pathway plays a 
significant role in the development of high-grade ovarian cancer and the drug-resistant 
ovarian cancer. STAT3 can be activated by various protein tyrosine kinases including 
epidermal growth factor receptor, interleukin, and IFN ligands. Inhibition of the STAT3 
pathway has been shown to enhance paclitaxel-induced apoptosis. In addition, IL-6 
expression was found to be associated with the generation of drug resistance. The 
comparative proteomic results have further identified RELA which is the p65 subunit of 
the NF-B complex (Figure 1.6). p65 was over-expressed more than 3 folds in recurrent 
tumors as compared to the primary tumors. The NF-B/RELA family of transcription 
factors is one of the most important and well-characterized signaling pathways in both 
normal and pathological conditions. It controls a variety of cellular functions including 
inflammatory and immune responses, cell growth and survival, and drug resistance to 
several chemotherapeutic agents85.  
1.4 CE-MS interface development 
CE has been proven to be a highly efficient separation technique and is considered a 
powerful technique for the analysis of biological samples. In addition, it’s relatively 
inexpensive and it is ideal in handling small amount of sample and reagent. As a result, 
online coupling of CE with MS provides an intriguing and attractive solution to combine 





Figure 1.5 Comparison of the coverage in the ERK/MAPK pathway achieved by the 
MuDPIT and CITP proteomic platform. 1 
Red: proteins only identified by CITP; blue: proteins identified by CITP with higher 
confidence (larger numbers of spectral counts and distinct peptide identifications per 
protein) than that achieved by MuDPIT; green: proteins identified by both CITP and 





Figure 1.6 differentially expressed proteins among primary and recurrent ovarian 




The coupling of CE to MS is not straightforward because of the requirement of a closed 
electric circuit that provides different electric fields for  capillary electrophoresis 
separation and electrospray ionization (ESI). After the first online CE-ESI-MS introduced 
in 1987 using sheathless design via metalized ESI emitter tip86, a variety of designs of 
both sheathless and sheath liquid interfaces have been proposed to maximize the coupling 
efficiency of CE-MS. By far, sheath liquid interfaces employing a sheath-flow or make-
up liquid is more commonly used than sheathless interfaces, especially in commercial 
applications, due to a variety of reasons including issues of stability, longevity and ease 
of use. There lies a great compromise between interfaces with optimal performances and 
those practical for commercial platforms. Those interfaces offering the lowest detection 
limit have been among the most fragile thus impractical for commercial use. As this 
hyphenated technique continuously gains popularity as a  promising alternative to LC-
MS for proteomic, metabolomics and pharmaceutical studies, active efforts have been 
devoted  to reliably and optimally couple CE separation with MS.  
1.4.1 Sheathliquid Interfaces 
Sheathliquid interfaces can be achieved through the use of additional flow or liquid that 
mixes with the CE effluent to establish electrical contact between an electrode and the 
background electrolyte to accomplish CE separation as well as stable electrospray 
operation. Coaxial sheath-liquid is the most common interface of this type which was 
first introduced by Smith et al in 198887 (Figure 1.7) which is configured by a continuous 
flow being delivered through a tube of larger diameter in a coaxial setting and merging 
with the CE effluent at the capillary outlet. Another function of the sheath flow is to 
modify the composition of the CE electrolyte to optimize the ESI process, so the sheath-
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liquid is usually composed of a mixture of water and organic modifier containing volatile 
acid. A gas flow is applied through a third coaxial capillary to neumatically assist 
electrospray process as well as facilitate the charged droplet desolvation. A rather firm 
electric contact is achieved using this co-axial sheath flow design making it a reliable CE-
MS interface. This type of interface is commonly adapted by most commercial CE 
instruments. However, this interface usually requires rather high operating flow rate of 
the sheath-liquid ranging from 1 to 10 µL/min while CE separation is operated at 100 
nL/min. Thus, the sheath-liquid are usually several times or even one order of magnitude 
higher than the intrinsic CE flow which causes significant analyte dilution as well as 
greatly compromised ionization efficiency, limiting the achievable detection sensitivity of 
the CE-MS platform. Additionally, the sheath flow is reported to influence the peak 
efficiency by introducing a parabolic flow and reduces the achievable peak efficiency88,89. 
Overall, the sheath-flow interface is considered a robust system and the availability of 
commercial sprayers enables it to become the most commonly used interface.  
Alternative to using a straight tube to deliver sheath liquid, sheath-flow interfaces can 
also be achieved using a tapered tube with the CE capillary sitting slightly back from the 
tip. The advantage of this design is that the mixing of the CE effluent and sheath liquid is 
more sufficient which leads to improved electric contact and ESI stability. Also sheath 
liquid is able to operate at lower flow rate because of the smaller tip aperture from the 





Figure 1.7 Schematic of a sheath-flow interface for CE-MS through coaxial sheath-
flow with sheath gas 
Electric contact is achieved through the mixing of sheath liquid with CE eluent to drive 
both CE separation and electrospray ionization processes. Additional sheath gas is used 







Recently, Dovichi’s90 group published a nanospray sheath-flow interface design using 
tapered sheath flow tube for electric contact and electrokinetic flow to drive both the 
separation and the electrospray91. In this design, the separation capillary is placed inside a 
tapered glass emitter and ESI voltage is applied in the sheath liquid reservoir. They 
performed large scale E. coli proteome analysis using this sheath flow CZE-ESI-MS 
platform after simple fractionation using solid-phase extraction (SPE) column. With less 
than 1 µg sample loading, they were able to identify 4902 peptides and 871 protein 
groups, which was even better than other three published work with more than 4 times 
the sample loading analyzed using RPLC based separation platforms92-94. This work also 
reported the largest proteome dataset using CE-MS/MS to date, demonstrating CZE-ESI-
MS/MS as a useful tool for proteomic analysis. 
The design from Dovichi’s group can also be categorized as liquid-junction interface 
which is another approach to couple CE and MS. The liquid-junction interface was first 
reported by Henion and co-workers95 where a small gap was used to separate CE 
capillary and ESI emitter to allow mixing between the CE eluent and sheath-liquid before 
entering the ESI emitter to complete the electric circuit. One advantage and 
distinguishable feature of liquid-junction designs from sheath-flow interfaces is the flow 
rates of the sheath-liquid are typically in the range of 60-200 nl/min, which significantly 
reduces the dilution factor while retaining the solution-modifying benefits. 
Up till now, the liquid junction interfacing has not been widely applied in proteomic 
studies. However, the results obtained so far are promising and intriguing for further 
development and applications. 
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1.4.2 Sheathless interfaces 
Sheathless interfacing is no doubt the most straightforward and ideal way for coupling 
CE with MS as no dilution is involved and the intrinsically low-flow rate operation of CE 
can be optimally reserved. Since nanoESI improves ionization efficiency96,97 and is 
friendlier towards hydrophilic compounds98 and aqueous solution96, the employment of 
sheathless CE-MS usually provides better flexibility in separation buffers as well as more 
sensitive and comprehensive detection. Various sheathless designs have been proposed in 
attempts to achieve robust and stable nanoESI operation.99 To name a few, ideas like 
tapered emitter coated with metal,73,100 electrically conductive polymer101 or carbon,102 or 
insertion of metal wire in the CE capillary103 as well as connecting the separation 
capillary with stainless tubing104 have all been proposed. While most of these interfaces 
have been proven to provide very high performances, there has been major bottlenecks in 
concern of dead volume dilution, electrolysis interference, manufacturing complexity, 
low mechanical duration, poor reproducibility, flow disturbance and costly. 
Sheathless interface via a porous tip reported by Moini seems to provide a better 
alternative105. The porous emitter approach is very straightforward and does not require 
any fluidic connection or material deposition. The fabrication of porous emitter is 
achieved through chemically etching a 3 cm portion from one end of the capillary using 
hydrofluoric acid to reduce the wall thickness to 5-10 µm. The thin wall at the emitter 
permits exchange of small ions through the size selective porous interface while 
minimizing the analytes leakage. Part of the porous portion is inserted in a stainless tube 
containing conductive buffer on which electric contact are being made. The relative 
simplicity in this approach provides significant advantage as compared to previous 
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sheathless interfaces. As a result, commercial instrument using this interface is being 
developed by Beckman Coulter and various applications with outstanding performance 
have been reported106-112. Significant improvement of urinary metabolome coverage over 
classical sheath-liquid interface was presented using this sheathless interface110 by 
Ramautar et al.  
The suitability of this sheathless interfacing was also evaluated by the group of Lindner 
where it was compared with nano-RPLC-ESI-MS by analyzing rat testis linker histones 
digests113. They observe a 60% increase in the number of identified peptides with 
sheathless CE-ESI-MS at comparable amounts of sample loading. They also observed 
more identifications in low-molecular weight peptides (usually lower than 1400 Da) by 
CE-ESI-MS as this group of peptides usually interacts poorly with the reverse-phase 
material in LC system. 
With the proven performance on peptides and intact proteins using this porous 
sprayer107,109, Bonvin et al. further evaluated the performance stability of this porous 
sprayer in terms of sensitivity and in analyzing low molecular weight pharmaceutical 
compounds. They carefully studied the operating parameters such as interface positioning 
and fragmentor voltage and source parameters. Methamphetamine, methadone and 
acebutolol were used as model compounds in this study and high sensitivity with LOD at 
5 ng/ml using a single quadrupole MS was demonstrated. 
1.5 Project description 
In order to obtain biomarkers to predict disease behavior and therapeutic response in 
combat with cancer, analyzing techniques and platforms that can overcome the great 
complexity of human proteome and the heterogeneity among different cell types with 
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high efficiency and sensitivity are necessary. Targeted proteomic studies enabled through 
microdissection for homogeneous cell population and targeted quantification through 
SRM MS greatly reduces the sample complexity and improves specificity and sensitivity. 
CITP/CZE’s unique feature of selective enrichment of low abundant analytes works 
ideally to solve the large dynamic range problem for protein abundance in biological 
samples which is one of the greatest challenges in proteomic analysis. Synergetic effort 
of CITP/CZE and targeted proteomic will be able to provide a better methodology for 
biomarker studies in terms of sensitivity, specificity and reproducibility. 
In order to demonstrate the capability of CITP/CZE based targeted proteomics, chapter 2 
described a multidimensional CITP/CZE-nano-RPLC separation platform coupled with 
MS in analyzing homogeneous tumor cell population obtained via LCM from a set of 
human astrocytoma tissues in search of glioblastoma biomarkers. Proteins extracted from 
homogeneous tumor cells from different grades of astrocytoma were fractionated and 
concentrated in CITP/CZE separation in the first dimension and then sequentially loaded 
onto nano-RPLC for additional separation and detected using tandem MS. Comparative 
proteomics among different grades relative to glioblastoma (GBM) was performed and 
the proteins up-regulated in GBM were further analyzed using statistic and biology tools 
in order to derive biological significant and confident information for potential 
glioblastoma specific biomarkers. The ultrahigh resolving power of CTIP/CZE was 
evidenced by the large number of distinct peptide identifications measured from each 
CITP fraction together with the low peptide fraction overlapping among identified 
peptides. Over 3000 proteins were identified while only 177, 120 and 594 proteins were 
uniquely found in grade II, grade III and IV astrocytomas samples respectively, 
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demonstrating high confidence and outstanding reproducibility of proteomic 
measurement performed using CITP. Meanwhile, 650 membrane proteins which count 
for 19% of the total identification represents the most extensive tissue proteomics 
identified so far in human Astrocytoma, also proved the advantage of CITP based 
technology in targeted tissue proteomics. Through the employment of this platform, over 
30 candidate biomarkers of glioblastoma that are highly associated with cancer function 
were discovered. A rigid validation process through immunohistochemistry (IHC) on 
tissue microarray (TMA) was also performed in this study and displayed consistent 
results.   
Starting from chapter 3, a series of effort was devoted into exploring ultrasensitive and 
high throughput targeted quantification platform for biomarker validation. Validation 
phase has been a main bottleneck in the pipeline of biomarker discovery as much more 
rigid criteria and larger sample cohorts are required before a valid biomarker can be 
established and applied into clinical use. Conventional immunology methodology is 
efficient, sensitive and low cost under the premise that the antibody against target 
biomarker candidate already exists. However, in most cases this premise does not stand 
and the development of immunoassay for the relatively large scale of biomarker 
candidates is very time-consuming and costly. LC-MS systems are widely used in 
proteomic studies, but its low throughput is proved to be problematic in biomarker 
validation. In chapter 3, we explored the targeted quantitation platform through online 
CITP/CZE-ESI-SRM MS via liquid junction interface. This work represnts the first effort 
to couple CITP/CZE online with SRM MS to the best of our knowledge. Through the 
combination of large sample loading capacity, analyte enrichment capability of 
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CITP/CZE and the improved sensitivity and selectivity provided by SRM-MS, the 
platform presents outstanding sensitivity and accuracy with a demonstrated LOQ at 50 
pM along with excellent signal to noise ratio (S/N). Systematic optimization and 
evaluation of this platform in terms of sample loading, focusing effect and 
reproducibility. were performed. The results demonstrated that this online CITP/CZE-
ESI-SRM MS is a potential powerful tool for targeted quantification in serve of 
biomarker validation. 
Chapter 4 describes an improved online CITP/CZE-ESI-SRM MS platform by using a 
novel sheathless interface which preserves large sample loading capacity while allows 
low nano-ESI operation. We developed a CE setup consisting of large bore separation 
capillary and a porous small size emitter in order to optimally exert the capability of 
CITP/CZE while eliminating the dilution caused by sheathliquid. We evaluated the 
advantage of this novel interface in terms of increased sample loading. Up to 2.5 µL of 
sample loading capacity was demonstrated with the new CITP/CZE setup while sample 
amount in low nano liter range could only be used in CZE separation. Commercial 
sheathless interface, in order to perform stable ESI, is restricted to small size capillary 
which results in an over 10 times signal intensity loss comparing to our interface. 
Systematic evaluation of resolving power, flow rate and sensitivity was performed which 
demonstrated a stable ESI operation at flow rate as low as 30 µl/min and a LOQ at 10 pM 




Chapter 2 :  Targeted Tissue Proteomic Analysis of Human 
Astrocytomas 
Reproduced with permission from Fang, X.; Wang, C.; Balgley, B. M.; Zhao, K.; Wang, 
W.; He, F.; Weil, R. J.; Lee, C. S.; J Proteome Res 2012, 11, 3937-3946. 
Copyright 2012 Americian Chemical Society 
This work was initially started by Dr. Xueping Fang and was completed as a 
collaborative work by Dr. Fang, me and all the contributing authors between multiple 
research organizations. My work in this project includes tryptic digest sample 
preparation, 2D CITP/CZE-nanoRPLC-ESI-MS/MS analyzing platform 
configuration/optimzation/operation, sample analysis, data collection and interpretation 
as well as data presentation for publication. 
2.1 Introduction 
Gliomas are the most common primary tumors of the brain, with an incidence of about 
30,000 new cases per year in the United States114,115. Most gliomas (> 80%) appear to 
arise from astrocytes, the most abundant type of glial cells, and are known as 
astrocytomas. Astrocytomas are divided into four grades by the World Health 
Organization (WHO). Grade I tumors are histologically benign and may be cured by 
surgical resection; most are found in children. 
The tumors seen in adults are infiltrative and are generally grade II-IV gliomas. Grade II 
tumors exhibit mild cellular proliferation, have moderate cellular pleomorphism, and 
infiltrate the surrounding brain which makes curative resection difficult. Grade III tumors 
are hypercellular, have a higher degree of proliferation, and are malignant and lead to 
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death in two to five years. Grade IV tumors, the glioblastoma (GBM), are exceptionally-
aggressive malignancies with increased mitotic activity, pronounced angiogenesis 
(microvascular proliferation), necrosis, and proliferative rates 3-5 times higher than grade 
III tumors114-116. Patients with GBM have a median survival of 12-15 months with 
aggressive therapy; fewer than 5% will survive more than five years114,117.  
The majority of human gliomas have a set of genetic alterations that cause the loss of 
protein regulation118. Studies based on DNA microarray analyses have indicated that 
GBMs overexpress various gene families related to cell adhesion, motility, invasion, and 
angiogenesis119. Approximately 50% of all GBMs are primary in origin while the other 
half arises secondarily from lower grade tumors. Current models of gliomagenesis 
coincide with the two clinically-recognized forms of GBM, de novo or primary and 
secondary or progression. In primary GBMs, EGFR gene amplifications, often combined 
with gene rearrangements that lead to a constitutively active, truncated receptor, occur in 
GBMs that generally express wild type p53114,117,120,121. In secondary GBMs, progression 
from a low grade to a high grade glioma involves the serial accumulation of genetic 
alterations that inactivate tumor suppressor genes such as p53, p16, Rb, PTEN, or activate 
oncogenes such as MDM2, CDKs 4 and 6114,117. 
While proteomic measurements provide a wealth of information complementary to the 
transcriptomic data, the inherent disadvantage of biomarker dilution in complex 
biological fluids such as cerebrospinal fluids122,123 and serum/plasma124 of GBM patients 
necessitates highly sensitive analytical approaches, often exceeding the dynamic range of 
currently available proteomic platforms. Thus, investigative studies directed at tissues 
obtained from the primary site of pathology currently afford the best opportunity for the 
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discovery of disease biomarkers125-127. For example, Melchior and co-workers128 
employed the shotgun-based multidimensional protein identification technique 
(MuDPIT)77 and a semi-top-down approach involving combined intact protein/peptide 
separations in proteomic studies of whole GBM tissues.   
Still, biologically relevant proteomic data can only be generated if the tissue samples 
investigated consist of homogeneous cell populations, in which no unwanted cells of 
different types and/or development stages obscure the results. For example, SM22, a 
dominant protein in smooth muscle cells, has been widely reported to be abnormally 
expressed in many solid tumors. However, Li and co-workers found that the highly 
expressed SM22 was mainly found in smooth muscle layers, blood vessels, and 
myofibroblasts instead of gastric cancer cells129. While limited two-dimensional 
polyacrylamide gel electrophoresis analyses of microdissected GBM tissues have been 
attempted130-133, these studies required significant manual effort and time to extract 
sufficient levels of protein for analysis, while providing little information on protein 
expression beyond a relatively small number of high abundance proteins.  
Besides sample amount constraints from microdissection-procured tissues134, the large 
variation of protein relative abundances having potential biological significance in 
mammalian systems presents a major analytical challenge for achieving comprehensive 
proteomic studies of clinical specimens. In contrast to universally enriching all analytes 
by a similar degree, the result of the capillary isotachophoresis (CITP) stacking process is 
that major components may be diluted, but trace compounds are concentrated135-137. Such 
selective enhancement toward low abundance proteins drastically reduces the range of 
relative protein abundances and greatly enhances the proteome coverage for the analysis 
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of human saliva and mouse brain mitochondrial proteomes74,75. In this work, we used 
CITP proteomic technology coupled with the label-free spectral counting approach68,69,138 
to compare protein expression profiles within microdissected astrocytoma tissues, 
including WHO grade II, III, and IV astrocytomas. 
2.2 Experimental Section 
2.2.1 Materials and Reagents 
Fused-silica capillaries (50 m i.d./365 m o.d. and 100 m i.d./365 m o.d.) were 
acquired from Polymicro Technologies (Phoenix, AZ). Acetic acid, dithiothreitol (DTT), 
and iodoacetamide (IAM) were obtained from Sigma (St. Louis, MO). Acetonitrile, 
ammonium acetate, hydroxypropyl cellulose (average MW 100,000), 
tris(hydroxymethyl)aminomethane (Tris), and urea were purchased from Fisher Scientific 
(Pittsburgh, PA). Pharmalyte 3-10 was acquired from Amersham Pharmacia Biotech 
(Uppsala, Sweden). Sequencing grade trypsin was obtained from Promega (Madison, 
WI). All solutions were prepared using water purified by a Neu-Ion system (Baltimore, 
MD) equipped with a UV sterilizing lamp and a 0.05 m membrane final filter. 
2.2.2 Tissue Microdissection and Proteomic Sample Preparation 
A set of fresh frozen brain biopsies, including grade II astrocytoma (n = 4), grade III 
anaplastic astrocytoma (n = 3), and grade IV GBM (n = 5), were obtained under an 
Institutional Review Board-approved protocol at the Cleveland Clinic Foundation. By 
following the procedures described in our previous studies139,140, these tissue sections (1 
cm x 1 cm x 10 µm) were microdissected using the Arcturus Laser Capture 
36 
 
Microdissection (LCM) System of Applied Biosystems (Foster City, CA) to gather 
approximately 100,000 tumor cells from each clinical specimen (Figure 2.1). 
The microdissected cells obtained from each specimen were individually processed and 
placed directly into a microcentrifuge tube containing 8 M urea and 20 mM Tris-HCl at 
pH 8.0. The soluble proteins were collected in the supernatant by centrifugation at 20,000 
g for 30 min. Proteins in the supernatant were reduced and alkylated by sequentially 
adding DTT and IAM with final concentrations of 10 mg/mL and 20 mg/mL, 
respectively. The solution was incubated at 37 0C for 1 hr in the dark and then diluted 8-
fold with 100 mM ammonium acetate at pH 8.0. Trypsin was added at a 1:40 (w/w) 
enzyme to substrate ratio and the solution was incubated at 37 0C overnight. Tryptic 
digests were desalted using a Peptide MacroTrap column (Michrom Bioresources, 
Auburn, CA), lyophilized to dryness using a SpeedVac (Thermo, San Jose, CA), and then 
stored at -80 0C.  
2.2.3 CITP-Based Tissue Proteomic Analysis 
A total of 12 proteomic samples, containing proteolytic digests processed from 4 grade II, 
3 grade III, and 5 grade IV astrocytoma tissue specimens, were prepared using a 2% 
pharmalyte solution with a final total protein concentration of approximately 1 µg/µL. 
Each proteomic sample was analyzed in duplicate. Similar to the procedures described in 
our previous studies74-76, a 80-cm long CITP capillary (100 µm i.d./365 µm o.d.) coated 
with hydroxypropyl cellulose was initially filled with a background electrophoresis buffer 
of 0.1 M acetic acid at pH 2.8. A 50-cm long sample plug, corresponding to a 4.0 µL 
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sample volume or 4 µg total protein loading, was hydrodynamically injected into the 
capillary.  
A positive electric voltage of 24 kV was applied to the inlet reservoir, which was filled 
with a 0.1 M acetic acid solution. The cathodic end of the capillary was housed inside a 
stainless steel tube (460 µm i.d./785 µm o.d.) using a coaxial liquid sheath flow 
configuration141. A sheath liquid composed of 0.1 M acetic acid was delivered at a flow 
rate of 1 µL/min using a Harvard Apparatus 22 syringe pump (South Natick, MA). The 
stacked and resolved peptides in the CITP capillary were sequentially fractionated and 
loaded into individual wells on a moving microtiter plate. The entire capillary content 
was separated and sampled into 18 individual fractions in less than 2 hr. The CITP 
separation and fractionation apparatus was operated on an in-house built robotic platform 
controlled by LabView (National Instruments, Austin, TX).  
To perform combined CITP/nano-reversed phase liquid chromatography (nano-RPLC) 
separations, peptides collected in individual wells were sequentially injected into dual 
trap columns (3 cm x 100 m i.d. x 365 m o.d.) packed with 5 m porous C18 particles. 
Each peptide fraction was subsequently analyzed by nano-RPLC equipped with an 
Ultimate dual-quaternary pump (Dionex, Sunnyvale, CA) and a dual nano-flow splitter 
connected to two pulled-tip fused-silica capillaries (50 m i.d. x 365 m o.d.). These two 
15-cm long capillaries were packed with 3.5-m Zorbax Stable Bond (Agilent, Palo Alto, 
CA) C18 particles.  
Nano-RPLC separations were performed in parallel in which a dual-quaternary pump 
delivered two identical 2-hr organic solvent gradients with an offset of 1 hr. Peptides 
were eluted at a flow rate of 200 nL/min using a 5-45% linear acetonitrile gradient over 
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100 min with the remaining 20 min for column regeneration and equilibration. The 
peptide eluants were monitored using a linear ion-trap mass spectrometer (LTQ, Thermo, 
San Jose, CA) equipped with an electrospray ionization interface and operated in a data 
dependent mode. Full scans were collected from 400 - 1400 m/z and 5 data dependent 





Figure 2.1 Demonstration of selective tissue microdissection of a relatively pure 
population of tumor cells. 
Left, a hypercellular focus of GBM cells, abutting the acellular space to the left of the 
slide, surrounded on the right by white matter (brain) infiltrated by tumor cells, but at a 
substantially lower cellular density; middle, the tumor cells selectively removed by LCM; 




2.2.4 MS Data Analysis 
Raw LTQ data were converted to peak list files by msn_extract.exe (Thermo). Open 
Mass Spectrometry Search Algorithm (OMSSA)142 developed at the National Center for 
Biotechnology Information was used to search the peak list files against the SwissProt 
sequence library with decoyed sequences appended. This decoyed database was 
constructed by reversing all sequences and appending them to the end of the sequence 
library. Searches were performed using the following parameters: fully tryptic, 1.5 Da 
precursor ion mass tolerance, 0.4 Da fragment ion mass tolerance, 1 missed cleavage, 
alkylated Cys as a fixed modification and variable modification of Met oxidation. 
Searches were run in parallel on a 14 node, 28 CPU Linux cluster (Linux Networx, 
Bluffdale, UT).  
False discovery rates (FDRs) were determined using a target-decoy search strategy 
introduced by Elias and co-workers143 and employed in our previous study for a 
comparative evaluation among commonly used tandem MS identification search 
algorithms144. An E-value threshold corresponding to a 1% FDR in total protein 
identifications was used as a cutoff in this analysis as this correlates with the maximum 
sensitivity versus specificity in our previous work144. Furthermore, proteins were reported 
as being identified by at least two distinct peptides among which contain at least one 
unique peptide. For a protein family with shared redundancy peptides sequences, only 
one member of a protein family was reported which has the best scoring in the search 
results. After generation of search data, the OMSSA XML result files were parsed using a 
Java parser and loaded into an Oracle 10g database for analysis and reporting using in-
house software  
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2.2.5 Protein Validation Using Immunohistochemistry (IHC) 
One of highly confident and differentially expressed proteins among astrocytomas, 
IQGAP1, was chosen from MS-based proteomic measurements for validation using IHC. 
IHC was performed on tissue microarray (TMA) sections by removing three 1.5 mm 
diameter cores (> 90% tumor cells) of tissue from each block at the laboratory of US 
Biomax (Rockville, MD). Negative and positive controls were conducted using the 
normal cerebral tissue and the skin tissue of malignant melanoma, respectively. 
The mouse primary antibody against IQGAP1 was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA) and incubated with a dilution ratio of 1:150 at 4 0C 
overnight. The biotinylated anti-mouse immunoglobulin was employed as the link 
antibody and was incubated for 30 min. The avidin-biotin-peroxidase complex (Vector 
Laboratories, Burlingame, CA) was utilized as the labeling reagent and incubated for 30 
min. A 10-min wash step with Tris buffered saline was carried out between each step. 
TMAs were counterstained by hematoxylin and mounted for examination by microscope. 
2.3 Results and Discussion 
Besides selective analyte enrichment, CITP further provides high resolving power to 
analyze complex proteomic mixtures. As demonstrated in our previous studies of human 
saliva and mouse brain mitochondrial proteomes74,75, approximately 85-90% of distinct 
peptides are identified in only a single CITP fraction. For the investigation of 
microdissected astrocytoma tissues, about 80-85% of distinct peptides were identified in 
each of 18 CITP fractions. In contrast, a high degree of peptide overlapping in strong 
cation-exchange chromatography, as the first separation dimension of MuDPIT77, is 
42 
 
generally observed with at least 40% of carryover of peptides that are identified in 
previous salt gradient fractions. The combination of selective analyte enrichment with 
excellent resolving power contributed to superior astrocytoma proteomic results with 
regard to the analytical reproducibility, the confidence in protein identification, and the 
overall tissue proteome coverage. 
2.3.1 Overall Performance of Human Astrocytoma Proteomes 
The overall tissue proteomic results are summarized in Table 2-1 with the complete 
protein lists provided in the Supporting Information. The number of proteins which are 
predicted to contain at least one or more transmembrane domains using TMHMM145 is 
also included in Table 2-1 and accounts for approximately 19% of total protein 
identifications. To the best of our knowledge, these data sets represent the most extensive 
tissue proteomics confidently identified so far in human astrocytomas. The coupling of 
tissue microdissection for tumor cell enrichment with CITP-based selective analyte 
concentration serves as a synergistic strategy to greatly increase tissue proteome 
coverage, including the characterization of low abundance proteins. 
Identification reproducibility was evaluated and was determined to be around 83-88% in 
identified proteins among technical duplicates of the same tissue specimen. Furthermore, 
the average number of distinct peptides leading to each protein identification was around 
6.8 and illustrated the broad sequence coverage of protein identification. The enhanced 
analytical reproducibility, together with the confidence of protein identification, ensures 
high impact inferences to be drawn from the proteomic investigations of archival 





Table 2-1 Number of Distinct Proteins Identified from Duplicated Runs for Each 
Microdissected Astrocytoma Tissue Specimen 
Specimen Number Grade II Grade III Grade IV 
 1 2,014 (403)* 2,196 (396) 2,663 (511) 
 2 2,007 (454) 2,314 (415) 2,566 (440) 
 3 2,483 (467) 2,346 (455) 2,327 (417) 
 4 2,395 (478)  2,540 (495) 
 5   2,207 (413) 






Figure 2.2 The Venn diagrams comparing (A) total proteins and (B) membrane 
proteins identified from grade II astrocytoma (black), grade III anaplastic 

















2.3.2 Comparisons among Different Grades of Astrocytomas 
GBMs (grade IV) are aggressive malignancies with an increased mitotic activity, 
pronounced angiogenesis (microvascular proliferation), necrosis, and more rapid 
proliferative rates than grade III tumors114-116. GBMs, in general, exhibited the largest 
number of identified proteins than those of grades II and III (Table 2-1). Besides the 
identification of many common proteins among different grades of astrocytomas (Figure 
2.12 A), only 177, 120, and 594 proteins were detected uniquely in grades II, III, and IV, 
respectively. Of the 650 membrane proteins identified, only 10, 3, and 46 membrane 
proteins were detected uniquely in grades II, III, and IV, respectively (Figure 2.2 B). 
Such high degree of overlapping in protein identification further supports the high 
confidence and the enhanced reproducibility of proteomic measurements performed with 
CITP. 
In addition to protein identification, monitoring quantitative changes in identified 
peptides, and by inference, proteins, is essential for the discovery of cancer-associated 
biomarkers. Due to constraints requiring the study of proteins in a tissue environment 
with limited sample availability, the protein expression profiles within targeted tumor 
cells selectively procured from astrocytoma tissues were quantitatively compared by 
coupling the CITP technology with the label-free MS-based spectral counting 
measurements68,69,138. Even though major components may be diluted and trace 
compounds are concentrated as a result of selective analyte enrichment in the CITP 
process135-137, the bandwidth of individual peptides/proteins, however, is proportional to 
the amount injected into the CITP capillary and therefore the abundance in the original 
proteome sample73. Thus, the analyte bandwidth established during the CITP separation, 
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correlated with the quantity of analyte, affects the distribution of each peptide within 
single or multiple CITP fractions, the peak width of peptide in subsequent nano-RPLC 
separation, and the number of total peptide hits (or tandem MS events) leading to 
individual protein identification and quantification through the spectral counting 
approach68,69,138.  
The Pearson correlation coefficient was employed to measure how well a linear equation 
describes the quantitative correlation between two proteomic runs to assess analytical 
reproducibility and allow for easy visual identification of outlier features (proteins). The 
calculation of the Pearson correlation coefficient was performed using the MATLAB 
Statistics Toolbox (MathWorks, Natick, MA). As shown in Figure 2.3, technical 
replicates of two adjacent GBM sections of the same specimen give a Pearson coefficient 
of greater than 0.99 over a dynamic range of around 104. 
A Student’s t-test was performed to compare the protein expression profiles within 
microdissected tumor cells among different grades of gliomas. Despite sharing over 
2,532 common proteins (Figure 2.2 A), highlighted areas shown in Figure 2.4 A and 2.4 
B specifically denote a large number of highly confident (p-value of less than 0.01) and 
differentially expressed (greater than 2-fold change) proteins discovered in comparative 





Figure 2.3 Pearson correlation coefficient plot of two proteomic runs analyzing 





Figure 2.4 Volcano plots of (a) grade IV vs. grade III and (b) grade IV vs. grade II. 
Comparison of expression difference of proteins between grade IV verses lower 
astrocytomas grades. Highly confident proteins (p value smaller than 0.01) with 





Figure 2.5 Unsupervised hierarchical clustering of forty proteins with the most 





Unsupervised hierarchical clustering was conducted using Cluster 3.0146. Arrays and 
genes were both clustered using the Euclidian distance similarity metric. The complete 
linkage method was applied for clustering grade III anaplastic astrocytoma with grade IV 
GBM. Forty proteins with the most significant p-values by t-test are shown in Figure 2.5. 
This clustering analysis reveals significant and consistent expression differences between 
the two disease grades and provides a tractable set of proteins as potential candidates for 
follow-on validation studies and functional investigation.  
2.3.3 Function and Network Analysis of Proteins Up-regulated in GBM 
Besides monitoring and comparing the protein expression profiles among different grades 
of astrocytomas, the approach of grouping individual expression changes into pathways 
of actions is not only useful in trying to interpret genome and proteome datasets, but also 
allows common biological themes to emerge from the comparative proteomic analyses147. 
Comparative proteomics involving measurements in changes of pathways or functional 
processes are expected to provide relevant tumor-associated markers and networks, 
molecular relationships among different stages of disease, and molecular mechanisms 
that drive the progression of cancer. From a practical perspective, the evaluation of 
comparative proteomic dataset within a biological context is essential for high-throughput 





Figure 2.6 Top functional pathways constructed from the up-regulated GBM 





Table 2-2 Proteins Related to Cancer Function and Up-Regulated in GBM 
Name Description Accession Location Family Spectral Counts  
     (Grades II/III/IV) 
 
B4GALNT1 -1,4-N-acetyl-galactosaminyl Q00973 cytoplasm enzyme (0/2/4) 
 Transferase 1 
 
BAG1 BCL2-associated athanogene Q99933 cytoplasm other (0/0/2) 
 
CASP1 caspase 1, apoptosis-related P29466 cytoplasm peptidase (0/2/4)  
 cysteine peptidase (interleukin      
 1, , convertase) 
 
CD97 CD97 molecule P48960 plasma G-protein (0/0/4)   
   membrane coupled receptor 
 
COL6A3 collagen, type VI,  3 P12111 extracellular other (6/14/87)  
   Space 
 
CTSS cathepsin S P25774 cytoplasm peptidase (0/0/5)  
 
DCN decorin P07585 extracellular other (2/2/9) 
   Space 
 
EGFR epidermal growth factor P00533 plasma kinase (5/9/47) 
 receptor (erythroblastic  membrane 
 (leukemia viral (v-erb-b) 
 oncogene homolog, avian) 
 
ERBB2 v-erb-b2 erythroblastic P04626 plasma kinase (0/0/4)  
 eukemia viral oncogene  membrane   
 homolog2, neuro/ glioblastoma     
 derived oncogene homolog  
 (avian) 
 
GBP1 guanylate binding protein 1, P32455 cytoplasm enzyme (2/4/16)  
 interferon- inducible, 67kDa 
 
IGFBP7 insulin-like growth factor Q16270 extracellular transporter (0/0/5)  
 Binding protein 7  space 
 
IL18 interleukin 18 (interferon-- Q14116 extracellular cytokine (0/0/3) 
 inducing factor)  space 
 
IQGAP1 Ras GTPase-activating-like P46940 plasma other (7/25/57) 
 protein IQGAP1  membrane 
 
ITGA2 integrin,  2 (CD49B,  2 P17301 plasma other (0/0/4) 
 subunit of VLA-2 receptor)  membrane 
 
ITGB2 integrin,  2 (complement P05107 plasma other (0/2/5)  
 component 3 receptor 3 and  membrane   




LGALS3 lectin, galactoside-binding, P17931 extracellular other (0/0/6)  
 soluble, 2 (galectin 3)  space   
 
LRPAP1 low density lipoprotein P30533 plasma transmembrane (0/2/5)  
 receptor-related protein  membrane receptor 
 associated protein 1     
 
MCM7 MCM7 minichromosome P33993 nucleus enzyme (0/0/6) 
 Maintenance deficient 7 
 (S. cerevisiae) 
 
MMP2 matrix metallopeptidase 2 P08253 extracellular peptidase (0/0/3)  
 (gelatinase A, 72kDa gelatinase,  space   
 72kDa type IV collagenase) 
 
MRE11A MRE11 meiotic recombination P49959 nucleus enzyme (0/0/3)  
 11 homolog A (S. cerevisiae) 
 
NEK9 NIMA (never in mitosis gene Q8TD19 nucleus kinase (0/2/5) 
 a)-related kinase 9     
 
N QO1 NAD(P)H dehydrogenase,  P15559 cytoplasm enzyme (0/0/5) 
 quinone 1     
 
OAS3 2'-5'-oligoadenylate Q9Y6K5 cytoplasm enzyme (0/2/8)  
 synthetase 3, 100kDa     
 
PML promyelocytic leukemia P29590 nucleus transcription (2/3/6)  
    regulator  
 
S100A10 S100 calcium binding protein P60903 cytoplasm other (2/2/10)  
 A10 (annexin II ligand, 
 calpactin I, light polypeptide 
 (p11))     
 
SMARCA4 SWI/SNF related, matrix P51532 nucleus transcription (0/0/3)  
 associated, actin dependent   regulator  
 regulator of chromatin, 
 subfamily a, member 4     
 
TBXAS thromboxane A synthase 1 P24557 plasma enzyme (0/0/4)  
 (platelet, cytochrome P450,  membrane   
 family 5, subfamily A) 
 
TFRC transferrin receptor (p90, CD71) P02786 plasma transporter (2/4/9) 
   membrane   
 
TIMP1 TIMP metallopeptidase P01033 extracellular other (0/0/3)  
 inhibitor 1  space   
 
TIMP2 TIMP metallopeptidase P16035 extracellular other (0/0/3)  
 inhibitor 2  space   
 






Figure 2.7 An up-regulated GBM protein network containing EGFR and Erbb2.  
Proteins in this network were up-regulated in GBM more than 2 fold. This protein network were 
completely revealed as benefited from improved proteome coverage and well know cancer related 




By employing the proteome dataset that is up-regulated in GBMs, the top functional 
pathways were mapped using the Ingenuity Pathway AnalysisTM program (Ingenuity 
Systems, Redwood City, CA), as shown in Figure 2.6. The significance value associated 
with the functional analysis for a dataset is a measure of how likely the proteins from the 
dataset under investigation participate in that function. The significance is expressed as a 
p-value, which is calculated using the right-tailed Fisher’s Exact Test. The p-value is 
calculated by comparing the number of user-specified proteins of interest that participate 
in a given function or pathway, relative to the total number of occurrences of these 
proteins in all functional/pathway annotations stored in the Ingenuity Pathway 
Knowledge Base. Table 2 lists the proteins that have been associated with the “cancer 
function” and that are uniquely up-regulated in GBM. Their spectral counting results 
among different grades of astrocytomas are also included in Table 2-2.   
Since CITP’s selective analyte enrichment greatly increases proteomic coverage, several 
protein networks were partially or completely revealed in these gliomas. For example, 
one of the protein networks, containing tyrosine kinase receptors of EGFR and its ErbB 
family member of Her2 (Erbb2), shown in Figure 2.7, is associated with the cell cycle 
dys-regulation and oncogenesis. Proteins shown in this network were up-regulated over 2 
fold in GBM relative to lower grade astrocytomas. Previous studies have shown that 
EGFR amplification, over-expression and/or mutation are commonly observed in primary 
GBM. EGFR is involved in several major cellular signal transduction pathways such as 
the Ras, NF-B, and PTEN pathways. It is believed that constantly activating these 
pathways contributes to cancer cell proliferation and survival. In addition to these well 
known cancer related plasma membrane proteins, two proteins expressed in the nucleus, 
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PIAS1 and PIAS2, were over-expressed in GBM. These two proteins regulate STAT 
expression in the Jak-Stat signaling pathway, which can promote astrocyte differentiation 
through cross-talk between Notch and the BMP-Smad signaling pathways148.  
2.3.4 Selection and Validation of IQGAP1 Using IHC 
The cell membrane protein IQGAP1, which was differentially expressed between 
different grades of gliomas (Figure 2.8) as measured by the spectral counting 
approach68,69,138, was selected for validation using IHC. IQGAP1 was chosen because of 
its role in key protein networks and pathways associated with the progression of brain 
tumors149-151. IHC was performed on TMA by removing three cores from each tissue 
block. For example, A1-A3 shown in Figure 2.9 were the cores removed from the same 
tissue block of patient diagnosed with grade 1 astrocytoma.  
A total of 60 tissue blocks, including 9 grade 1, 19 grade 2, 18 grade 3, and 14 grade 4, 
were employed for the validation studies of IQGAP1. Additionally, normal cerebral 
tissue (L5-M15) and the skin cancer, melanoma (M16), served as negative and positive 
controls, respectively. As shown in Figure 2.9, both the staining intensity and the 
percentage score are reproducible among the cores removed from the same tissue block. 
Furthermore, the staining index, given for each case as the product by multiplying the 
percentage score with the staining intensity, increases with increasing tumor grade from 





Figure 2.8 IQGAP1 expression relative to correlation with astrocytoma grade. 
Quantification of protein IQGAP1 through label free spectral counting plotted along with 





Figure 2.9 Scoring of TMA with IHC staining of IQGAP1.  
“Intensity” refers to staining intensity using IHC; “percentage” refers to the percentage of 
tumor cells within each TMA that were positive by IHC; and “grade” refers to WHO 
grade I-IV gliomas. 
 
   
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
A 1C 1C 1B 1D 1D 1D 1D 1D 1C 1A 1B 1B 1C 1B 1B 1D
B 1C 1D 1C 1B 1D 1C 1B 1D 1D 1C 1D 1B 1B 1B 1C 1C
C 1A 1D 1D 2D 1D 1D 1D 2D 2D 2D 1B 1B 1D 1C 1C 1B
D 1D 1C 1D 1B 1B 1C 2D 2D 2D 1D 1C 1D 2D 2D 2D 1C
E 1B 1B 2D 2D 1B 1B 1B 1C 1B 1B 1A 1B 1B 1B 1B 1B
F 1B 2D 2D 2D 2D 2D 2D 2D 1D 2D 1C 1C 1C 2D 2D 2C
G 2D 2D 2D 3D 3D 3D 2B 2C 2C 3D 3D 3D 3D 3D 3D 2D
H 3D 3D 2D 2C 2C 3C 3D 3C 2C 2C 2B 1D 1B 1A 2D 2B
I 2C 3D 3D 3D 3D 3D 3D 2D 2D 2D 3D 3D 3D 3D 3D 3D
J 3D 3D 3D 2D 2D 2D 2D 2D 3D 3D 3D 3D 2D 2D 2D 2B
K 2B 2B 3D 3D 3D 3D 3D 3D 3D 3D 3D 3D 3D 3D 2C 2B
L 2C 3D 3D 3D 0A 0A 0A 0A 0A 0A 0A 0A 0A 0A 0A 0A




0 Negative A 0-25% 3
1 Weak positive B 26-50% 4
2 Moderate positive C 51-75% cerebral tissue




Comprehensive and comparative proteomic profiling of relatively pure populations of 
glioma cells obtained from selectively microdissected tumors demonstrates the ability of 
this combined approach to accurately and reliably discover and validate proteins that may 
correlate directly with and predict prognosis, survival, and response to therapy in 
patients. This work represents the largest catalog of proteins indentified and quantified 
among different grades of astrocytomas reported to date. Our proteomic results, including 
an enhanced analytical reproducibility, a high confidence in protein identification, and 
the broad tissue proteome coverage, illustrate the utility of proteomic discovery using 
targeted tissue microdissection in combination with CITP’s selective analyte enrichment 
and its elevated resolving power prior to tandem MS measurements.   
Despite sharing many common proteins, there are significant differences in protein 
expression among different grades of the infiltrative astrocytomas. The greatest number 
of differentially-expressed proteins was found in GBM, many of which are proteins 
frequently identified in other cancer types, including the plasma membrane proteins 
EGFR and Erbb2. Furthermore, two nuclear proteins up-regulated in GBM, PIAS1 and 
PIAS2, regulate STAT expression in the Jak-Stat signaling pathway, which can promote 
astrocyte differentiation through cross-talk between Notch and the BMP-Smad signaling 
pathways148. 
IQGAP1, a cell membrane protein, was selected from comparative proteomic studies for 
validation using IHC. IQGAP1 is a prominent member of several key protein networks 
and pathways that have been associated with the progression of brain tumors149-151. To 
facilitate high-throughput IHC measurements, analysis of IQGAP1 expression was 
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performed in a large TMA, including 60 astrocytoma specimens and validated MS-based 
proteomic profiling of microdissected astrocytoma tissues. 
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3.1 Introduction 
Capillary electrophoresis (CE) coupled with mass spectrometry (MS) has been well 
recognized as a complementary analytical technology to more conventional liquid 
chromatography-mass spectrometry (LC-MS). By combining the high resolving power of 
CE with the highly sensitive and information-rich detection of MS, this hyphenated 
technique has enjoyed successful applications in many fields of scientific research, such 
as biomarker discovery and verification62,152-154, metabolomics155,156, identification and 
quantification of environmental pollutants157 and food quality control158. While much less 
widely applied than LC-MS, the number of publications related to development and 
application of CE-MS continues to increase due to its potential capability in performing 
sensitive and high throughput sample analysis159-161. Online coupling of CE with 
electrospray ionization (ESI)-MS has been demonstrated via a co-axial sheath-flow 
interface162 or a sheathless interface using either a metal sheath capillary86, a metal coated 
capillary163 or a T-junction design that connects separation capillary with electrospray 
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tip164. With the goal to refine this technology and broaden its utility, every aspect of the 
CE-MS technique has attracted attention, including CE capillary modification165-167, ESI 
emitter fabrication168 and high efficiency CE-MS interface design169. Recently, Maxwell 
and co-workers have designed a stainless hollow needle with a beveled spray tip as a 
more robust sheath liquid interface170. A conductive tip made by HF etching a fused silica 
capillary to porous was introduced by Moini105. The performance of sheath-less setup 
utilizing the etched porous tip was demonstrated by Busnel et al.109, showing its 
capability in performing CE-ESI-MS analysis in a broad range of flow rates (from low 
nL/min to sub µL/min) with exquisite sensitivity. Two CE operation modes, capillary 
zone electrophoresis (CZE) and transient capillary isotachophoresis/capillary zone 
electrophoresis (CITP/CZE), have shown to be most compatible with online MS analysis 
and have thus been most widely used. Heemskerk et al. reported an improved ionization 
efficiency for phosphopeptides using CZE-ESI-MS under ultra low ESI flow rate (below 
20 nL/min) recently111. Ramautar and co-workers reported enhanced coverage of urinary 
metabolome using CITP/CZE-ESI-MS110. Busnel and co-workers applied both CZE and 
CITP/CZE in a sheathless CE-ESI-MS setup and reported nanomolar and subnanomolar 
detection limits respectively109.  Thus far, CE-MS has been primarily used for the 
qualitative analysis of biomolecules or small molecules. With the growing interest in 
identifying biomarkers for diagnostic, prognostic and predictive applications, new 
analytical tools capable of effectively quantifying low abundant targets in complex 
biological matrix are needed.   
Triple quadrupole MS operating in a selected reaction monitoring (SRM) mode has 
demonstrated extremely high sensitivity, dynamic range and specificity in quantifying 
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targeted analytes in a complex chemical or biological sample matrix171. The SRM MS-
based quantitation method has been extensively investigated and primarily used in 
combination with LC for quantitation of metabolites172,173, and increasingly for peptide 
measurements, e.g. verification of protein biomarkers171,174,175.  Online coupling CE with 
SRM MS, though still in its infancy, has already demonstrated its unique capability in 
sample quantitation with significantly less sample consumption as compared to LC-SRM 
MS based technique. Jeong et al. recently demonstrated the detection and quantitation of 
underivatized amino acids using CZE-SRM MS via a sheathless interface176. Li and co-
workers have reported a highly sensitive method using CZE-SRM MS177, and 10- to 20-
fold sensitivity improvements over HPLC-SRM MS were demonstrated as well as linear 
response for Leu-enkephalin from 1.5 nM to 10 µM in a BSA tryptic digest background. 
Here we report the use of CITP/CZE for online SRM MS quantitation. CITP is a static-
state electrophoresis, which utilizes the conductivity difference between sample ions and 
background ions to achieve a sample stacking mechanism. CITP has been mainly used as 
a preconcentration method prior to sample separation by which a concentration factor of 
~1000 can be achieved when applied to dilute samples. CITP/CZE is a hybrid mode 
capable of achieving both sample concentration (selectively) and separation 
simultaneously73. As a result of the selective focusing and high resolving power, trace 
compounds are less masked by the major compounds after CITP/CZE and thus become 
more detectable by MS. Fang et al. have demonstrated the use of CITP/CZE MS for 
candidate biomarker discovery using tissue samples74,75.  Our goal is to utilize the 
intrinsic focusing feature of CITP/CZE to achieve ultrasensitive sample quantitation and 
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evaluate the lower limit of quantitation using CITP/CZE-SRM MS for quantifying 
targeted peptides in complex biological matrix.  
3.2 Experimental Section 
3.2.1 Chemicals 
Bovine serum albumin (BSA) tryptic digest standard was purchased from Protea 
(Morgantown, WV). Leu-enkephalin, angiotensin II, kemptide, ammonium acetate, 
methanol and acetic acid were purchased from Sigma (St. Louis, MO). Fused silica 
capillaries were purchased from Polymicro Technologies (Phoenix, AZ). 
3.2.2 Sample Preparation 
BSA tryptic digest solution was used to evaluate the performance of the online CE-ESI-
MS platform. Stock solution of BSA digest was prepared by dissolving 500 pmol of BSA 
digest standard in 100 µL leading electrolyte (LE) solution consisting of 25 mM 
ammonium acetate in deionized water with the solution pH adjusted by adding acetic acid 
to pH=4. Working solutions with concentrations ranging from 10 nM to 3.75 µM were 
obtained by diluting stock solution with LE. Preparation of samples for CZE experiments 
was similar except LE was substituted with 0.1 M acetic acid in deionized water. 0.1 M 
acetic acid solution was subsequently mixed with methanol at volume ratio 9:1 as 
background electrolyte (BGE) solution for better electrospray operation. 
A mixture of three peptides (Leu-Enkephalin, Angiotensin II and Kemptide) spiked into 
BSA tryptic digest at different concentrations were used in the CITP/CZE-SRM MS 
sample quantitation experiments. Stock solution with 10 µM concentration for each 
peptide was prepared in water and stocked in aliquots.   The stock solution was then 
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diluted using BSA background matrix (50 nM BSA digest in 25 mM LE) to obtain a 
peptide concentration series for CITP/CZE-SRM MS quantitation.  
3.2.2 CITP/CZE-ESI-MS Interface 
Figure 3.1 shows the schematic of the interface developed to couple CITP/CZE online 
with an ESI-triple quadrupole (QQQ) mass spectrometer. The CITP/CZE separation 
capillary (75 µm i.d., 150 µm o.d., and 88 cm long) was inserted into a large bore 
capillary (200 µm i.d., 360 µm o.d., and 5 cm long) concentrically using a PEEK cross. 
The free end of the large bore capillary was first pulled into a fine tip using a Sutter P-
2000 laser puller and then chemically etched to remove a part of the tip using HF 
solution168 to form an ESI emitter with a ~50 µm opening, as shown by the inserted 
picture at the bottom right of the Figure 3.1.  The tapered i.d. of the large bore ESI 
emitter capillary also allowed the separation capillary to be inserted as far as possible 
until it hit the inner wall of the emitter capillary to both minimize the dead volume and 
provide a consistent coupling between the CITP/CZE separation capillary and the ESI 
emitter, as shown by the inserted picture at the bottom middle of the Figure 3.1. Before 
each CITP/CZE-ESI-QQQ MS analysis, a sheath flow of BGE serving as electrically 
conductive solution was introduced to completely fill the annular space between the 
separation capillary and the ESI emitter capillary.  The liquid junction formed at the ESI 
emitter allows a second voltage to be applied for stable electrospray operation and 
maintains the electric contact. To minimize the sample dilution, the sheath-flow was 
turned off during the CITP/CZE-ESI-QQQ MS analysis. To avoid electric contact 
interruption by the air bubbles generated from the redox reaction at the metal contact of 
the ESI voltage, which could rapidly damage the separation capillary due to the high 
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separation voltage (~30 kV), the second voltage for ESI was applied to the sheath flow 
waste line through a flow split design, as shown in Figure 3.1, which was flushed with 
the sheath liquid to avoid bubble accumulation after each experiment. 
The separation capillary was coated with hydroxypropyl cellulose to minimize 
electroosmotic flow. The separation capillary was filled with BGE solution before each 
experiment. Samples were loaded into the separation capillary by the hydrodynamic 
method178 at constant gas pressure (1 psi). Sample loading was adjusted by varying the 
length of loading time. The CITP/CZE separation voltage of 27 kV was applied to the 
sample inlet of the capillary using a Glassman high voltage power supply. A ~ 1 kV 
electric potential at the ESI emitter liquid junction was created under the separation 
voltage when the sheath flow liquid waste line was grounded. Analytes were eluted from 
the separation capillary hydrodynamically by applying 1 psi nitrogen back pressure to the 
trailing electrolyte (TE) reservoir (Figure 3.1) after a fixed separation time, determined 





Figure 3.1 Graph of CITP/CZE-ESI-QQQ MS setup used in this study. 
Upper part is the schematic of the whole setup (not to scale). Lower left shows the actual 
interface and the position of the emitter relative to MS inlet, as well as the off-flow path 
grounding design adapted to avoid redox reaction generated bubbles. Lower middle and 
lower right show close view of the in-house fabricated emitter and the size of the 
opening.   
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3.2.3 MS Optimization and Data Processing 
An Agilent QQQ mass spectrometer (model 6430) was used for all sample analyses. The 
standard ESI interface of the instrument was modified with a multi-capillary/dual ion 
funnel interface179 making the performance of the instrument similar to Agilent’s latest 
triple quadrupole MS product (model 6490), as shown by the inserted picture at the 
bottom left of the Figure 3.1.   The ESI voltage of the MS was varied in the range of -200 
to -500 V for the optimum ESI sensitivity and signal stability considering the ~ 1 kV 
potential at ESI emitter liquid junction as described above under CITP/CZE operating 
condition. A dry nitrogen flow of 10 L/min and a gas temperature of 320 °C were used 
for optimum MS sensitivity. Both full scan MS and SRM were used in this study. In 
SRM mode, specific mass to charge ratio (m/z) precursor ions were selected in the first 
quadrupole (Q1) and fragmented in the second quadrupole (Q2 collision cell) via 
collision induced dissociation under sufficient collision energy. The specific m/z product 
ions were then selected in the third quadrupole (Q3) and monitored by the MS detector.  
Each selected precursor/product ion pair in SRM MS is referred to as a SRM transition. 
Through monitoring the unique transitions of the selected analytes, both high sensitivity 
and specificity can be achieved in sample quantification.  SRM MS operating parameters 
for each peptide in this study were optimized using direct infusion of the peptide standard 
with 1 µM concentration at 500 nL/min. Three most intense fragments were selected for 
each peptide as SRM transitions regardless of the fragment ion types. The collision 
energy for each SRM transition was optimized and recorded for the highest product ion 
intensity. The dwell time for each SRM transition was set at 65 milliseconds to ensure at 
least 12 data points for each analyte peak in extracted CITP/CZE SRM MS 
69 
 
chromatogram. All the SRM transitions and their related optimum collision energies for 
three peptides selected for SRM MS quantitation in this study are listed in Table 3.1. 
Data analysis was performed by using Agilent MassHunter Qualitative Analysis Software 
(version B.02.00). Symmetric 0.5 m/z tolerance was used to extract the selected ion 
chromatograms. Unit resolutions were used for both Q1 and Q3 in SRM data acquisition. 
Peak retention time, peak area and peak width were obtained through manual integration. 
In S/N calculation, peak height was used as signal and the software default setting, peak-
to-peak definition, in the range of 3-minutes before and after the target peak was used for 
noise measurement. In this default setting, the noise value for the selected range is 
calculated as the difference between the highest and the lowest peak abundance values. 
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Leu-enkephalin  [YGGFL+H]+  556.3 397.3 (a4
+)  65  14  
556.3 425.3 (b4
+)  65  12  
556.3 278.3 (b3
+)  65  22  
Angiotensin II  [DRVYIHPF+2H]2+ 523.8 784.5 (b6
+)  65  14  
523.8 756.5 (a6
+)  65  20  
523.8 647.4 (b5
+)  65  20  
Kemptide  [LRRASLG+2H]2+ 386.7 567.4 (b5
+-NH3)  65  17  
386.7 549.4 (b5
+-NH3-H2O) 65  18  
386.7 539.4 (a5
+-NH3) 65  22  
BSA peptide  [VGTR+H]+  432.3 230.1 (a3
+) 65 20 
The bolded transitions indicate the transition used for quantitation of each peptide. The non bolded/italicized 
transitions were used to confirm the peptide’s identity. The italicized transition of BSA peptide was used to 
monitor the platform’s reproducibility.  
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3.3 Results and Discussion 
3.3.1 CITP/CZE Sample Loading Capability and Optimization 
As one of the unique features, CITP is capable of selectively enriching/focusing the low 
abundance compounds in a complex mixture. During the CITP stacking process, analytes 
migrate into different bands under a constant electric field according to their different 
electric mobility. At the completion of the CITP stacking process, low abundance 
analytes are concentrated to a much greater extent than the major components in a 
mixture73. The CITP stacking mechanism enables relatively large (~µL) sample loading 
as compared to the much smaller (~nL) sample loading of traditional CZE, providing a 
basis for more sensitive detection for trace analytes. The CITP/CZE separation is a hybrid 
technique capable of simultaneously achieving high sensitivity and resolution by a 
combination of ion stacking and separation processes. To evaluate capability of 
CITP/CZE relative to CZE, both CITP/CZE and CZE were coupled online with ESI-MS.  
Figure 2 compares the analyte intensity between CITP/CZE-ESI-MS and CZE-ESI-MS at 
two different sample loading time using BSA tryptic digest.  With 1.5 min sample 
loading time, which yielded a small sample plug, equivalent ion intensity was measured 
between CITP/CZE-ESI-MS and CZE-ESI-MS, as shown by the base peak ion 
chromatograms (BPC) in Figure 3.2A (the top two panels) and the extracted ion 
chromatograms (EIC) for selected peptide (m/z = 432.3) in Figure 3.2B (the top two 
panels). Similar peak widths (0.456 min and 0.499 min) were also observed between 
CITP/CZE-ESI-MS and CZE-ESI-MS at this short sample loading time. It is also 
expected that different peptide peaks will be more resolved in CZE-ESI-MS as compared 
to CITP/CZE-ESI-MS, as shown in Figure 3.2A, due to the additional time required to 
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complete the CITP ion stacking process before the analyte peaks are separated from each 
other in the CITP/CZE-ESI-MS. When the sample loading time was increased to 3 min, 
corresponding to an injection of a longer sample plug, the benefit of CITP/CZE-ESI-MS 
becomes more obvious, as shown by the bottom two panels of Figure 3.2A and B. While 
CZE-ESI-MS yielded essentially no gain in peak intensity and showed peak broadening 
(0.711 min), the analyte peak intensity in CITP/CZE-ESI-MS was increased by 
approximately 4-fold while the peak width remained essentially the same (0.477 min). 
The increased sample loading volume in CITP/CZE-ESI-MS also resulted in the 
detection of more analyte peaks due to the effective ion focusing. The apparent nonlinear 
dependence between sample loading time and the detected analyte peak intensity under 
these two loading time in CITP/CZE-ESI-MS is due to the hydrodynamic sample loading 
method used in the experiment. Under the small gas pressure (~1 psi), which was kept at 
constant by using a high precision digital gas pressure regulator, there is an 
approximately one minute time delay between the application of the gas pressure and 
fully developed liquid flow in the separation capillary. With this considered the detected 
peak intensity in CITP/CZE-ESI-MS is proportional to the sample loading time (i.e. the 





Figure 3.2 Comparison of CITP/CZE and CZE with different sample loading time 
using BSA digest for selected ion m/z 432.3 [VGTR+H]+. 
Comparison of CITP/CZE and CZE with different sample loading time using BSA digest 


















Figure 3.3 Sample loading capacity optimization. 
(A) BPC from CITP/CZE-ESI MS with different sample loading time. (B) AUC (area 
under the curve) of BPC presented in panel A with different sample loading time. (C) 
Retention time of peptide m/z 432.3 [VGTR+H]+. Sample condition: 3.75 µM BSA digest 


























































In order to optimize the sample loading capacity of CITP/CZE for the length of the 
separation capillary and the separation voltage used in the experiment, a series of 
different sample loading times ranging from 1.5 minutes to 15 minutes were evaluated 
and the ion intensity was measured at each sample loading time using BSA tryptic digest. 
Figure 3.3A shows the BPCs from the CITP/CZE-ESI-MS measurements at different 
sample loading time. The optimum loading time under the current CITP/CZE setup is 
defined as the maximum sample loading volume to allow the sample stacking and 
separation to be fully developed in the remaining length of the capillary. As indicated by 
the experimental measurements in Figure 3.3A, peptide intensity continues to increase as 
the sample loading time increases from 1.5 minutes to 7.5 minutes while the 
electrophoresis peak width remains essentially the same. Beyond 10 minutes sample 
loading time, significant peak broadening and loss of separation quality was observed. 
This observation was further implied by the area under curve (AUC) of BPC vs. loading 
time in Figure 3.3B.  As sample loading was increased beyond 10 minutes, the rate of 
area increase (e.g. the slope of the curve) was decreased. This is largely due to the peak 
overlapping as a result of insufficient separation time at large sample loading time. 
Consequently, 7.5 minutes sample loading time was selected as the optimum sample 
loading time, corresponding to about 1 µL of sample loading volume or 25% of the total 
separation capillary volume, since it provided the best balance among sample loading 
volume, completion of sample stacking and sufficient analyte separation. The variation of 
the retention time (RT) under different sample loading time, as shown in Figure 3.3C for 
BSA peptide m/z 432.3 [VGTR+H]+, is due to a combination of ion focusing time and 
separation time change in CITP/CZE operation mode. In the pure CITP mode, the ion 
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focusing time is expected to increase as the sample loading time increases. In the pure 
CZE mode, the sample retention time decreases as the sample loading time increases. The 
final RT in CITP/CZE mode is determined by both ion focusing time and separation time. 
The data in Figure 3.3C indicate that RT increases initially as sample loading time 
increases due to the dominant change of ion focusing time. Beyond 7.5 min sample 
loading time, RT decreases as the sample loading time increases indicating the change of 
ion separation time becomes the dominant factor in determining the change of sample 
RT.  Good reproducibility of RT was also measured with the variance smaller than 4%. 
3.3.2 CITP/CZE-ESI-MS Sample Quantitation 
The initial evaluation of CITP/CZE-ESI-MS for sample quantitation was performed by 
using BSA digest solution of different concentrations ranging from 20 nM to 3.75 µM. 
The peak areas for randomly selected BSA peptides were measured from triplicate 
CITP/CZE-ESI-MS analyses of each sample concentrations. Full scan MS from m/z 300 
to 2250 was used in the experiments. Figure 3.4 shows the peak areas for two selected 
peptide ions m/z 582.5 [LVNELTEFAK+2H]2+ and m/z 432.3 [VGTR+H]+ at different 
BSA tryptic digest solution concentrations. Good reproducibility (CV<24%) and linearity 





Figure 3.4 Peak area calibration curve, for selected BSA peptide ions of m/z 582.5 
[LVNELTEFAK+2H]2+ 
(A) and m/z 432.3 [VGTR+H]+ (B) at different sample concentrations extracted from 




























































Figure 3.5 Different ion focusing effect observed for different ions. 
EIC for Leu-Enkephalin (top), Angiotensin II (middle) and Kemptide (bottom) at 100 nM 











To further determine the limit of quantitation (LOQ) for the CITP/CZE-ESI-MS 
instrument platform and investigate the matrix effect on the instrument LOQ, SRM MS 
analysis, as the most sensitive and specific MS operating mode, was used to quantify a 
set of samples containing three peptides (Leu-enkephalin, Angiotensin II and Kemptide) 
spiked into 50 nM BSA tryptic digest solution at different concentrations ranging from 50 
pM to 5 µM. With an estimated 1 µL sample loading volume, the corresponding peptide 
loading amount was from 50 attomoles to 5 picomoles. Each sample solution also 
contains 25 mM LE as required by CITP/CZE separation.  Three SRM transitions were 
monitored for each spiked in peptide and triplicate CITP/CZE-ESI-MS analyses were 
performed at each sample concentration.  One additional SRM transition from a BSA 
peptide (m/z 432.3 [VGTR+H]+) was also monitored during each CITP/CZE-ESI-MS 
analysis to ensure the stability of the instrument. This additional transition can also be 
used to normalize the peak intensity of the targeted peptides improving the precision of 
the quantification. (Table 2-1) 
Different ion focusing was initially observed for three different spiked in peptides during 
the CITP/CZE-ESI-MS analyses under the current CITP/CZE-ESI-MS setup and 
operating conditions. Figure 3.5 shows the selected ion chromatograms for these peptides 
corresponding to SRM transitions 556.3 to 397.3 for Leu-enkephalin, 523.8 to 784.5 for 
Angiotensin II, and 386.7 to 567.4 for Kemptide respectively. Leu-enkephalin peak in 
Figure 3.5 is shown to be much broader than Kemptide and Angiotensin II peaks along 
with lower intensity indicating a poor CITP focusing for Leu-enkephalin ions. This 
different ion focusing characteristic can be explained by the Kohlrausch equation137, 
CA  =  CL/{[L/(L + R)] [(A + R)/A]}             
80 
 
Where CA is the final analyte concentration, CL is the concentration of LE, µ is 
electrophoretic mobility with A and R stands for analyte and counter ion respectively. 
Given constant leading electrolyte concentration, the final concentration of the analyte is 
determined by its electrophoretic mobility μA. The order of electrophoretic mobility for 
these three peptides is Kemptide > Angiotensin II > Leu-enkephalin based on their 
relative elution time. This electrophoretic mobility order is consistent with their peak 
width and peak intensity shown in Figure 3.5 as analyte with higher electrophoretic 
mobility gets better focused and thus forms a narrower peak with higher intensity.   
Figure 3.6 shows the CITP/CZE-ESI-SRM MS quantitation curves for Angiotensin II 
(Figure 3.6A) and Kemptide (Figure 3.6B) using the same SRM transitions as Figure 3.5.  
Good linearity was observed from 50 pM to 500 nM for Angiotensin II and 50 pM to 100 
nM for Kemptide. The EICs for the lowest concentration of each corresponding peptide 
from three replicates are also shown in the figure with signal-to-noise ratio (S/N) being 
63.2, 32.6, 52.9 for Kemptide and 13.5, 21.1, 9.3 for Angiotensin II, respectively. 
Judging from the S/N, the LOQ for Angiotensin II is about 50 pM while the LOQ for 
Kemptide is significantly less than 50 pM. The shift of the linear dynamic range to a 
lower concentration range for Kemptide may be primarily attributed to the better 
electrospray ionization efficiency of Kemptide than that of Angiotensin II aside from 
their focusing ability difference, which is consistent with the larger slope of the trendline 
for Kemptide (e.g. 4x1012 and 2x1012 for Kemptide and Angiotensin II respectively), 
indicating a better CITP/CZE-ESI-SRM MS sensitivity for Kemptide. Due to the relative 
poor CITP focusing for Leu-enkephalin ions as compared to Kemptide and Angiotensin 
II ions, as discussed above, the LOQ for Leu-enkephalin was estimated to be about 500 
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nM (data not shown).  Table 3-2 CV from triplicate SRM MS analyses of Kemptide and 
Angiotensin II at each concentration for selected SRM transitions. further lists the CV 
values for CITP/CZE-ESI-SRM MS measurements at each concentration for both 
peptides. Median CV values of 12% and 18% for Kemptide and Angiotensin II indicate a 
good reproducibility for CITP/CZE-ESI-SRM MS sample quantitation.  Significantly 
better LOQ (~ 30 times better) is demonstrated through this study for the CITP/CZE-ESI-
SRM MS sample quantitation as compared to a recent study using CZE-ESI-SRM MS177. 
The extracted ion chromatograms from the triplicate sample analyses shown in Figure 6 
also indicate a good reproducibility in peak retention time (RSD 0.8% and 0.9% 
respectively). The retention time RSD among triplicate sample analyses across the 
concentration series is smaller than 5% with an average of 2.4% for Angiotensin II and 
3.6% for Kemptide. Considering the RT variation introduced by the manual control of the 






Figure 3.6 Calibration curve of CITP/CZE-ESI-SRM MS quantitation of 
Angiotensin II (A) and Kemptide (B) and EIC from three replicate SRM 







































































Table 3-2 CV from triplicate SRM MS analyses of Kemptide and Angiotensin II at 
each concentration for selected SRM transitions. 
Sample Concentration 
(Mol/L) 
Kemptide  (386.7-567.4) Angiotensin II (523.8-784.5) 
Peak area (%CV) Peak area (%CV) 
5.00E-11 9.3 25 
1.00E-10 3.0 21 
2.50E-10 16 6.1 
5.00E-10 2.8 24 
1.00E-09 13 29 
5.00E-09 16 3.3 
1.00E-08 11 15 
5.00E-08 12 24 






This study demonstrates the online coupling of CITP/CZE separations with triple 
quadrupole-based SRM MS by using a high efficiency interface. A LOQ of less than 50 
pM was demonstrated using a mixture of 3 peptides spiked in a BSA digest sample 
matrix at different concentrations. A linear dynamic range of 4 orders of magnitude was 
achieved with excellent reproducibility. The relatively short (30 min) analysis time using 
CITP/CZE-ESI-SRM MS also makes it suitable for high throughput sample analysis. We 
also noted the importance of the peptide selection in the optimum CITP/CZE-ESI-SRM 
MS quantitation due to the different peptide focusing abilities and ionization efficiencies. 
The selection of peptide SRM transition and optimization of CITP/CZE-ESI-SRM MS 
operating condition largely dictated the achievable instrument LOQ.  
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Chapter 4 : CITP/CZE-nanoESI-SRM MS via a Novel 
Sheathless Interface for High Sensitivity Sample 
Quantification 
Reproduced with permission from Wang, C.; Lee, C. S.; Smith, R. D.; Tang, K., 
Analytical Chemistry 2013, 85, 7308-7315 
Copyright 2013 American Chemical Society 
This is an independent work accomplished by me under guidance of Dr. Cheng Lee, Dr. 
Richard Smith and Dr. Keqi Tang.   
4.1 Introduction 
Capillary electrophoresis mass spectrometry (CE-MS) has been an attractive analytical 
technique since its inception86,162,163 due to its high separation efficiency, broad sample 
compatibility and high sensitivity detection. The utility of the CE-MS has been well 
demonstrated in e.g., proteomics169,180, metabolomics155,181 and peptidomics182 for 
performing glycoform profiling of intact proteins183,184, metabolomic profiling of clinical 
samples185-187 protein phosphorylation studies188,189. Key reasons that CE-MS is still not 
considered as the method of choice in the routine chemical or biological sample analysis 
compared to more conventional liquid chromatography (LC)-MS are its small sample 
loading capacity and less robust interface. Seeking effective solutions to these two 




Capillary electrophoresis is intrinsically a small scale separation technique with a total 
volume of typically less than several microliters. The sample loading capacity in a typical 
capillary zone electrophoresis (CZE) separation is about 1% of the total capillary volume 
as required to maintain a good separation quality, which limits the sample loading 
volume to the nanoliter range. While small sample consumption is advantageous when 
sample amount is strictly limited, it is more often a drawback limiting the measurement 
dynamic range. To overcome this limitation, transient capillary isotachophoresis 
(CITP/CZE) was developed to increase the sample loading capacity through in situ 
sample enrichment137. A sample loading capacity over 30% of the total separation 
capillary volume has been demonstrated for CITP/CZE separations73,137,190-192, increasing 
the sample loading volume to several microliters. In addition, the capability of CITP/CZE 
in selectively enriching low abundance analytes in a complex mixture also makes the 
technique effective in many biological applications as important disease related 
biomarkers often exist in a complex biomatrixes at extremely low abundances73,75. 
However, in order to achieve microliter sample loading volumes, larger i.d. (> 75 µm) 
separation capillary are needed, which poses a new challenge to the CITP/CZE-MS 
interface design. The most efficient CITP/CZE-MS interface benefits from the use of a 
smaller i.d. (< 30 µm) capillary emitter to operate electrospray ionization (ESI) in the 
nanoliters per minute flow rate range (nanoESI) as it is well documented that nanoESI 
both improves analyte ionization efficiency97 and reduces ionization bias98. 
Online coupling of CE with MS is typically achieved by using a sheath liquid87 or a 
sheathless interface. In the sheath liquid interface, either a sheath liquid flowing coaxially 
with the separation liquid or a liquid-junction91,170,177 at the ESI emitter tip is used to 
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provide the electric contact for ESI voltage. Sample dilution due to the use of sheath 
liquid limits the achievable sensitivity. To overcome this problem, several sheathless 
interface designs were developed in which the electric contact for ESI voltage was 
realized by using a special metal73,100, conductive polymer101 and carbon102 coated ESI 
emitter or inserting a metal wire into the CE separation capillary103. Other alternative 
sheathless interface designs involving the use of a micro-tee193 or a stainless tubing104 to 
connect the separation capillary with the ESI emitter to close electrical circuit for CE 
separation voltage and ESI voltage have also been reported. However, these interface 
designs, sheath liquid or sheathless, all suffer from one or multiple problems including 
sample dilution, low mechanical robustness, and poor reproducibility. The latest 
sheathless interface design developed by Moini using a chemically etched porous ESI 
emitter105 showed a much improved CE-MS performance. This interface design has been 
recently commercialized by Beckman Coulter (Brea, CA), and has led to several 
successful applications106-108,110,112,183,185,194,195. While this latest sheathless interface 
design effectively addresses several of the common problems of earlier interface designs, 
the sample loading capacity is still limited by the need to use small i.d. separation 
capillary in order to accommodate stable nanoESI operation.   
Here we report the development of a new sheathless CITP/CZE-MS interface design that 
combines the capability for large sample loading volume with stable nanoESI operation. 
The new interface effectively resolves the mismatch of existing interface designs between 
the need to use large i.d. separation capillary for large sample loading capacity and small 
i.d. emitter capillary for stable nanoESI operation. The overall novelty of the interface 
design includes a large bore separation capillary for large sample loading capacity, a 
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dilution free sheathless interface using porous emitter and a smaller emitter capillary for 
robust nanoESI operation. Detailed characterization of the new interface was performed 
to show its achievable sample loading capacity, separation peak capacity, reproducibility, 
and detection sensitivity. The use of the new sheathless CITP/CZE-MS interface to 
quantify targeted peptides in bovine serum albumin (BSA) digest matrix and its 
achievable system limit is also systematically evaluated in the study. Since the main 
focus of this study is on characterizing the new sheathless CITP/CZE-MS interface 
technology, samples with intermediate complexity were used in all the experiments.  A 
follow up study will focus on the biological applications of this new interface technology 
using more complex human serum and plasma samples. 
4.2 Experimental Section 
4.2.1 Chemicals 
BSA tryptic digest standard was purchased from Protea (Morgantown, WV). Bradykinin, 
angiotensin I, neurotensin, fibrinopeptide, substance P, kemptide, leu-enkephalin, 
angiotensin II, melittin, renin, ammonium acetate, methanol, acetic acid and hydrofluoric 
acid (49%) (HF) were purchased from Sigma (St. Louis, MO). Fused silica capillaries 
were purchased from Polymicro Technologies (Phoenix, AZ). Epoxy (EP42HT-2) was 
purchased from Masterbond (Hackensack, NJ). 
4.2.2 Sample Separation 
BSA tryptic digest standard was purchased from Protea (Morgantown, WV). Bradykinin, 
angiotensin I, neurotensin, fibrinopeptide, substance P, kemptide, leu-enkephalin, 
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angiotensin II, melittin, renin, ammonium acetate, methanol, acetic acid and hydrofluoric 
acid (49%) (HF) were purchased from Sigma (St. Louis, MO). Fused silica capillaries 
were purchased from Polymicro Technologies (Phoenix, AZ). Epoxy (EP42HT-2) was 
purchased from Masterbond (Hackensack, NJ). 
A stock solution of ten peptide mixture (bradykinin, angiotensin I, neurotensin, 
fibrinopeptide, substance P, kemptide, leu-enkephalin, angiotensin II, melittin, and renin) 
at 10 µM concentration for each peptide was first prepared in deionized water and 
stocked in aliquots. The stock solution was subsequently diluted to 3.75 µM using LE 
solution to serve as a working solution for the performance evaluation and optimization 
of the online sheathless CITP/CZE-nanoESI-MS platform. The stock solution of ten 
peptide mixture was further mixed with 50 nM BSA tryptic digest in 25 mM LE at 
different concentrations ranging from 10 pM to 500 nM for each peptide in the 
CITP/CZE SRM MS sample quantification experiments. Among the 10 peptides in the 
sample mixture, leu-enkephalin, angiotensin II and kemptide were selected as 
representative targets in CITP/CZE-selected reaction monitoring (SRM) MS experiments 
due to their good signal intensity displayed in our previous study190.   
4.2.3 Sheathless CITP/CZE-MS Interface 
The upper part of Figure 4.1 shows the experimental setup used in this study which is a 
modified setup used in our previous work.1 Briefly, one end of the separation capillary 
was inserted in a sealed reservoir for hydrodynamic sample loading or system flushing as 
well as the application of separation voltage while the joint between the other end of the 
separation capillary and porous emitter capillary was enclosed in a metal tube containing 
electrically conductive liquid using a peek cross. A syringe filled with conductive liquid 
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was also connected to the peek cross to fill and refresh the metal tube prior and between 
each sample analysis. A second ESI voltage was applied directly on the metal tube and 
the CITP/CZE-nanESI was interfaced with a triple quadrupole mass spectrometry. The 
new sheathless CITP/CZE-MS interface design, as shown in the lower part of Figure 4.1, 
involves the use of two different capillaries. A larger i.d. fused silica capillary (360 µm 
o.d., 100 µm i.d., and 95 cm long) was used as the separation capillary with its inner 
surface coated with hydroxypropyl cellulose to minimize electroosmotic flow. The 
coating was prepared by first flushing capillary with 1 mL 1M HCL, by applying 15 psi 
N2 back pressure to the solvent reservoir, and then flushing 200 µl 5% hydroxypropyl 
cellulose using 20 psi N2 back pressure. Finally, the capillary was flushed with deionized 
water to remove excessive hydroxypropyl cellulose. A smaller i.d. capillary (90 µm o.d., 
20 µm i.d., and ~4 cm long) was used as ESI emitter.  
A section of the emitter capillary, ~ 3 cm long from one end, was chemically etched to 
make it porous using the method described by Moini 105 to provide electric contact and 
serve as ESI emitter without further sharpening the emitter tip (etching experiments using 
HF must be conducted in hood. Goggle, rubber gloves and aprons are required for 
personnel protection), and the other end of the emitter capillary was subsequently 
inserted into the separation capillary. The assembly was then sealed by carefully 
wrapping the acid resistant epoxy around the joint and the epoxy was cured at room 
temperature overnight. Extended epoxy cure time at elevated temperature may be needed 
if dealing with stronger acid and is optional with the current setup in this study. The joint 
was then enclosed in a short metal tube (0.04” i.d., 1/16” o.d., and 5 cm long) filled with 
the contact solution of 2% (by volume) acetic acid in deionized water to form a 
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sheathless CITP/CZE MS interface. The interface contact solution was refreshed after 
each CITP/CZE MS sample analysis to ensure a good electric contact for the 
measurement reproducibility.  
Due to the existence of size change at the capillary joint, it is important to keep all the 
connecting union and cross clean to prevent capillary blockage. Moreover, buffers and 
samples should be prepared with filtered deionized water. Prior to each run, the 
separation capillary was filled with BGE solution and flushed for 15 min by applying 15 
psi back pressure in the BEG reservoir (Figure 4.1). Samples were loaded into the 
separation capillary at the same back pressure with the loading amount adjusted by 
varying the length of loading time. After sample loading, the sample reservoir at the 
capillary inlet was replaced by the BGE reservoir and a 30 kV separation voltage was 
applied to the sample inlet using a Glassman high voltage power supply.  A second 
voltage varying from 1.5 to 1.7 kV was applied to the metal tube at the emitter end of the 
capillary for stable electrospray operation using a Bertan high voltage power supply. The 
ESI voltage was adjusted for each emitter capillary to achieve optimum sensitivity and 
signal stability at each CITP/CZE flow rate. Position of the emitter relative to the MS 
inlet was also optimized for best signal intensity and stability. During CITP/CZE 
analysis, a smaller gas pressure varying from 1 psi to 3 psi, referred as eluting pressure, 





Figure 4.1 Schematic of CITP/CZE-nanoESI-QQQ MS setup used in this study. 




The new sheathless CITP/CZE-MS interface developed in this study has the benefit of 
achieving both large sample loading capacity and dilution free nanoESI operation 
simultaneously for significantly better sensitivity. The detachable design between the 
large i.d. separation capillary and small i.d. ESI emitter capillary also provides more 
flexibility in accommodating different experiment requirements. As the separation 
capillary and emitter capillary are prepared separately, the sizes of the separation 
capillary and emitter capillary can be altered independently and special treatment of the 
separation capillary can be performed easily. In addition, the porous emitter can be 
readily replaced without the need to change the separation capillary with little effort in 
case of blockage or broken emitter.  
For the performance comparison, a sheathless CITP/CZE-MS interface using a single 
capillary (140 µm o.d., 30 µm i.d., and 95 cm long) was also prepared. The capillary was 
first neutrally coated with hydroxypropyl cellulose and a 3 cm section from one end of 
the capillary was then chemically etched to porous. The sample loading volume and 
eluting pressure was adjusted to obtain the optimum operating conditions for the 
interface. 
4.2.4 Flow Rate Calibration 
To correctly determine the liquid flow rate based on the gas pressure applied at the 
separation capillary inlet reservoir, the complete CITP/CZE setup was first calibrated 
experimentally. The liquid flow rates at different gas pressures were determined by using 
a calibrated pipet (1 to 5 mL, Drummond Scientific, Broomall, PA) to collect the liquid 
exiting the ESI emitter and measure the time for collecting 1 µL liquid under a given gas 
pressure. The experimental measurements showed a linear dependence of liquid flow rate 
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on the gas pressure (Figure 4.2). Prior to each CITP/CZE-ESI-MS experiment, the flow 
rate at 15 psi gas pressure was measured so that the sample loading time and the eluting 
pressure could be adjusted accordingly to ensure the reproducibility of the sample loading 
volume and ESI flow rate. 
4.2.5 MS Optimization and Data Processing 
All the CITP/CZE-nanoESI-MS analyses were performed using a triple quadruple mass 
spectrometer (TSQ Quantum ultra, Thermo Fisher Scientific, MA). The inlet capillary of 
the mass spectrometer was maintained at 200 °C. Unit resolution (0.7 Da peak width) 
was used for Q3 in full scan MS and for both Q1 and Q3 in SRM operating mode. All the 
MS spectra were recorded in profile mode. In full scan MS mode, m/z range from 300 to 
1400 was used with a scan time of 0.3 sec. Three most intense transitions and their 
corresponding collision energies for each targeted peptide in CITP/CZE-nanoESI-SRM 
MS sample quantification experiment were determined by using a fully automated 
compound optimization procedure in Thermo TSQ Tune view. Table 1 listed all the 
transitions and their corresponding collision energies for six targeted peptides used for 
sample quantification in which three peptides from BSA digest were used as quality 
control analytes to ensure measurement reproducibility.  
All the data analyses of the raw MS files were carried out using Thermo Xcalibur Qual 
Browser 2.2. In the chromatogram ranges setting, peak algorithm was selected as ICIS. 
No smoothing or baseline subtraction was used and the default setting was used for mass 
tolerant. Auto peak detection with default parameters was used for all the peak extraction 
and peak area measurement while manual integration was also used to verify all the peak 




Figure 4.2 Measured liquid flow rate as a function of gas pressure applied at the 




























4.3 Results and Discussion 
4.3.1 Sample Loading Optimization 
The performance of the new CITP/CZE-MS interface was first evaluated for its sample 
loading capacity and separation quality. CITP/CZE separations were carried out under 
different sample volumes ranging from 0.27 µL to 3.07 µL using a 10 peptide mixture 
(3.75 µM concentration for each peptide) in 25 mM ammonium acetate. Sample loading 
volume was varied by adjusting the loading time at a given gas pressure (15 psi) as 
calculated according to the flow rate calibration described in the experimental section.  
Figure 4.3 shows the extracted ion chromatogram (EIC) at different sample loading 
volumes with the ESI flow rate measured at 60 nL/min. Well focused narrow peaks were 
achieved except two late eluting peaks (peak 9 and 10 in Figure 4.3) as focusing factor 
decreases as the electric mobility of analyte ion decreases. The focusing factor of the later 
eluting peptides can be further increased by increasing the LE concentration190. Baseline 
separation of the ten peptides was achieved at sample loading volumes of 1.39 µL (Figure 
4.3A) and 1.95 µL (Figure 4.3B), which equal to 18% and 26% of the total separation 
capillary volume respectively. Good separation was still achieved even at 2.5 µL sample 
loading volume which accounted for 33% of the total capillary volume (Figure 4.3C). 
Significant peak overlapping and loss of separation quality was observed at the sample 
loadings beyond 2.5 µL due to incomplete CITP sample focusing and insufficient 
separation time. The loading capacity result shown in Figure 4.3 is consistent with our 
previous study using a sheath liquid interface190 in which up to 1/3 of the total separation 
volume was allowed in CITP/CZE before a significant loss of separation quality was 
observed. The consistency between these two studies using completely different 
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interfaces implies that the size change from 20 µm to 100 µm at the junction between the 
emitter capillary and the separation capillary in the current sheathless interface has minor 
effect on the separation quality. A possible explanation could be that the analyte band 
speed under the experimental operating condition was significantly faster than the speed 
of the liquid flow, providing effective analyte peak compression in the ESI process. 
Despite some overlapping and peak broadening of the late eluting peaks 9 and 10 at 2.5 
µL sample loading volume (Figure 4.3C), a separation window of more than 20 minutes 
was observed for all the sample loading volumes shown in Figure 4.3. In addition, the 
signal intensity keeps increasing as the sample loading volume increases.  Since all of our 
selected peptide targets in the following sample quantification study elute much earlier 
than peaks 9 and 10, unless specified otherwise, 2.5 µL (33%) sample loading volume 
was chosen in all the subsequent experiments to maximize the measurement sensitivity. It 
was also observed experimentally that the CITP/CZE separation quality at a given sample 






Figure 4.3 Extracted ion chromatograms (EICs) of CITP/CZE separations using a 
10 peptide mixture solution at different sample loading volumes. 
The labeled peaks from 1 to 10 are melittin, kemptide, substance p, bradykinin, 
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enkephalin [YGGFL+H]+ 556.3 397.2 (a4
+) 25 19 
556.3 425.2 (b4
+) 25 16 
556.3 278.1 (b3
+) 25 25 
Angiotensin II [DRVYIHPF+2H]2+ 523.8 263.1 (y2
+) 25 20 
523.8 784.4 (b6
+) 25 18 
523.8 647.4 (b5
+) 25 22 
Kemptide [LRRASLG+2H]2+ 386.7 567.3 (b5
+-NH3) 25 18 
386.7 409.3 (b3
+-NH3) 25 25 
386.7 539.4 (a5
+-NH3) 25 22 
BSA peptide I [LVNELTEFAK+2H]2+ 582.3 951.5 (y8
+) 25 18 
582.3 595.3 (y5
+) 25 20 
582.3 837.4 (y7
+) 25 16 
BSA peptide II [HLVDEPQNLIK+2H]2+ 653.4 712.4 (y6
+) 25 26 
653.4 251.2 (b2
+) 25 26 
653.4 1056.7 (y9
+) 25 23 
BSA peptide III [CCTESLVNR+2H]2+ 512.7 637.2 (b6
+) 25 17 
512.7 581.7 (a6
+- 28) 25 16 
The bolded transitions indicate the transition used for quantification of each peptide. The non 
bolded/italicized transitions were used to confirm the peptide’s identity. The italicized transition of BSA 
peptide was used to monitor the platform’s reproducibility and calibration. 
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4.3.2 Performance Characterization of the Sheathless CITP/CZE-MS Interface 
Following the initial sample loading volume optimization, the CITP/CZE- QQQ MS 
instrumental platform with the new sheathless interface was characterized systematically 
using the ten peptides spiked in 50 nM BSA digest in 25 mM LE at different 
concentrations. The mass spectrometry was operated in a highly sensitive SRM mode in 
which specific precursor-to-fragment ion transitions were monitored for each analyte in 
the sample solution. Three peptides (leu-enkephalin, kemptide and angiotensin II) in the 
sample mixture were chosen as the representative peptide targets in this study due to their 
good electrospray ionization efficiencies from our previous study190 and three peptides 
from BSA digest were also chosen to evaluate the stability of the instrument platform. 
Three most abundant transitions for each selected peptide, as listed in Table 4-1, were 
monitored in all the CITP/CZE-SRM MS analyses. 
The advantage of analyte focusing was evaluated by comparing CITP/CZE with CZE at 
the same sample loading volume. With 2.5 µL sample loading and identical experimental 
setup as well as operating parameters, a broad kemptide peak with a flat top peak 
intensity caused by the long sample plug was resulted from CZE operation. In contrast, a 
sharp narrow peak was obtained in CITP/CZE separation mode which displays a 77 times 
higher peak intensity implying an approximately two orders of magnitude gain in signal 





Figure 4.4 EICs for kemptide from A) CZE-MS and B) CITP/CZE-MS analyses. 
Sample condition: 2.5 µL of 50 nM peptide in 50 nM BSA digest using solvent 0.1 M 
acetic acid in deionized water for CZE and 2.5 µL of 50 nM peptide in 50 nM BSA digest 































One of the unique features of the new sheathless CITP/CZE-MS interface developed in 
this study is its capability to use large i.d. separation capillary for increased sample 
loading volume and small i.d. emitter capillary for stable nanoESI operation 
simultaneously, both which are critical to the sensitivity achieved. This is evident by 
comparing the performance of the new interface with a conventional sheathless 
CITP/CZE-MS interface in which a single capillary (30 µm i.d., 360 µm o.d., and 95 cm 
long) was used for both CTIP/CZE separation and nanoESI operation113,195.The same 
sample as in the focusing experiment (Figure 4.4) was used for the evaluation. With the 
same 33% of the sample loading volume with respect to the total capillary volume, 220 
nL sample was loaded using the conventional sheathless CITP/CZE-MS interface while 
2.5 µL sample was loaded using the new sheathless CITP/CZE interface. Separations in 
both interface configurations were performed under equal linear velocity of 0.75 cm/min 
to achieve similar separation quality, corresponding to 60 nL/min in the new interface 
and 5 nL/min in the conventional single capillary interface. Figure 4.5 shows the 
sensitivity comparison between these two interfaces using kemptide EIC. While similar 
peak widths were observed for both interface configurations, the kemptide peak intensity 
using the new CITP/CZE-MS interface (Figure 4.5A) shows a 11 fold improvement as 
compared to using the conventional sheathless CITP/CZE-MS interface (Figure 4.5B), 






Figure 4.5 Sensitivity comparison of kemptide EIC using interfaces with different 
sizes 
A) the new sheathless CTIP/CZE-MS interface with a 100 µm i.d. separation capillary 
and a 20 µm i.d. ESI emitter, and B) a conventional sheathless CITP/CZE-MS interface 
with a single 30 µm i.d. capillary for both CITP/CZE separation and ESI emitter. Sample 
condition: 50 nM target peptides spiked in 50 nM BSA digest in 25 mM LE. 
 
  


























Figure 4.6 SRM TIC of CITP/CZE separations at different flow rates. 
The labeled peaks from 1 to 6 are kemptide, BSA peptide III, BSA peptide II, angiotensin 
II, BSA peptide I, and leu-enkephalin, respectively. Sample condition: 50 nM target 
































































The benefit of operating electrospray at reduced flow rate was further demonstrated by 
operating the sheathless CTIP/CZE-ESI-SRM MS at different flow rates ranging from 30 
nL/min to 377 nL/min. Figure 4.6 shows the total ion chromatogram (TIC) for kemptide, 
angiotensin II, leu-enkephalin and three selected BSA peptides from the CTIP/CZE-ESI-
SRM MS analyses using the new sheathless interface at four representative ESI flow 
rates of 188 nL/min, 87 nL/min, 58 nL/min and 32 nL/min, respectively. As the flow rate 
decreased from 188 nL/min (Figure 4.6A) to 32 nL/min (Figure 4.6D), the effective 
separation window for all six monitored peptides increased from 10 min to 33 min and all 
the peptide peaks became increasingly separated from each other indicating a higher 
separation resolution at a lower ESI flow rate. The best CITP/CZE separation was 
achieved at 32 nL/min while a complete loss of separation was observed at the flow rate 
exceeding 261 nL/min.  
Figure 4.7 further shows the change of peak elution time, peak width and peak intensity 
as a function of ESI flow rate. While the retention time for all the peptide peaks 
consistently increases with the decrease of the ESI flow rate (Figure 4.7A), the peak 
widths remain essentially unchanged (Figure 4.7B). More importantly, the intensity for 
all the peptide peaks increases as the flow rate decreases (Figure 4.7C) down to 58 
nL/min because of higher ESI efficiency at lower flow rate. The observed decrease of the 
peak intensity at 32 nL/min flow rate for angiotensin II and leu-enkephalin relative to the 
peak intensity at 58 nL/min might be related to the stability of the electrospray implying 
an even smaller i.d. ESI emitter is needed. The peak capacity of the CITP/CZE separation 
can be also estimated based on the experimental measurements shown in Figure 4.6 and 
Figure 4.7. In Table 4-2, the peak capacity at different flow rates was calculated using the 
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average peak width at half peak height for five peptide peaks with Leu-enkephalin peak 
(peak 6) excluded from the peak width calculation due to its incomplete focusing. A peak 
capacity as high as over 200 was estimated for the sheathless CITP/CZE separation at 32 
nL/min and good separation efficiency can be maintained at ESI flow rate lower than 100 
nL/min. 
4.3.3 Targeted Peptide Quantification 
The analytical utility of the sheathless CITP/CZE-SRM MS was further evaluated for its 
linear dynamic range, limit of quantification (LOQ), and reproducibility. Triplicate 
analyses were performed using peptides (Table 4-1) spiked in 50 nM BSA digest at 
different concentrations from 10 pM to 500 nM. Flow rate of 60 nL/min was used in the 
CITP/CZE-SRM MS quantification due to the overall good ESI stability, peak capacity 
and sensitivity as discussed above. Quantification of each peptide was carried out using 
the most abundant transition (bolded in Table 4-1). One additional BSA peptide 
(italicized in Table 4-1) was also monitored as “internal standard” during each 
CITP/CZE-ESI-MS analysis to ensure the measurement stability and correct the small 





Figure 4.7 CITP/CZE peak elution time (A), peak width (B) and peak intensity (C) 
at different flow rates. 
kemptide  (),  angiotensin II (),  leu-enkephalin (),  BSA peptide I (),  BSA peptide II 






































































































































































































































Figure 4.8 CITP/CZE-SRM MS quantification of kemptide (A) and angiotensin II 
(B) in BSA digest matrix. 
Top: Calibration curve between peak area and sample concentration; Middle: EICs from 
SRM measurements at 10 pM, 25 pM, 50 pM sample concentrations; Bottom: peak area 
CV at different concentrations. 
  
Concentration (nM) 0.010 0.025 0.05 0.5 5 50 100 250 500
CV
(%)
Kemptide 12 8 6 11 22 15 18 9 10


































































































Figure 4.8 shows the CITP/CZE-nanoESI-SRM MS quantification results for kemptide 
(Figure 4.8A) and angiotensin II (Figure 4.8B).  Good linearity (R2 > 0.97) for both 
targeted peptides between the concentration and peak area was observed in the 
concentration range from 10 pM to 500 nM, indicating 4.5 orders of magnitude linear 
dynamic range. Based on the signal-to-noise ratio (S/N) and the measurement CV shown 
in Figure 4.8, The LOQs for both kemptide and angiotensin II is estimated to be at 10 pM 
which corresponds to 25 attomoles total sample loading. The LOQ for kemptide is 
significantly better than the LOQ for angiotensin II mainly due to the better CITP 
focusing and lower chemical background for kemptide. The LOQ for leu-enkephalin was 
estimated to be about 500 pM (data not shown) due to insufficient CITP focusing. Good 
measurement reproducibility was also observed as the CVs for all the peak area and peak 






Table 4-3 Retention time deviation of triplicate CITP/CZE-SRM MS analyses at 

















1.0E‐11  7%  2%  2%  3%  0%  3% 
2.5E‐11  5%  8%  6%  7%  9%  7% 
5.0E‐11  5%  5%  5%  5%  6%  5% 
5.0E‐10  9%  9%  10%  9%  9%  9%  9% 
5.0E‐09  5%  6%  0%  6%  6%  8%  5% 
5.0E‐08  5%  7%  7%  6%  6%  7%  6% 
1.0E‐07  4%  5%  0%  5%  5%  0%  3% 
2.5E‐07  1%  2%  4%  1%  2%  3%  2% 
5.0E‐07  9%  2%  1%  9%  2%  2%  4% 




A detailed experimental evaluation of the new sheathless CITP/CZE-MS interface in this 
study showed its capabilities of both high sample loading capacity and stable nanoESI 
operation and demonstrated its utility in achieving high sensitivity CITP/CZE-nanoESI 
SRM MS sample quantification. Sample loading volume in µL range for CITP/CZE 
separation is provided by using a large bore separation capillary in the new interface 
without the degradation of separation quality, enabling a sample loading capacity 
comparable to that in typical nanoLC separations. The new interface also allows stable, 
dilution free ESI operation at low nanoliters per minute flow rate which was shown to 
simultaneously improve the CITP/CZE separation quality and MS detection sensitivity. 
The high accuracy for sample quantification (CV < 22%) and the low picomolar LOQ 
using the new sheathless CITP/CZE-ESI-SRM MS instrument platform make it suited for 
high sensitivity quantitative sample analysis. This sheathless CITP/CZE-MS interface 
design can be easily coupled to multiple mass spectrometers or used in different CE 
operation modes for ultrasensitive analysis. It may also provide a basis for coupling with 
other separation methods to perform multidimensional separations. Our future work will 
focus on exploring the potential of the new sheathless CITP/CZE-MS for high sensitivity 
proteomics measurements. 
4.5 Acknowledgements 
This work was partially supported by grants from the National Institutes of Health: 
National Cancer Institute (1R33CA155252), National Institute of General Medical 
Sciences (8 P41 GM103493-10), National Cancer Institute (R21 CA143177), and 
113 
 
National Institute of General Medical Science (R21 GM103536). All the experiments 
were performed in the Environmental Molecular Sciences Laboratory, a U.S. DOE 
national scientific user facility located at the Pacific Northwest National Laboratory 
(PNNL) in Richland, Washington. PNNL is a multi-program national laboratory operated 




Chapter 5 : Conclusion 
Understanding disease-related changes including protein expression level, post-
translational modifications and functional pathway has profound impact in our 
understanding of how disease occurs and develops, which is essential to develop effective 
stradegies for disease prevention and treatment. While the conventional discovery based 
approaches have encountered challenges in obtaining biological and clinical relevant 
information, a shift in proteomic field began to take place from discovery proteomics to 
targeted proteomics. Sensitive, reproducible and quantitative analysis focused on a subset 
of the proteome not only helps to reduce the sample complexity, more importantly it 
allows researchers to address specific biological questions to their line of inquiry. In 
addition, targeted proteomics enables matching of the proteomic data to the data 
mountain generated from high-throughput biology experiments like DNA sequencing and 
genome analysis for researchers to utilize and build on this knowledge.  
Our goal was to demonstrate the application of a CITP/CZE based multidimensional 
separation platform in targeted tissue proteomic analysis, which provides selective 
analyte enrichment and high resolving power with minimal interference from the cell 
heterogeneity in samples. We also wanted to provide a CITP/CZE based hyphenation 
strategy as an alternative to the nanoLC-MS systems, which would allow ultrasensitive 
quantitation with optimal enrichment and resolving power while improving the 
throughput and versatility compared with nanoLC-MS.  
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5.1 Realization of Research Objectives 
5.1.1 Targeted Tissue Proteomic through CITP/CZE Based Multidimensional Platform 
Considering sample complexity and cell heterogeneity of human tissues, disease related 
information can only be obtained from homogeneous cell population that is free from 
interference and misleading information from unwanted cells. Targeted analysis was 
performed on homogeneous tumor cells microdissected from astrocytoma tumor tissues 
using LCM to identify confident biomarker candidate. The selective enriching capability 
of CITP/CZE towards low abundance analytes in complex protein/peptide mixtures and 
the intrinsic high resolving power together with LCM displayed a synergetic effort in 
reducing the complexity as well as the dynamic range of proteins which always pose 
great challenges in analysis of biological samples.  
Comparing other multidimensional separation platform such as MuDPIT which consists 
of SCX and RPLC as first and second separation, or 2D RPLC which utilizes high pH 
and low pH RPLC, the CITP/CZE-nanoRPLC-ESI-MS platform demonstrated significant 
advantages in several aspects. First of all, CITP/CZE provides pre-concentration of 
analytes which can improve signal intensity with several orders of magnitudes while none 
of the fore-mentioned separation platform performs sample enriching, let alone selective 
enrichment which brings the trace analytes to more detectable region of MS. Secondly, 
CITP/CZE displayed outstanding resolving power with more than 80% of peptides 
detected only in one fraction, comparing with only 40% in SCX separation as a result of 
low resolving power. Peptide overlapping in multiple fractions is likely to cause loss of 
sensitivity because of analyte dilution as well as increasing the chance of peak 
overlapping in detection. Thirdly, CE and RPLC separate analytes based on different 
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physiochemical properties generating “orthogonal separation” when coupled together, 
where co-eluting peptides in one dimension are likely to get well separated in the other 
dimension. Low pH-high pH-RPLC multidimensional separation, on the other hand, only 
demonstrates small orthogonality between the two dimensions which in turns would be 
expected to display inferior separation power comparing with CE-RPLC separation. 
The utilization of the CITP/CZE based multidimensional separation platform achieved 
successive handling of 1 µg of each sample  loading and displayed comprehensive 
identification of more than 3000 unique proteins with 19% attributed to membrane 
proteins. Comparative proteomics and pathway function mapping allowed identification 
of confident biomarkers which were further validated using immuno quantification assay. 
5.1.2 Online CITP/CZE-ESI-SRM MS for Targeted Quantification 
The second goal, of providing ultrasensitive targeted quantification techniques through 
CITP/CZE was achieved in online coupling with SRM MS via both sheathliquid and 
sheathless interfaces which demonstrate both robustness and sensitivity. Again, the 
selective enrichment and high resolving power of CITP/CZE plays a key role in 
achieving ultrasensitive quantification of target peptides in biological background at LOQ 
of 10 pM while good CV and S/N was achieved even at the limit point of sample 
concentration. The online interfacing of CITP/CZE with MS through in house developed 
interfaces were designed to optimally reserve the enriching factor and resolving power by 
minimizing sheathliquid dilution and dead volume for peak broadening.  
In interface design and development, factors like sample loading capacity, electrolysis 
interference, firm electric contact and nano flow rate operation in addition to dilution and 
dead volume were our top concerns. In sheathliquid interface design, we avoided the use 
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of metal in the main separation path and adopted an off-path waste line to ESI voltage 
application to eliminate the electrolysis interruption of the separation procedure. And 
electrokinetic pumped sheathflow was employed instead of pressure pumped flow to 
operate ESI at nano range. In order to further improve the sensitivity of the platform, a 
sheathless interface was then developed to substitute the sheathliquid design. We 
preserved the usage of large bore capillary to ensure the sample loading capacity which is 
essential to sensitive detection of trace analytes and managed to couple with improved 
ionization efficiency with nanoESI operation via small size porous emitter. Overall, the 
work in the chapter 3 and 4 demonstrates the excellent capability of online CITP/CZE-
ESI-MS through both sheathliquid and sheathless interface for targeted quantitative 
analysis, proving the platform to be a potential powerful tool in biomarker validation 
research field for improved sensitivity and throughput. 
5.2 Future Research Directions 
5.2.1 Application in Real Samples with High Complexity 
Work introduced in Chapter 3 and 4 utilized sample of medium complexity as proof of 
concept demonstration and was more focused on fundamental aspects of technology 
development of the online CITP/CZE-ESI-SRM MS platform. Further application of the 
platform to complex samples like human saliva, plasma or to particular research subjects 
such as PTM analysis will help validate the capability of the analysis platform within a 
more specific research context and determine the strength and weakness towards different 




Our work on online CITP/CZE-MS for quantitation in SRM mode was the first work 
published to the best of our knowledge, so it has been hard to test the performance 
improvement over other existing interfaces or platform. It would be valuable to test same 
samples on other literature published interfaces or on commercial products with same 
experiment conditions to get a side-by-side comparison for better understanding of the 
performance of this platform. Moreover, in order to achieve our goal as to provide a 
platform as an alternative for current LC-MS system it would be beneficial to conduct a 
direct comparison between these two platforms to understand the differences and 
advantages.  
5.2.2 Incorporation of LC based separation for multidimensional separation platform 
Although we have adopted a multidimensional separation platform as described in 
Chapter 2, the LC separation performed as the second dimension has always been a 
bottleneck for higher throughput analysis. Therefore, the length and size of LC column is 
also limited to obtain reasonable analysis time in trade for separation performance. In 
addition, the analyte enrichment is compromised during fraction collection where in 
theory the greatest signal increase is expected. 
Concerning the effectiveness of the interface development to couple CITP/CZE with MS 
and the proven performance, switching the order of CITP/CZE and LC separation should 
have significant improvement in terms of sensitivity, throughput and provides much room 
to further improve the performance of the multidimensional separation platform without 
sacrificing throughput. Firstly, the concentrated analyte bands can be detected in their 
optimal concentration which will be big advantage toward the low abundance compounds 
in the sample. Secondly, the dimension of LC separation can be extended and separation 
119 
 
be performed at longer duration to achieve better separation without slowing down the 
entire throughput. Thirdly, large sample loading is enabled which will in turn benefit the 
detection sensitivity of trace analytes.  
In my future studies, I plan to employ an LC system that is adopted from PRISM system 
as describe in one of co-workers previous publications which has proven to display 
outstanding separation and sensitivity. The LC separation would consist of a 200 µm i.d. 
50 cm long capillary column packed with 3 µm C18 particles and 100 min or even longer 
LC run would be employed. Fraction collected from LC separation would be sequentially 
injected into the online sheathless CITP/CZE-ESI-SRM MS platform described in 
Chapter 4 for further separation, selective concentration and targeted quantitation. 
Analysis results would be compared with single dimension CITP/CZE-ESI-SRM MS as 
well as conventional PRISM system to provide useful insight of the capabilities of the 
new two-dimensional separation platform. 
5.2.3 Application in fields other than proteomics 
Capillary electrophoresis is known for its versatility in different operation mode and its 
wide compatibility with different samples from small molecules like amino acids, 
metabolites to large molecules like peptides or even intact proteins. In addition, the high 
resolving power of CE separation is often useful to separation isomers which are 
inseparable in LC. Having demonstrated the feasibility and capability of the online CE-
MS platform in peptides, we would like to examine the use of the platform in other fields 
of study such as metabolomics or intact proteins which does not usually behave well in 
LC separation due to the similarity in structures and extreme small/large molecular 
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weight.  The long term goal is to develop applicable analyzing platforms based on this 








(1) Xue, A.; Gandy, R. C.; Chung, L.; Baxter, R. C.; Smith, R. C.: Discovery of 
diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF 
MS. Pancreatology 2012, 12, 124-129. 
(2) Kosanam, H.; Prassas, I.; Chrystoja, C. C.; Soleas, I.; Chan, A.; 
Dimitromanolakis, A.; Blasutig, I. M.; Ruckert, F.; Gruetzmann, R.; Pilarsky, C.; 
Maekawa, M.; Brand, R.; Diamandis, E. P.: LAMC2: A promising new pancreatic cancer 
biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues. Mol 
Cell Proteomics 2013. 
(3) McKinney, K. Q.; Lee, J.-G.; Sindram, D.; Russo, M. W.; Han, D. K.; 
Bonkovsky, H. L.; Hwang, S.-I.: Identification of differentially expressed proteins from 
primary versus metastatic pancreatic cancer cells using subcellular proteomics. Cancer 
Genomics Proteomics 2012, 9, 257-263. 
(4) Wang, Y.; Kuramitsu, Y.; Ueno, T.; Suzuki, N.; Yoshino, S.; Iizuka, N.; Zhang, 
X.; Akada, J.; Oka, M.; Nakamura, K.: Proteomic differential display identifies 
upregulated vinculin as a possible biomarker of pancreatic cancer. Oncol Rep 2012, 28, 
1845-1850. 
(5) Takadate, T.; Onogawa, T.; Fukuda, T.; Motoi, F.; Suzuki, T.; Fujii, K.; Kihara, 
M.; Mikami, S.; Bando, Y.; Maeda, S.; Ishida, K.; Minowa, T.; Hanagata, N.; Ohtsuka, 
H.; Katayose, Y.; Egawa, S.; Nishimura, T.; Unno, M.: Novel prognostic protein markers 
of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics 
using formalin-fixed paraffin-embedded tissues. Int J Cancer 2013, 132, 1368-1382. 
122 
 
(6) Tan, F.; Jiang, Y.; Sun, N.; Chen, Z.; Lv, Y.; Shao, K.; Li, N.; Qiu, B.; Gao, Y.; 
Li, B.; Tan, X.; Zhou, F.; Wang, Z.; Ding, D.; Wang, J.; Sun, J.; Hang, J.; Shi, S.; Feng, 
X.; He, F.; He, J.: Identification of isocitrate dehydrogenase 1 as a potential diagnostic 
and prognostic biomarker for non-small cell lung cancer by proteomic analysis. Mol Cell 
Proteomics 2012, 11. 
(7) Gamez-Pozo, A.; Sanchez-Navarro, I.; Calvo, E.; Agullo-Ortuno, M. T.; Lopez-
Vacas, R.; Diaz, E.; Camafeita, E.; Nistal, M.; Madero, R.; Espinosa, E.; Lopez, J. A.; 
Fresno Vara, J. Á.: PTRF/cavin-1 and MIF proteins are identified as non-small cell lung 
cancer biomarkers by label-free proteomics. PLoS One 2012, 7. 
(8) Yang, J.; Song, Y.-C.; Song, T.-S.; Hu, X.-Y.; Guo, Y.-M.; Li, Z.-F.; Dang, C.-
X.; Huang, C.: Identification of novel low molecular weight serum peptidome biomarkers 
for non-small cell lung cancer (NSCLC). J Clin Lab Anal 2012, 26, 148-154. 
(9) Chen, W.-L.; Kuo, K.-T.; Chou, T.-Y.; Chen, C.-L.; Wang, C.-H.; Wei, Y.-H.; 
Wang, L.-S.: The role of cytochrome c oxidase subunit Va in non-small cell lung 
carcinoma cells: association with migration, invasion and prediction of distant metastasis. 
BMC Cancer 2012, 12, 273-273. 
(10) Kang, J.-H.; Mori, T.; Kitazaki, H.; Niidome, T.; Takayama, K.; Nakanishi, Y.; 
Katayama, Y.: Kinase activity of protein kinase cα in serum as a diagnostic biomarker of 
human lung cancer. Anticancer Res 2013, 33, 485-488. 
(11) Liu, Y.; Luo, X.; Hu, H.; Wang, R.; Sun, Y.; Zeng, R.; Chen, H.: Integrative 
proteomics and tissue microarray profiling indicate the association between 
overexpressed serum proteins and non-small cell lung cancer. PLoS One 2012, 7. 
123 
 
(12) Kikuchi, T.; Hassanein, M.; Amann, J. M.; Liu, Q.; Slebos, R. J. C.; Rahman, S. 
M. J.; Kaufman, J. M.; Zhang, X.; Hoeksema, M. D.; Harris, B. K.; Li, M.; Shyr, Y.; 
Gonzalez, A. L.; Zimmerman, L. J.; Liebler, D. C.; Massion, P. P.; Carbone, D. P.: In-
depth proteomic analysis of nonsmall cell lung cancer to discover molecular targets and 
candidate biomarkers. Mol Cell Proteomics 2012, 11, 916-932. 
(13) Ueda, K.; Tatsuguchi, A.; Saichi, N.; Toyama, A.; Tamura, K.; Furihata, M.; 
Takata, R.; Akamatsu, S.; Igarashi, M.; Nakayama, M.; Sato, T.-A.; Ogawa, O.; Fujioka, 
T.; Shuin, T.; Nakamura, Y.; Nakagawa, H.: Plasma Low-molecular-weight Proteome 
Profiling Identified Neuropeptide-Y as a Prostate Cancer Biomarker Polypeptide. J 
Proteome Res 2013. 
(14) Takakura, M.; Yokomizo, A.; Tanaka, Y.; Kobayashi, M.; Jung, G.; Banno, M.; 
Sakuma, T.; Imada, K.; Oda, Y.; Kamita, M.; Honda, K.; Yamada, T.; Naito, S.; Ono, M.: 
Carbonic anhydrase I as a new plasma biomarker for prostate cancer. ISRN Oncol 2012, 
2012, 768190-768190. 
(15) Qian, X.; Li, C.; Pang, B.; Xue, M.; Wang, J.; Zhou, J.: Spondin-2 (SPON2), a 
more prostate-cancer-specific diagnostic biomarker. PLoS One 2012, 7. 
(16) Profumo, A.; Mangerini, R.; Rubagotti, A.; Romano, P.; Damonte, G.; 
Guglielmini, P.; Facchiano, A.; Ferri, F.; Ricci, F.; Rocco, M.; Boccardo, F.: 
Complement C3f serum levels may predict breast cancer risk in women with gross cystic 
disease of the breast. J Proteomics 2013, 85, 44-52. 
(17) Washam, C. L.; Byrum, S. D.; Leitzel, K.; Ali, S. M.; Tackett, A. J.; Gaddy, D.; 
Sundermann, S. E.; Lipton, A.; Suva, L. J.: Identification of PTHrP(12-48) as a plasma 
124 
 
biomarker associated with breast cancer bone metastasis. Cancer Epidemiol Biomarkers 
Prev 2013, 22, 972-983. 
(18) Xiang, M.; Zhou, W.; Gao, D.; Fang, X.; Liu, Q.: Inhibitor of apoptosis protein-
like protein-2 as a novel serological biomarker for breast cancer. Int J Mol Sci 2012, 13, 
16737-16750. 
(19) Semaan, S. M.; Wang, X.; Marshall, A. G.; Sang, Q.-X. A.: Identification of 
Potential Glycoprotein Biomarkers in Estrogen Receptor Positive (ER+) and Negative 
(ER-) Human Breast Cancer Tissues by LC-LTQ/FT-ICR Mass Spectrometry. J Cancer 
2012, 3, 269-284. 
(20) Hodgkinson, V. C.; Agarwal, V.; Elfadl, D.; Fox, J. N.; McManus, P. L.; 
Mahapatra, T. K.; Kneeshaw, P. J.; Drew, P. J.; Lind, M. J.; Cawkwell, L.: Pilot and 
feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 
14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-
positive breast cancer. J Proteomics 2012, 75, 2745-2752. 
(21) Greenwood, C.; Metodieva, G.; Al-Janabi, K.; Lausen, B.; Alldridge, L.; Leng, 
L.; Bucala, R.; Fernandez, N.; Metodiev, M. V.: Stat1 and CD74 overexpression is co-
dependent and linked to increased invasion and lymph node metastasis in triple-negative 
breast cancer. J Proteomics 2012, 75, 3031-3040. 
(22) Yang, W. S.; Moon, H.-G.; Kim, H. S.; Choi, E.-J.; Yu, M.-H.; Noh, D.-Y.; Lee, 
C.: Proteomic approach reveals FKBP4 and S100A9 as potential prediction markers of 
therapeutic response to neoadjuvant chemotherapy in patients with breast cancer. J 
Proteome Res 2012, 11, 1078-1088. 
125 
 
(23) Yan, H.; Yang, K.; Xiao, H.; Zou, Y.-J.; Zhang, W.-B.; Liu, H.-Y.: Over-
expression of cofilin-1 and phosphoglycerate kinase 1 in astrocytomas involved in 
pathogenesis of radioresistance. CNS Neurosci Ther 2012, 18, 729-736. 
(24) Banerjee, H. N.; Mahaffey, K.; Riddick, E.; Banerjee, A.; Bhowmik, N.; Patra, 
M.: Search for a diagnostic/prognostic biomarker for the brain cancer glioblastoma 
multiforme by 2D-DIGE-MS technique. Mol Cell Biochem 2012, 367, 59-63. 
(25) Hu, Y.; Ylivinkka, I.; Chen, P.; Li, L.; Hautaniemi, S.; Nyman, T. A.; Keski-Oja, 
J.; Hyytiainen, M.: Netrin-4 promotes glioblastoma cell proliferation through integrin β4 
signaling. Neoplasia 2012, 14, 219-227. 
(26) Song, J. Y.; Bae, H. S.; Koo, D. H.; Lee, J. K.; Jung, H. H.; Lee, K. W.; Lee, N. 
W.: Candidates for tumor markers of cervical cancer discovered by proteomic analysis. J 
Korean Med Sci 2012, 27, 1479-1485. 
(27) Drake, R. R.; White, K. Y.; Fuller, T. W.; Igwe, E.; Clements, M. A.; Nyalwidhe, 
J. O.; Given, R. W.; Lance, R. S.; Semmes, O. J.: Clinical collection and protein 
properties of expressed prostatic secretions as a source for biomarkers of prostatic 
disease. J Proteomics 2009, 72, 907-917. 
(28) Schaaij-Visser, T. B. M.; de Wit, M.; Lam, S. W.; Jimenez, C. R.: The cancer 
secretome, current status and opportunities in the lung, breast and colorectal cancer 
context. Biochim Biophys Acta 2013. 
(29) Whelan, S. A.; He, J.; Lu, M.; Souda, P.; Saxton, R. E.; Faull, K. F.; Whitelegge, 
J. P.; Chang, H. R.: Mass spectrometry (LC-MS/MS) identified proteomic biosignatures 
of breast cancer in proximal fluid. J Proteome Res 2012, 11, 5034-5045. 
126 
 
(30) Fijneman, R. J. A.; de Wit, M.; Pourghiasian, M.; Piersma, S. R.; Pham, T. V.; 
Warmoes, M. O.; Lavaei, M.; Piso, C.; Smit, F.; Delis-van Diemen, P. M.; van 
Turenhout, S. T.; Terhaar sive Droste, J. S.; Mulder, C. J. J.; Blankenstein, M. A.; 
Robanus-Maandag, E. C.; Smits, R.; Fodde, R.; van Hinsbergh, V. W. M.; Meijer, G. A.; 
Jimenez, C. R.: Proximal fluid proteome profiling of mouse colon tumors reveals 
biomarkers for early diagnosis of human colorectal cancer. Clin Cancer Res 2012, 18, 
2613-2624. 
(31) Principe, S.; Kim, Y.; Fontana, S.; Ignatchenko, V.; Nyalwidhe, J. O.; Lance, R. 
S.; Troyer, D. A.; Alessandro, R.; Semmes, O. J.; Kislinger, T.; Drake, R. R.; Medin, J. 
A.: Identification of prostate-enriched proteins by in-depth proteomic analyses of 
expressed prostatic secretions in urine. J Proteome Res 2012, 11, 2386-2396. 
(32) Hoskins, E. R.; Hood, B. L.; Sun, M.; Krivak, T. C.; Edwards, R. P.; Conrads, T. 
P.: Proteomic analysis of ovarian cancer proximal fluids: validation of elevated 
peroxiredoxin 1 in patient peripheral circulation. PLoS One 2011, 6. 
(33) White, K. Y.; Rodemich, L.; Nyalwidhe, J. O.; Comunale, M. A.; Clements, M. 
A.; Lance, R. S.; Schellhammer, P. F.; Mehta, A. S.; Semmes, O. J.; Drake, R. R.: 
Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in 
prostate cancer and benign disease seminal plasma fluids. J Proteome Res 2009, 8, 620-
630. 
(34) Wang, P.; Whiteaker, J. R.; Paulovich, A. G.: The evolving role of mass 
spectrometry in cancer biomarker discovery. Cancer Biol Ther 2009, 8, 1083-1094. 
(35) Espina, V.; Heiby, M.; Pierobon, M.; Liotta, L. A.: Laser capture microdissection 
technology. Expert Rev Mol Diagn 2007, 7, 647-657. 
127 
 
(36) Shekouh, A. R.; Thompson, C. C.; Prime, W.; Campbell, F.; Hamlett, J.; 
Herrington, C. S.; Lemoine, N. R.; Crnogorac-Jurcevic, T.; Buechler, M. W.; Friess, H.; 
Neoptolemos, J. P.; Pennington, S. R.; Costello, E.: Application of laser capture 
microdissection combined with two-dimensional electrophoresis for the discovery of 
differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 2003, 
3, 1988-2001. 
(37) Liu, Y.; Wu, J.; Yan, G.; Hou, R.; Zhuang, D.; Chen, L.; Pang, Q.; Zhu, J.: 
Proteomic analysis of prolactinoma cells by immuno-laser capture microdissection 
combined with online two-dimensional nano-scale liquid chromatography/mass 
spectrometry. Proteome Sci 2010, 8, 2-2. 
(38) Zhu, J.; Nie, S.; Wu, J.; Lubman, D. M.: Target proteomic profiling of frozen 
pancreatic CD24+ adenocarcinoma tissues by immuno-laser capture microdissection and 
nano-LC-MS/MS. J Proteome Res 2013, 12, 2791-2804. 
(39) Karring, H.; Poulsen, E. T.; Runager, K.; Thogersen, I. B.; Klintworth, G. K.; 
Hojrup, P.; Enghild, J. J.: Serine protease HtrA1 accumulates in corneal transforming 
growth factor beta induced protein (TGFBIp) amyloid deposits. Mol Vis 2013, 19, 861-
876. 
(40) Kirkpatrick, D. S.; Gerber, S. A.; Gygi, S. P.: The absolute quantification 
strategy: a general procedure for the quantification of proteins and post-translational 
modifications. Methods 2005, 35, 265-273. 
(41) Addona, T. A.; Abbatiello, S. E.; Schilling, B.; Skates, S. J.; Mani, D. R.; Bunk, 
D. M.; Spiegelman, C. H.; Zimmerman, L. J.; Ham, A.-J. L.; Keshishian, H.; Hall, S. C.; 
Allen, S.; Blackman, R. K.; Borchers, C. H.; Buck, C.; Cardasis, H. L.; Cusack, M. P.; 
128 
 
Dodder, N. G.; Gibson, B. W.; Held, J. M.; Hiltke, T.; Jackson, A.; Johansen, E. B.; 
Kinsinger, C. R.; Li, J.; Mesri, M.; Neubert, T. A.; Niles, R. K.; Pulsipher, T. C.; 
Ransohoff, D.; Rodriguez, H.; Rudnick, P. A.; Smith, D.; Tabb, D. L.; Tegeler, T. J.; 
Variyath, A. M.; Vega-Montoto, L. J.; Wahlander, A.; Waldemarson, S.; Wang, M.; 
Whiteaker, J. R.; Zhao, L.; Anderson, N. L.; Fisher, S. J.; Liebler, D. C.; Paulovich, A. 
G.; Regnier, F. E.; Tempst, P.; Carr, S. A.: Multi-site assessment of the precision and 
reproducibility of multiple reaction monitoring-based measurements of proteins in 
plasma. Nat Biotechnol 2009, 27, 633-641. 
(42) Prakash, A.; Rezai, T.; Krastins, B.; Sarracino, D.; Athanas, M.; Russo, P.; Zhang, 
H.; Tian, Y.; Li, Y.; Kulasingam, V.; Drabovich, A.; Smith, C. R.; Batruch, I.; Oran, P. 
E.; Fredolini, C.; Luchini, A.; Liotta, L.; Petricoin, E.; Diamandis, E. P.; Chan, D. W.; 
Nelson, R.; Lopez, M. F.: Interlaboratory reproducibility of selective reaction monitoring 
assays using multiple upfront analyte enrichment strategies. J Proteome Res 2012, 11, 
3986-3995. 
(43) Mustafa, G. M.; Petersen, J. R.; Ju, H.; Cicalese, L.; Snyder, N.; Haidacher, S. J.; 
Denner, L.; Elferink, C.: Biomarker Discovery for Early Detection of Hepatocellular 
Carcinoma (HCC)in Hepatitis C (HCV) Infected Patients. Mol Cell Proteomics 2013. 
(44) Everley, R. A.; Kunz, R. C.; McAllister, F. E.; Gygi, S. P.: Increasing Throughput 
in Targeted Proteomics Assays: 54-Plex Quantitation in a Single Mass Spectrometry Run. 
Analytical Chemistry 2013, 85, 5340-5346. 
(45) Hood, L.: Systems biology: integrating technology, biology, and computation. 
Mech Ageing Dev 2003, 124, 9-16. 
129 
 
(46) Aebersold, R.; Cravatt, B. F.: Proteomics--advances, applications and the 
challenges that remain. Trends Biotechnol 2002, 20, 1-2. 
(47) Drube, J.; Zurbig, P.; Schiffer, E.; Lau, E.; Ure, B.; Gluer, S.; Kirschstein, M.; 
Pape, L.; Decramer, S.; Bascands, J.-L.; Schanstra, J. P.; Mischak, H.; Ehrich, J. H. H.: 
Urinary proteome analysis identifies infants but not older children requiring pyeloplasty. 
Pediatr Nephrol 2010, 25, 1673-1678. 
(48) Theodorescu, D.; Schiffer, E.; Bauer, H. W.; Douwes, F.; Eichhorn, F.; Polley, R.; 
Schmidt, T.; Schofer, W.; Zurbig, P.; Good, D. M.; Coon, J. J.; Mischak, H.: Discovery 
and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl 2008, 2, 
556-570. 
(49) Schiffer, E.; Vlahou, A.; Petrolekas, A.; Stravodimos, K.; Tauber, R.; Geschwend, 
J. E.; Neuhaus, J.; Stolzenburg, J.-U.; Conaway, M. R.; Mischak, H.; Theodorescu, D.: 
Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res 
2009, 15, 4935-4943. 
(50) Schiffer, E.; Bick, C.; Grizelj, B.; Pietzker, S.; Schofer, W.: Urinary proteome 
analysis for prostate cancer diagnosis: cost-effective application in routine clinical 
practice in Germany. Int J Urol 2012, 19, 118-125. 
(51) Haubitz, M.; Good, D. M.; Woywodt, A.; Haller, H.; Rupprecht, H.; Theodorescu, 
D.; Dakna, M.; Coon, J. J.; Mischak, H.: Identification and validation of urinary 
biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-




(52) Zimmerli, L. U.; Schiffer, E.; Zurbig, P.; Good, D. M.; Kellmann, M.; Mouls, L.; 
Pitt, A. R.; Coon, J. J.; Schmieder, R. E.; Peter, K. H.; Mischak, H.; Kolch, W.; Delles, 
C.; Dominiczak, A. F.: Urinary proteomic biomarkers in coronary artery disease. Mol 
Cell Proteomics 2008, 7, 290-298. 
(53) von Zur Muhlen, C.; Schiffer, E.; Zuerbig, P.; Kellmann, M.; Brasse, M.; Meert, 
N.; Vanholder, R. C.; Dominiczak, A. F.; Chen, Y. C.; Mischak, H.; Bode, C.; Peter, K.: 
Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery 
atherosclerosis in symptomatic patients. J Proteome Res 2009, 8, 335-345. 
(54) Snell-Bergeon, J. K.; Maahs, D. M.; Ogden, L. G.; Kinney, G. L.; Hokanson, J. 
E.; Schiffer, E.; Rewers, M.; Mischak, H.: Evaluation of urinary biomarkers for coronary 
artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther 2009, 11, 1-
9. 
(55) Jantos-Siwy, J.; Schiffer, E.; Brand, K.; Schumann, G.; Rossing, K.; Delles, C.; 
Mischak, H.; Metzger, J.: Quantitative urinary proteome analysis for biomarker 
evaluation in chronic kidney disease. J Proteome Res 2009, 8, 268-281. 
(56) Kistler, A. D.; Mischak, H.; Poster, D.; Dakna, M.; Wuthrich, R. P.; Serra, A. L.: 
Identification of a unique urinary biomarker profile in patients with autosomal dominant 
polycystic kidney disease. Kidney Int 2009, 76, 89-96. 
(57) Good, D. M.; Zurbig, P.; Argiles, A.; Bauer, H. W.; Behrens, G.; Coon, J. J.; 
Dakna, M.; Decramer, S.; Delles, C.; Dominiczak, A. F.; Ehrich, J. H. H.; Eitner, F.; 
Fliser, D.; Frommberger, M.; Ganser, A.; Girolami, M. A.; Golovko, I.; Gwinner, W.; 
Haubitz, M.; Herget-Rosenthal, S.; Jankowski, J.; Jahn, H.; Jerums, G.; Julian, B. A.; 
Kellmann, M.; Kliem, V.; Kolch, W.; Krolewski, A. S.; Luppi, M.; Massy, Z.; Melter, 
131 
 
M.; Neususs, C.; Novak, J.; Peter, K.; Rossing, K.; Rupprecht, H.; Schanstra, J. P.; 
Schiffer, E.; Stolzenburg, J.-U.; Tarnow, L.; Theodorescu, D.; Thongboonkerd, V.; 
Vanholder, R.; Weissinger, E. M.; Mischak, H.; Schmitt-Kopplin, P.: Naturally occurring 
human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell 
Proteomics 2010, 9, 2424-2437. 
(58) Raedler, T. J.; Wittke, S.; Jahn, H.; Koessler, A.; Mischak, H.; Wiedemann, K.: 
Capillary electrophoresis mass spectrometry as a potential tool to detect lithium-induced 
nephropathy: Preliminary results. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32, 
673-678. 
(59) Weissinger, E. M.; Schiffer, E.; Hertenstein, B.; Ferrara, J. L.; Holler, E.; Stadler, 
M.; Kolb, H.-J.; Zander, A.; Zurbig, P.; Kellmann, M.; Ganser, A.: Proteomic patterns 
predict acute graft-versus-host disease after allogeneic hematopoietic stem cell 
transplantation. Blood 2007, 109, 5511-5519. 
(60) Haselberg, R.; de Jong, G. J.; Somsen, G. W.: Capillary electrophoresis-mass 
spectrometry for the analysis of intact proteins 2007-2010. Electrophoresis 2011, 32, 66-
82. 
(61) Albalat, A.; Mischak, H.; Mullen, W.: Clinical application of urinary 
proteomics/peptidomics. Expert Rev Proteomics 2011, 8, 615-629. 
(62) Mischak, H.; Schanstra, J. P.: CE-MS in biomarker discovery, validation, and 
clinical application. Proteomics Clin Appl 2011, 5, 9-23. 
(63) Metzger, J.; Chatzikyrkou, C.; Broecker, V.; Schiffer, E.; Jaensch, L.; Iphoefer, 
A.; Mengel, M.; Mullen, W.; Mischak, H.; Haller, H.; Gwinner, W.: Diagnosis of 
132 
 
subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by 
urinary proteome analysis. Proteomics Clin Appl 2011, 5, 322-333. 
(64) Zuberovic, A.; Wetterhall, M.; Hanrieder, J.; Bergquist, J.: CE MALDI-TOF/TOF 
MS for multiplexed quantification of proteins in human ventricular cerebrospinal fluid. 
Electrophoresis 2009, 30, 1836-1843. 
(65) Wiese, S.; Reidegeld, K. A.; Meyer, H. E.; Warscheid, B.: Protein labeling by 
iTRAQ: a new tool for quantitative mass spectrometry in proteome research. Proteomics 
2007, 7, 340-350. 
(66) Wang, W.; Guo, T.; Rudnick, P. A.; Song, T.; Li, J.; Zhuang, Z.; Zheng, W.; 
Devoe, D. L.; Lee, C. S.; Balgley, B. M.: Membrane proteome analysis of microdissected 
ovarian tumor tissues using capillary isoelectric focusing/reversed-phase liquid 
chromatography-tandem MS. Anal Chem 2007, 79, 1002-1009. 
(67) Guo, T.; Wang, W.; Rudnick, P. A.; Song, T.; Li, J.; Zhuang, Z.; Weil, R. J.; 
DeVoe, D. L.; Lee, C. S.; Balgley, B. M.: Proteome analysis of microdissected formalin-
fixed and Paraffin-embedded tissue specimens. J Histochem Cytochem 2007, 55, 763-
772. 
(68) Liu, H.; Sadygov, R. G.; Yates, J. R.: A model for random sampling and 
estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004, 76, 
4193-4201. 
(69) Ishihama, Y.; Oda, Y.; Tabata, T.; Sato, T.; Nagasu, T.; Rappsilber, J.; Mann, M.: 
Exponentially modified protein abundance index (emPAI) for estimation of absolute 
protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell 
Proteomics 2005, 4, 1265-1272. 
133 
 
(70) Balgley, B. M.; Wang, W.; Song, T.; Fang, X.; Yang, L.; Lee, C. S.: Evaluation of 
confidence and reproducibility in quantitative proteomics performed by a capillary 
isoelectric focusing-based proteomic platform coupled with a spectral counting approach. 
Electrophoresis 2008, 29, 3047-3054. 
(71) Dai, L.; Li, C.; Shedden, K. A.; Misek, D. E.; Lubman, D. M.: Comparative 
proteomic study of two closely related ovarian endometrioid adenocarcinoma cell lines 
using cIEF fractionation and pathway analysis. Electrophoresis 2009, 30, 1119-1131. 
(72) Hanrieder, J.; Zuberovic, A.; Bergquist, J.: Surface modified capillary 
electrophoresis combined with in solution isoelectric focusing and MALDI-TOF/TOF 
MS: a gel-free multidimensional electrophoresis approach for proteomic profiling--
exemplified on human follicular fluid. J Chromatogr A 2009, 1216, 3621-3628. 
(73) An, Y.; Cooper, J. W.; Balgley, B. M.; Lee, C. S.: Selective enrichment and 
ultrasensitive identification of trace peptides in proteome analysis using transient 
capillary isotachophoresis/zone electrophoresis coupled with nano-ESI-MS. 
Electrophoresis 2006, 27, 3599-3608. 
(74) Fang, X.; Yang, L.; Wang, W.; Song, T.; Lee, C.; Devoe, D.; Balgley, B.: 
Comparison of Electrokinetics-Based Multidimensional Separations Coupled with 
Electrospray Ionization-Tandem Mass Spectrometry for Characterization of Human 
Salivary Proteins. Anal Chem 2007, 79, 5785-5792. 
(75) Fang, X.; Wang, W.; Yang, L.; Chandrasekaran, K.; Kristian, T.; Balgley, B. M.; 
Lee, C. S.: Application of capillary isotachophoresis-based multidimensional separations 
coupled with electrospray ionization-tandem mass spectrometry for characterization of 
mouse brain mitochondrial proteome. Electrophoresis 2008, 29, 2215-2223. 
134 
 
(76) Fang, X.; Balgley, B. M.; Wang, W.; Park, D. M.; Lee, C. S.: Comparison of 
multidimensional shotgun technologies targeting tissue proteomics. Electrophoresis 
2009, 30, 4063-4070. 
(77) Wolters, D. A.; Washburn, M. P.; Yates, J. R.: An automated multidimensional 
protein identification technology for shotgun proteomics. Anal Chem 2001, 73, 5683-
5690. 
(78) Jinawath, N.; Vasoontara, C.; Jinawath, A.; Fang, X.; Zhao, K.; Yap, K.-L.; Guo, 
T.; Lee, C. S.; Wang, W.; Balgley, B. M.; Davidson, B.; Wang, T.-L.; Shih, I.-M.: 
Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin 
resistant ovarian carcinoma. PLoS One 2010, 5. 
(79) Chen, Z.; Fadiel, A.; Xia, Y.: Functional duality of merlin: A conundrum of 
proteome complexity. Med Hypotheses 2006, 67, 1095-1098. 
(80) Huang, K.-C.; Park, D. C.; Ng, S.-K.; Lee, J. Y.; Ni, X.; Ng, W.-C.; Bandera, C. 
A.; Welch, W. R.; Berkowitz, R. S.; Mok, S. C.; Ng, S.-W.: Selenium binding protein 1 
in ovarian cancer. Int J Cancer 2006, 118, 2433-2440. 
(81) Chekhun, V. F.; Lukyanova, N. Y.; Urchenko, O. V.; Kulik, G. I.: The role of 
expression of the components of proteome in the formation of molecular profile of 
human ovarian carcinoma A2780 cells sensitive and resistant to cisplatin. Exp Oncol 
2005, 27, 191-195. 
(82) Smith-Beckerman, D. M.; Fung, K. W.; Williams, K. E.; Auersperg, N.; Godwin, 
A. K.; Burlingame, A. L.: Proteome changes in ovarian epithelial cells derived from 
women with BRCA1 mutations and family histories of cancer. Mol Cell Proteomics 
2005, 4, 156-168. 
135 
 
(83) Duan, Z.; Foster, R.; Bell, D. A.; Mahoney, J.; Wolak, K.; Vaidya, A.; Hampel, 
C.; Lee, H.; Seiden, M. V.: Signal transducers and activators of transcription 3 pathway 
activation in drug-resistant ovarian cancer. Clin Cancer Res 2006, 12, 5055-5063. 
(84) Haura, E. B.; Zheng, Z.; Song, L.; Cantor, A.; Bepler, G.: Activated epidermal 
growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell 
lung cancer. Clin Cancer Res 2005, 11, 8288-8294. 
(85) Chen, L.-F.; Greene, W. C.: Shaping the nuclear action of NF-kappaB. Nat Rev 
Mol Cell Biol 2004, 5, 392-401. 
(86) Olivares, J. A.; Nguyen, N. T.; Yonker, C. R.; Smith, R. D.: On-line mass 
spectrometric detection for capillary zone electrophoresis. Analytical Chemistry 1987, 59, 
1230-1232. 
(87) Smith, R. D.; Udseth, H. R.: Capillary zone electrophoresis-MS. Nature 1988, 
331, 639-640. 
(88) Mokaddem, M.; Gareil, P.; Belgaied, J.-E.; Varenne, A.: A new insight into 
suction and dilution effects in capillary electrophoresis coupled to mass spectrometry via 
an electrospray ionization interface. Part I-Suction effect. Electrophoresis 2008, 29, 
1957-1964. 
(89) Mokaddem, M.; Gareil, P.; Belgaied, J.-E.; Varenne, A.: New insight into suction 
and dilution effects in CE coupled to MS via an ESI interface. II--dilution effect. 
Electrophoresis 2009, 30, 1692-1697. 
(90) Yan, X.; Essaka, D. C.; Sun, L.; Zhu, G.; Dovichi, N. J.: Bottom-up proteome 
analysis of E. coli using capillary zone electrophoresis-tandem mass spectrometry with an 
electrokinetic sheath-flow electrospray interface. Proteomics 2013, 13, 2546-2551. 
136 
 
(91) Wojcik, R.; Dada, O. O.; Sadilek, M.; Dovichi, N. J.: Simplified capillary 
electrophoresis nanospray sheath-flow interface for high efficiency and sensitive peptide 
analysis. Rapid Communications in Mass Spectrometry 2010, 24, 2554-2560. 
(92) Cargile, B. J.; Bundy, J. L.; Freeman, T. W.; Stephenson, J. L.: Gel based 
isoelectric focusing of peptides and the utility of isoelectric point in protein identification. 
J Proteome Res 2004, 3, 112-119. 
(93) Iwasaki, M.; Miwa, S.; Ikegami, T.; Tomita, M.; Tanaka, N.; Ishihama, Y.: One-
dimensional capillary liquid chromatographic separation coupled with tandem mass 
spectrometry unveils the Escherichia coli proteome on a microarray scale. Anal Chem 
2010, 82, 2616-2620. 
(94) Xia, S.; Tao, D.; Yuan, H.; Zhou, Y.; Liang, Z.; Zhang, L.; Zhang, Y.: Nano-flow 
multidimensional liquid chromatography platform integrated with combination of protein 
and peptide separation for proteome analysis. J Sep Sci 2012, 35, 1764-1770. 
(95) Wachs, T.; Sheppard, R. L.; Henion, J.: Design and applications of a self-aligning 
liquid junction-electrospray interface for capillary electrophoresis-mass spectrometry. J 
Chromatogr B Biomed Appl 1996, 685, 335-342. 
(96) Wilm, M.; Mann, M.: Analytical Properties of the Nanoelectrospray Ion Source. 
Analytical Chemistry 1996, 68, 1-8. 
(97) Wilm, M. S.; Mann, M.: Electrospray and Taylor-Cone theory, Dole's beam of 
macromolecules at last? International Journal of Mass Spectrometry and Ion Processes 
1994, 136, 167-180. 
137 
 
(98) Bahr, U.; Pfenninger, A.; Karas, M.; Stahl, B.: High-Sensitivity Analysis of 
Neutral Underivatized Oligosaccharides by Nanoelectrospray Mass Spectrometry. 
Analytical Chemistry 1997, 69, 4530-4535. 
(99) Zamfir, A. D.: Recent advances in sheathless interfacing of capillary 
electrophoresis and electrospray ionization mass spectrometry. Journal of 
Chromatography A 2007, 1159, 2-13. 
(100) Wahl, J. H.; Gale, D. C.; Smith, R. D.: Sheathless capillary electrophoresis-
electrospray ionization mass spectrometry using 10 μm I.D. capillaries: Analyses of 
tryptic digests of cytochrome c. Journal of Chromatography A 1994, 659, 217-222. 
(101) Maziarz, E. P.; Lorenz, S.; White, T.; Wood, T.: Polyaniline: A conductive 
polymer coating for durable nanospray emitters. Journal of the American Society for 
Mass Spectrometry 2000, 11, 659-663. 
(102) Chang, Y. Z.; Her, G. R.: Sheathless Capillary Electrophoresis/Electrospray Mass 
Spectrometry Using a Carbon-Coated Fused-Silica Capillary. Analytical Chemistry 1999, 
72, 626-630. 
(103) Cao, P.; Moini, M.: A novel sheathless interface for capillary 
electrophoresis/electrospray ionization mass spectrometry using an in-capillary electrode. 
Journal of the American Society for Mass Spectrometry 1997, 8, 561-564. 
(104) Figeys, D.; Ducret, A.; Yates, J. R.; Aebersold, R.: Protein identification by solid 
phase microextraction[mdash]capillary zone 
electrophoresis[mdash]microelectrospray[mdash]tandem mass spectrometry. Nat Biotech 
1996, 14, 1579-1583. 
138 
 
(105) Moini, M.: Simplifying CE-MS operation. 2. Interfacing low-flow separation 
techniques to mass spectrometry using a porous tip. Anal Chem 2007, 79, 4241-4246. 
(106) Faserl, K.; Sarg, B.; Kremser, L.; Lindner, H.: Optimization and Evaluation of a 
Sheathless Capillary Electrophoresis–Electrospray Ionization Mass Spectrometry 
Platform for Peptide Analysis: Comparison to Liquid Chromatography–Electrospray 
Ionization Mass Spectrometry. Analytical Chemistry 2011, 83, 7297-7305. 
(107) Haselberg, R.; Ratnayake, C. K.; de Jong, G. J.; Somsen, G. W.: Performance of a 
sheathless porous tip sprayer for capillary electrophoresis–electrospray ionization-mass 
spectrometry of intact proteins. Journal of Chromatography A 2010, 1217, 7605-7611. 
(108) Ramautar, R.; Shyti, R.; Schoenmaker, B.; Groote, L.; Derks, R. E.; Ferrari, M.; 
Maagdenberg, A. J. M.; Deelder, A.; Mayboroda, O.: Metabolic profiling of mouse 
cerebrospinal fluid by sheathless CE-MS. Anal Bioanal Chem 2012, 404, 2895-2900. 
(109) Busnel, J.-M.; Schoenmaker, B.; Ramautar, R.; Carrasco-Pancorbo, A.; 
Ratnayake, C.; Feitelson, J. S.; Chapman, J. D.; Deelder, A. M.; Mayboroda, O. A.: High 
capacity capillary electrophoresis-electrospray ionization mass spectrometry: coupling a 
porous sheathless interface with transient-isotachophoresis. Anal Chem 2010, 82, 9476-
9483. 
(110) Ramautar, R.; Busnel, J.-M.; Deelder, A. M.; Mayboroda, O. A.: Enhancing the 
coverage of the urinary metabolome by sheathless capillary electrophoresis-mass 
spectrometry. Anal Chem 2012, 84, 885-892. 
(111) Heemskerk, A. A. M.; Busnel, J.-M.; Schoenmaker, B.; Derks, R. J. E.; 
Klychnikov, O.; Hensbergen, P. J.; Deelder, A. M.; Mayboroda, O. A.: Ultra-low flow 
139 
 
electrospray ionization-mass spectrometry for improved ionization efficiency in 
phosphoproteomics. Anal Chem 2012, 84, 4552-4559. 
(112) Heemskerk, A. A.; Wuhrer, M.; Busnel, J. M.; Koeleman, C. A.; Selman, M. H.; 
Vidarsson, G.; Kapur, R.; Schoenmaker, B.; Derks, R. J.; Deelder, A. M.: Coupling 
porous sheathless interface MS with transient‐ITP in neutral capillaries for improved 
sensitivity in glycopeptide analysis. Electrophoresis 2013, 34, 383-387. 
(113) Faserl, K.; Sarg, B.; Kremser, L.; Lindner, H.: Optimization and evaluation of a 
sheathless capillary electrophoresis-electrospray ionization mass spectrometry platform 
for peptide analysis: comparison to liquid chromatography-electrospray ionization mass 
spectrometry. Anal Chem 2011, 83, 7297-7305. 
(114) Lacroix, M.; Abi-Said, D.; Fourney, D. R.; Gokaslan, Z. L.; Shi, W.; DeMonte, 
F.; Lang, F. F.; McCutcheon, I. E.; Hassenbusch, S. J.; Holland, E.; Hess, K.; Michael, 
C.; Miller, D.; Sawaya, R.: A multivariate analysis of 416 patients with glioblastoma 
multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001, 95, 190-198. 
(115) Ichimura, K.; Ohgaki, H.; Kleihues, P.; Collins, V. P.: Molecular pathogenesis of 
astrocytic tumours. J Neurooncol 2004, 70, 137-160. 
(116) Holland, E. C.: Gliomagenesis: genetic alterations and mouse models. Nat Rev 
Genet 2001, 2, 120-129. 
(117) Maher, E. A.; Furnari, F. B.; Bachoo, R. M.; Rowitch, D. H.; Louis, D. N.; 
Cavenee, W. K.; DePinho, R. A.: Malignant glioma: genetics and biology of a grave 
matter. Genes Dev 2001, 15, 1311-1333. 
(118) Kitange, G. J.; Templeton, K. L.; Jenkins, R. B.: Recent advances in the 
molecular genetics of primary gliomas. Curr Opin Oncol 2003, 15, 197-203. 
140 
 
(119) Sallinen, S. L.; Sallinen, P. K.; Haapasalo, H. K.; Helin, H. J.; Helen, P. T.; 
Schraml, P.; Kallioniemi, O. P.; Kononen, J.: Identification of differentially expressed 
genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 
2000, 60, 6617-6622. 
(120) Bachoo, R. M.; Maher, E. A.; Ligon, K. L.; Sharpless, N. E.; Chan, S. S.; You, M. 
J.; Tang, Y.; DeFrances, J.; Stover, E.; Weissleder, R.; Rowitch, D. H.; Louis, D. N.; 
DePinho, R. A.: Epidermal growth factor receptor and Ink4a/Arf: convergent 
mechanisms governing terminal differentiation and transformation along the neural stem 
cell to astrocyte axis. Cancer Cell 2002, 1, 269-277. 
(121) Maher, E. A.; Brennan, C.; Wen, P. Y.; Durso, L.; Ligon, K. L.; Richardson, A.; 
Khatry, D.; Feng, B.; Sinha, R.; Louis, D. N.; Quackenbush, J.; Black, P. M.; Chin, L.; 
DePinho, R. A.: Marked genomic differences characterize primary and secondary 
glioblastoma subtypes and identify two distinct molecular and clinical secondary 
glioblastoma entities. Cancer Res 2006, 66, 11502-11513. 
(122) Ohnishi, M.; Matsumoto, T.; Nagashio, R.; Kageyama, T.; Utsuki, S.; Oka, H.; 
Okayasu, I.; Sato, Y.: Proteomics of tumor-specific proteins in cerebrospinal fluid of 
patients with astrocytoma: usefulness of gelsolin protein. Pathol Int 2009, 59, 797-803. 
(123) Schuhmann, M. U.; Zucht, H. D.; Nassimi, R.; Heine, G.; Schneekloth, C. G.; 
Stuerenburg, H. J.; Selle, H.: Peptide screening of cerebrospinal fluid in patients with 
glioblastoma multiforme. Eur J Surg Oncol 2010, 36, 201-207. 
(124) Kumar, D. M.; Thota, B.; Shinde, S. V.; Prasanna, K. V.; Hegde, A. S.; 
Arivazhagan, A.; Chandramouli, B. A.; Santosh, V.; Somasundaram, K.: Proteomic 
141 
 
identification of haptoglobin α2 as a glioblastoma serum biomarker: implications in 
cancer cell migration and tumor growth. J Proteome Res 2010, 9, 5557-5567. 
(125) Nirmalan, N. J.; Harnden, P.; Selby, P. J.; Banks, R. E.: Mining the archival 
formalin-fixed paraffin-embedded tissue proteome: opportunities and challenges. Mol 
Biosyst 2008, 4, 712-720. 
(126) Rifai, N.; Gillette, M. A.; Carr, S. A.: Protein biomarker discovery and validation: 
the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24, 971-983. 
(127) Cottingham, K.: Tissues tell the real tale of breast cancer. J Proteome Res 2007, 
6, 2052-2052. 
(128) Melchior, K.; Tholey, A.; Heisel, S.; Keller, A.; Lenhof, H.-P.; Meese, E.; Huber, 
C. G.: Proteomic study of human glioblastoma multiforme tissue employing 
complementary two-dimensional liquid chromatography- and mass spectrometry-based 
approaches. J Proteome Res 2009, 8, 4604-4614. 
(129) Li, N.; Zhang, J.; Liang, Y.; Shao, J.; Peng, F.; Sun, M.; Xu, N.; Li, X.; Wang, R.; 
Liu, S.; Lu, Y.: A controversial tumor marker: is SM22 a proper biomarker for gastric 
cancer cells? J Proteome Res 2007, 6, 3304-3312. 
(130) Iwadate, Y.; Sakaida, T.; Hiwasa, T.; Nagai, Y.; Ishikura, H.; Takiguchi, M.; 
Yamaura, A.: Molecular classification and survival prediction in human gliomas based on 
proteome analysis. Cancer Res 2004, 64, 2496-2501. 
(131) Odreman, F.; Vindigni, M.; Gonzales, M. L.; Niccolini, B.; Candiano, G.; Zanotti, 
B.; Skrap, M.; Pizzolitto, S.; Stanta, G.; Vindigni, A.: Proteomic studies on low- and 
high-grade human brain astrocytomas. J Proteome Res 2005, 4, 698-708. 
142 
 
(132) Li, J.; Zhuang, Z.; Okamoto, H.; Vortmeyer, A. O.; Park, D. M.; Furuta, M.; Lee, 
Y. S.; Oldfield, E. H.; Zeng, W.; Weil, R. J.: Proteomic profiling distinguishes 
astrocytomas and identifies differential tumor markers. Neurology 2006, 66, 733-736. 
(133) Gimenez, M.; Souza, V. C. d. O.; Izumi, C.; Barbieri, M. R.; Chammas, R.; Oba-
Shinjo, S. M.; Uno, M.; Marie, S. K. N.; Rosa, J. C.: Proteomic analysis of low- to high-
grade astrocytomas reveals an alteration of the expression level of raf kinase inhibitor 
protein and nucleophosmin. Proteomics 2010, 10, 2812-2821. 
(134) Bonner, R. F.; Emmert-Buck, M.; Cole, K.; Pohida, T.; Chuaqui, R.; Goldstein, 
S.; Liotta, L. A.: Laser capture microdissection: molecular analysis of tissue. Science 
1997, 278, 1481-1481. 
(135) Gebauer, P.; Bocek, P.: Recent progress in capillary isotachophoresis. 
Electrophoresis 2000, 21, 3898-3904. 
(136) Foret, F.; Szoko, E.; Karger, B. L.: Trace analysis of proteins by capillary zone 
electrophoresis with on-column transient isotachophoretic preconcentration. 
Electrophoresis 1993, 14, 417-428. 
(137) Stegehuis, D. S.; Irth, H.; Tjaden, U. R.; Van der Greef, J.: Isotachophoresis as an 
on-line concentration pretreatment technique in capillary electrophoresis. J Chromatogr 
1991, 538, 393-402. 
(138) Rappsilber, J.; Ryder, U.; Lamond, A. I.; Mann, M.: Large-scale proteomic 
analysis of the human spliceosome. Genome Res 2002, 12, 1231-1245. 
(139) Furuta, M.; Weil, R. J.; Vortmeyer, A. O.; Huang, S.; Lei, J.; Huang, T.-N.; Lee, 
Y.-S.; Bhowmick, D. A.; Lubensky, I. A.; Oldfield, E. H.; Zhuang, Z.: Protein patterns 
143 
 
and proteins that identify subtypes of glioblastoma multiforme. Oncogene 2004, 23, 
6806-6814. 
(140) Zhuang, Z.; Lee, Y. S.; Zeng, W.; Furuta, M.; Valyi-Nagy, T.; Johnson, M. D.; 
Vnencak-Jones, C. L.; Woltjer, R. L.; Weil, R. J.: Molecular genetic and proteomic 
analysis of synchronous malignant gliomas. Neurology 2004, 62, 2316-2319. 
(141) Yang, L.; Lee, C. S.; Hofstadler, S. A.; Smith, R. D.: Characterization of 
microdialysis acidification for capillary isoelectric focusing-microelectrospray ionization 
mass spectrometry. Anal Chem 1998, 70, 4945-4950. 
(142) Geer, L. Y.; Markey, S. P.; Kowalak, J. A.; Wagner, L.; Xu, M.; Maynard, D. M.; 
Yang, X.; Shi, W.; Bryant, S. H.: Open mass spectrometry search algorithm. J Proteome 
Res 2004, 3, 958-964. 
(143) Elias, J. E.; Haas, W.; Faherty, B. K.; Gygi, S. P.: Comparative evaluation of 
mass spectrometry platforms used in large-scale proteomics investigations. Nat Methods 
2005, 2, 667-675. 
(144) Balgley, B. M.; Laudeman, T.; Yang, L.; Song, T.; Lee, C. S.: Comparative 
evaluation of tandem MS search algorithms using a target-decoy search strategy. Mol 
Cell Proteomics 2007, 6, 1599-1608. 
(145) Krogh, A.; Larsson, B.; von Heijne, G.; Sonnhammer, E. L.: Predicting 
transmembrane protein topology with a hidden Markov model: application to complete 
genomes. J Mol Biol 2001, 305, 567-580. 
(146) Eisen, M. B.; Spellman, P. T.; Brown, P. O.; Botstein, D.: Cluster analysis and 




(147) Lin, B.; White, J. T.; Lu, W.; Xie, T.; Utleg, A. G.; Yan, X.; Yi, E. C.; Shannon, 
P.; Khrebtukova, I.; Lange, P. H.; Goodlett, D. R.; Zhou, D.; Vasicek, T. J.; Hood, L.: 
Evidence for the presence of disease-perturbed networks in prostate cancer cells by 
genomic and proteomic analyses: a systems approach to disease. Cancer Res 2005, 65, 
3081-3091. 
(148) He, F.; Sun, Y. E.: Glial cells more than support cells? Int J Biochem Cell Biol 
2007, 39, 661-665. 
(149) Hart, M. J.; Callow, M. G.; Souza, B.; Polakis, P.: IQGAP1, a calmodulin-binding 
protein with a rasGAP-related domain, is a potential effector for cdc42Hs. EMBO J 1996, 
15, 2997-3005. 
(150) Grohmanova, K.; Schlaepfer, D.; Hess, D.; Gutierrez, P.; Beck, M.; Kroschewski, 
R.: Phosphorylation of IQGAP1 modulates its binding to Cdc42, revealing a new type of 
rho-GTPase regulator. J Biol Chem 2004, 279, 48495-48504. 
(151) Li, Z.; McNulty, D. E.; Marler, K. J. M.; Lim, L.; Hall, C.; Annan, R. S.; Sacks, 
D. B.: IQGAP1 promotes neurite outgrowth in a phosphorylation-dependent manner. J 
Biol Chem 2005, 280, 13871-13878. 
(152) Mischak, H.; Delles, C.; Klein, J.; Schanstra, J. P.: Urinary proteomics based on 
capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and 
validation of biomarkers, and clinical application. Adv Chronic Kidney Dis 2010, 17, 
493-506. 
(153) Gamagedara, S.; Ma, Y.: Biomarker analysis for prostate cancer diagnosis using 
LC-MS and CE-MS. Bioanalysis 2011, 3, 2129-2142. 
145 
 
(154) Simionato, A. V. C.; Carrilho, E.; Maggi Tavares, M. F.: CE-MS and related 
techniques as a valuable tool in tumor biomarkers research. Electrophoresis 2010, 31, 
1214-1226. 
(155) Barbas, C.; Moraes, E. P.; Villasenor, A.: Capillary electrophoresis as a 
metabolomics tool for non-targeted fingerprinting of biological samples. J Pharm Biomed 
Anal 2011, 55, 823-831. 
(156) Monton, M. R. N.; Soga, T.: Metabolome analysis by capillary electrophoresis-
mass spectrometry. J Chromatogr A 2007, 1168, 237-246. 
(157) Rodriguez Robledo, V.; Smyth, W. F.: The application of CE-MS in the trace 
analysis of environmental pollutants and food contaminants. Electrophoresis 2009, 30, 
1647-1660. 
(158) Ravelo-Perez, L. M.; Asensio-Ramos, M.; Hernandez-Borges, J.; Rodriguez-
Delgado, M. A.: Recent food safety and food quality applications of CE-MS. 
Electrophoresis 2009, 30, 1624-1646. 
(159) Ban, E.; Park, S. H.; Kang, M.-J.; Lee, H.-J.; Song, E. J.; Yoo, Y. S.: Growing 
trend of CE at the omics level: the frontier of systems biology--an update. 
Electrophoresis 2012, 33, 2-13. 
(160) Desiderio, C.; Rossetti, D. V.; Iavarone, F.; Messana, I.; Castagnola, M.: 
Capillary electrophoresis--mass spectrometry: recent trends in clinical proteomics. J 
Pharm Biomed Anal 2010, 53, 1161-1169. 
(161) Suntornsuk, L.: Recent advances of capillary electrophoresis in pharmaceutical 
analysis. Anal Bioanal Chem 2010, 398, 29-52. 
146 
 
(162) Smith, R. D.; Barinaga, C. J.; Udseth, H. R.: Improved electrospray ionization 
interface for capillary zone electrophoresis-mass spectrometry. analytical chemistry 
1988, 60, 1948-1952. 
(163) Smith, R. D.; Olivares, J. A.; Nguyen, N. T.; Udseth, H. R.: Capillary zone 
electrophoresis-mass spectrometry using an electrospray ionization interface. analytical 
chemistry 1988, 60, 436-441. 
(164) Lee, E. D.; Muck, W.; Henion, J. D.; Covey, T. R.: On-line capillary zone 
electrophoresis-ion spray tandem mass spectrometry for the determination of dynorphins. 
J Chromatogr 1988, 458, 313-321. 
(165) Haselberg, R.; de Jong, G. J.; Somsen, G. W.: Capillary electrophoresis-mass 
spectrometry of intact basic proteins using Polybrene-dextran sulfate-Polybrene-coated 
capillaries: system optimization and performance. Anal Chim Acta 2010, 678, 128-134. 
(166) Huhn, C.; Ramautar, R.; Wuhrer, M.; Somsen, G. W.: Relevance and use of 
capillary coatings in capillary electrophoresis-mass spectrometry. Anal Bioanal Chem 
2010, 396, 297-314. 
(167) Liu, Y.; Fu, X.; Bai, Y.; Zhai, M.; Liao, Y.; Liao, J.; Liu, H.: Improvement of 
reproducibility and sensitivity of CE analysis by using the capillary coated dynamically 
with carboxymethyl chitosan. Anal Bioanal Chem 2011, 399, 2821-2829. 
(168) Kelly, R. T.; Page, J. S.; Luo, Q.; Moore, R. J.; Orton, D. J.; Tang, K.; Smith, R. 
D.: Chemically etched open tubular and monolithic emitters for nanoelectrospray 
ionization mass spectrometry. Anal Chem 2006, 78, 7796-7801. 
147 
 
(169) Ramautar, R.; Heemskerk, A. A. M.; Hensbergen, P. J.; Deelder, A. M.; Busnel, 
J.-M.; Mayboroda, O. A.: CE-MS for proteomics: Advances in interface development and 
application. J Proteomics 2012, 75, 3814-3828. 
(170) Maxwell, E. J.; Zhong, X.; Zhang, H.; van Zeijl, N.; Chen, D. D. Y.: Decoupling 
CE and ESI for a more robust interface with MS. Electrophoresis 2010, 31, 1130-1137. 
(171) Meng, Z.; Veenstra, T. D.: Targeted mass spectrometry approaches for protein 
biomarker verification. J Proteomics 2011, 74, 2650-2659. 
(172) Rangiah, K.; Hwang, W.-T.; Mesaros, C.; Vachani, A.; Blair, I. A.: Nicotine 
exposure and metabolizer phenotypes from analysis of urinary nicotine and its 15 
metabolites by LC-MS. Bioanalysis 2011, 3, 745-761. 
(173) Blair, I. A.: Analysis of endogenous glutathione-adducts and their metabolites. 
Biomed Chromatogr 2010, 24, 29-38. 
(174) Kim, K.; Kim, S. J.; Yu, H. G.; Yu, J.; Park, K. S.; Jang, I.-J.; Kim, Y.: 
Verification of biomarkers for diabetic retinopathy by multiple reaction monitoring. J 
Proteome Res 2010, 9, 689-699. 
(175) Kuzyk, M. A.; Smith, D.; Yang, J.; Cross, T. J.; Jackson, A. M.; Hardie, D. B.; 
Anderson, N. L.; Borchers, C. H.: Multiple reaction monitoring-based, multiplexed, 
absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics 2009, 8, 
1860-1877. 
(176) Jeong, J.-S.; Kim, S.-K.; Park, S.-R.: Capillary electrophoresis mass spectrometry 
with sheathless electrospray ionization for high sensitivity analysis of underivatized 
amino acids. Electrophoresis 2012, 33, 2112-2121. 
148 
 
(177) Li, Y.; Wojcik, R.; Dovichi, N. J.; Champion, M. M.: Quantitative Multiple 
Reaction Monitoring of Peptide Abundance Introduced via a Capillary Zone 
Electrophoresis-Electrospray Interface. Anal Chem 2012, 84, 6116-6121. 
(178) Kuhr, W. G.: Capillary electrophoresis. analytical chemistry 1990, 62, 403R-
414R. 
(179) Ibrahim, Y.; Tang, K.; Tolmachev, A. V.; Shvartsburg, A. A.; Smith, R. D.: 
Improving mass spectrometer sensitivity using a high-pressure electrodynamic ion funnel 
interface. J Am Soc Mass Spectrom 2006, 17, 1299-1305. 
(180) Krenkova, J.; Foret, F.: On-line CE/ESI/MS interfacing: Recent developments 
and applications in proteomics. PROTEOMICS 2012, 12, 2978-2990. 
(181) Ramautar, R.; Mayboroda, O. A.; Somsen, G. W.; de Jong, G. J.: CE-MS for 
metabolomics: Developments and applications in the period 2008–2010. 
ELECTROPHORESIS 2011, 32, 52-65. 
(182) Herrero, M.; Ibañez, E.; Cifuentes, A.: Capillary electrophoresis-electrospray-
mass spectrometry in peptide analysis and peptidomics. ELECTROPHORESIS 2008, 29, 
2148-2160. 
(183) Haselberg, R.; de Jong, G. J.; Somsen, G. W.: Low-Flow Sheathless Capillary 
Electrophoresis–Mass Spectrometry for Sensitive Glycoform Profiling of Intact 
Pharmaceutical Proteins. Analytical Chemistry 2013, 85, 2289-2296. 
(184) Thakur, D.; Rejtar, T.; Karger, B. L.; Washburn, N. J.; Bosques, C. J.; Gunay, N. 
S.; Shriver, Z.; Venkataraman, G.: Profiling the Glycoforms of the Intact α Subunit of 
Recombinant Human Chorionic Gonadotropin by High-Resolution Capillary 
Electrophoresis−Mass Spectrometry. Analytical Chemistry 2009, 81, 8900-8907. 
149 
 
(185) Ramautar, R.; Busnel, J.-M.; Deelder, A. M.; Mayboroda, O. A.: Enhancing the 
Coverage of the Urinary Metabolome by Sheathless Capillary Electrophoresis-Mass 
Spectrometry. Analytical Chemistry 2011, 84, 885-892. 
(186) Lee, R.; West, D.; Phillips, S. M.; Britz-McKibbin, P.: Differential Metabolomics 
for Quantitative Assessment of Oxidative Stress with Strenuous Exercise and Nutritional 
Intervention: Thiol-Specific Regulation of Cellular Metabolism with N-Acetyl-l-Cysteine 
Pretreatment. Analytical Chemistry 2010, 82, 2959-2968. 
(187) Ibáñez, C.; Simó, C.; Martín-Álvarez, P. J.; Kivipelto, M.; Winblad, B.; Cedazo-
Mínguez, A.; Cifuentes, A.: Toward a Predictive Model of Alzheimer’s Disease 
Progression Using Capillary Electrophoresis–Mass Spectrometry Metabolomics. 
Analytical Chemistry 2012, 84, 8532-8540. 
(188) Bachmann, S.; Bakry, R.; Huck, C. W.; Polato, F.; Corradini, D.; Bonn, G. K.: 
Peptide mapping using capillary electrophoresis offline coupled to matrix-assisted laser 
desorption ionization time of flight mass spectrometry. ELECTROPHORESIS 2011, 32, 
2830-2839. 
(189) Dong, Y.-M.; Chien, K.-Y.; Chen, J.-T.; Lin, S.-J.; Wang, T.-C. V.; Yu, J.-S.: 
Site-specific separation and detection of phosphopeptide isomers with pH-mediated 
stacking capillary electrophoresis-electrospray ionization-tandem mass spectrometry. 
Journal of Separation Science 2013, n/a-n/a. 
(190) Wang, C.; Lee, C. S.; Smith, R. D.; Tang, K.: Ultrasensitive Sample Quantitation 
via Selected Reaction Monitoring Using CITP/CZE-ESI-Triple Quadrupole MS. Anal 
Chem 2012, 84, 10395-10403. 
150 
 
(191) Wen, Y.; Li, J.; Ma, J.; Chen, L.: Recent advances in enrichment techniques for 
trace analysis in capillary electrophoresis. ELECTROPHORESIS 2012, 33, 2933-2952. 
(192) Kašička, V.: Recent developments in CE and CEC of peptides (2009–2011). 
ELECTROPHORESIS 2012, 33, 48-73. 
(193) Tong, W.; Link, A.; Eng, J. K.; Yates, J. R.: Identification of Proteins in 
Complexes by Solid-Phase Microextraction/Multistep Elution/Capillary 
Electrophoresis/Tandem Mass Spectrometry. Analytical Chemistry 1999, 71, 2270-2278. 
(194) Busnel, J.-M.; Schoenmaker, B.; Ramautar, R.; Carrasco-Pancorbo, A.; 
Ratnayake, C.; Feitelson, J. S.; Chapman, J. D.; Deelder, A. M.; Mayboroda, O. A.: High 
capacity capillary electrophoresis-electrospray ionization mass spectrometry: coupling a 
porous sheathless interface with transient-isotachophoresis. Analytical chemistry 2010, 
82, 9476-9483. 
(195) Heemskerk, A. A.; Busnel, J.-M.; Schoenmaker, B.; Derks, R. J.; Klychnikov, O.; 
Hensbergen, P. J.; Deelder, A. M.; Mayboroda, O. A.: Ultra-Low Flow Electrospray 
Ionization-Mass Spectrometry for Improved Ionization Efficiency in Phosphoproteomics. 
Analytical chemistry 2012, 84, 4552-4559. 
